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Abstract
The mammalian Target of Rapamycin (mTOR) kinase is a central regulator of
cellular growth and metabolism and plays an important role in ageing and age-
related diseases. The increase of in vitro data collected to extend our knowledge
on its regulation, and consequently improve drug intervention, has highlighted
the complexity of the mTOR network. This complexity is also aggravated by
the intrinsic time-dependent nature of cellular regulatory network cross-talks and
feedbacks. Systems biology constitutes a powerful tool for mathematically for-
malising biological networks and investigating such dynamical properties.
The present work discusses the development of three dynamical models of the
mTOR network. The first aimed at the analysis of the current literature-based
hypotheses of mTOR Complex 2 (mTORC2) regulation. For each hypothesis, the
model predicted specific differential dynamics which were systematically tested
by in vitro experiments. Surprisingly, no current hypothesis could explain the
data and a new hypothesis of mTORC2 activation was proposed. The second
model extended the previous one with an AMPK module. In this study AMPK
was reported to be activated by insulin. Using a hypothesis ranking approach
based on model goodness-of-fit, AMPK activity was in silico predicted and in
vitro tested to be activated by the insulin receptor substrate (IRS). Finally, the
last model linked mTOR with the oxidative stress response, mitochondrial reg-
ulation, DNA damage and FoxO transcription factors. This work provided the
characterisation of a dynamical mechanism to explain the state transition from
normal to senescent cells and the irreversibility of the senescent phenotype.
Keywords: ageing, systems biology, mathematical modelling, mTOR network, in-
sulin signalling, AMPK, cellular senescence, oxidative-stress response,
mitochondria, FoxO, Mfn2.
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Chapter 1
Introduction
1.1 Motivation
The insulin/insulin-like signalling and Target of Rapamycin (IIS/TOR) network
is a central regulator of cellular growth and metabolism and plays an impor-
tant role in ageing and age-related diseases. In response to metabolic stimuli
such as insulin, nutrients or energy, a cascade of signalling events modulated by
post-translational modifications, in particular phosphorylation, occurs to promote
TOR activity. Once phosphorylated, TOR governs cellular processes essential for
development and ultimately ageing, such as promotion of cell growth, prolifera-
tion and metabolism, improvement of mitochondrial function, and inhibition of
autophagy and apoptosis. Hence, understanding the functional mechanisms of
the IIS/TOR network is an essential component in extending our knowledge on
ageing and age-related diseases.
The increase of in vitro data collected to extend our knowledge on its regulation
and consequently improve drug intervention, has notably highlighted the com-
plexity of the mTOR network. This complexity is also increased by the intrinsic
time-dependent nature of cellular regulatory networks cross-talks and feedbacks.
This high level of complexity found in many biological signalling pathways raised
interest for systems biology in the scientific community. Systems biology con-
stitutes a powerful tool for mathematically formalising biological networks and
investigating their dynamical properties. In this work, the regulatory mechanisms
of the mammalian TOR network were investigated in detail using a combined in
silico-in vitro systems biology approach.
1
1. Introduction
1.2 Objectives
In the first two years of my doctorate, I developed two computational models of
the TOR signalling network that further our understanding of the influence of
growth factors and nutrition on cellular decisions. Calibrated on immunoblot-
based experimental data, provided by the team of Kathrin Thedieck, Freiburg
University, Germany, these models were used to investigate and test hypotheses
of activation of mTOR Complex 2 and AMPK. As mTOR and AMPK are im-
portant regulators of FoxO and autophagy, understanding their functional mech-
anism represents a crucial aspect in ageing.
In the last year of my doctorate, I developed a mathematical model which inte-
grated knowledge from several biochemical processes of interest in ageing research.
Through the interaction with the team of Professor Thomas Von Zglinicki, In-
stitute for Ageing and Health, Newcastle University, UK, a new process-oriented
modelling project was begun with the aim of combining behaviours of some of
the most studied components in ageing research: insulin/TOR, ROS, FoxO and
mitochondria. This work aimed to establish the first mathematical extended
framework for cellular senescence. At this initial stage, my main objective was
to formally provide a mechanism for explaining the transition of cell state from
normal to senescent.
By investigating systems dynamics with detailed in vitro time-course experimen-
tal data and network modelling with a focus on functional outcomes at the cellular
level, these projects contributed to a better understanding and opened new av-
enues for future research on TOR signalling in development and ageing and for
therapies of age-related diseases.
1.3 Outline
This thesis follows a tree structure based on a TOR-focused introduction on
ageing, insulin/TOR network and systems modelling, and three systems biology
projects (see Figure 1.1).
In Chapter 2, a general introduction on ageing and the recent implications of
TOR in ageing and age-related diseases are presented in order to contextualise
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this work inside a theoretical framework.
In Chapter 3, the insulin/TOR network is discussed from a molecular biology
perspective. In this chapter the upstream and downstream signalling pathways
of both mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) are
extensively described.
Chapter 4 introduces systems biology in the specific case of dynamical models
optimised over experimental data sets as well as the most prominent analyses
from dynamical systems theory. A review of the recent published mTOR mathe-
matical models is proposed in order to link systems modelling with TOR biology.
Chapter 5 describes the differential investigation of three hypotheses of mTORC2
activation and the discovery of a new class I PI3K independent of p70-S6K-
negative feedback loop, which promotes mTORC2 activity upon insulin stimu-
lation. The article related to this work and published in Science Signalling is
attached in Appendix A.
In Chapter 6, the previously described model was extended with the inclusion
of AMPK regulation. Using a hypothesis ranking approach based on model
goodness-of-fit, AMPK activity was in silico predicted and in vitro tested to
be activated by the insulin receptor substrate (IRS) upon insulin stimulation.
The article related to this work and published in FEBS Journal is attached in
Appendix B.
Chapter 7 discusses a new mathematical model linking mTOR with the oxidative
stress response, mitochondria regulation, DNA damage through FoxO transcrip-
tion factors and Mfn2. This work provides the formalisation of a dynamical
mechanism to explain the state transition from normal to senescent cells and
their irreversibility.
Finally, a general conclusion of this thesis is presented in Chapter 8.
3
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Figure 1.1: Thesis structure.
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Chapter 2
TOR in ageing and age-related
diseases
The process of ageing and its role in disease has intrigued mankind for centuries.
Despite this, a clear understanding of why and how ageing occurs is still far from
being achieved. Among the proposed ageing theories, the disposable soma theory
is one of the most comprehensive, widely applicable and well established. In this
theory the problem of allocating resources to remove or repair molecular damage
is central. One of the key systems that responds to resource availability is the
nutrient sensing network. This network is a widely conserved intracellular system
that serves to detect nutrient availability and govern an appropriate cellular re-
sponse. Many studies have shown that inhibition of this network by nutritional,
pharmacological and genetic intervention extends lifespan in a wide range of or-
ganisms including yeast, worms, flies and rodents. Of particular interest is the
finding that Rapamycin, which inhibits a key component of the nutrient sensing
network, suitably named the target of Rapamycin (TOR), is effective in extend-
ing lifespan in a similar range of organisms. Rapamycin was originally discovered
in Easter island and shown to inhibit growth and proliferation within the cell,
and is widely used to prevent organ transplantation rejection. It is an established
drug and as a candidate for pharmacological intervention aimed at prolonging
lifespan and healthspan, and reducing the impact of age-related diseases.
This chapter presents a summary on the biology of ageing and age-related diseases
with particular emphasis on TOR.
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2.1 Theoretical foundations on ageing
This section introduces the theoretical foundations of this study through a top-
down approach. Firstly, the disposable soma theory and the resource allocation
problem are introduced. Secondly, the connection between this evolutionary the-
ory of ageing and TOR-dependent cellular regulation is proposed.
2.1.1 The disposable soma theory
Ageing is a progressive loss of function accompanied by increasing mortality and
decreasing fertility with age. The disposable soma theory [Finch and Kirkwood,
2000; Kirkwood, 1977, 1981; Kirkwood and Rose, 1991; Shanley and Kirkwood,
2000] considers the problem an organism faces in partitioning limited resources
acquired from the environment between the physiological functions of mainte-
nance/repair and reproduction. Investment in maintenance/repair will slow the
rate of ageing whereas investment in reproduction is essential for producing off-
spring. The optimal decision that maximises Darwinian fitness will depend on
the amount of resources available and on the environmental conditions but in
general investment in maintenance/repair is inevitably less than required for in-
definite survival and the accumulation of damage results in ageing. In the wild,
life is constantly compromised by multiple extrinsic factors such as predators,
food deprivation and temperature variability. In an unprotected environment,
the risk of mortality is therefore high (see Figure 2.1A). Moreover, an organism
is continuously challenged by internal damage, for instance due to injury, infec-
tions, diseases, malnutrition, toxins, oxidative stress, which must be repaired.
Maintainance is crucial in order to preserve the soma in good enough condition
for survival to ensure opportunities to reproduce. The physiological functions of
repair and maintenance require a considerable amount of energy which has to
be carefully allocated in the organism. This investment is compromised by the
competing energy demand for reproduction which includes maintenance of the
germline cells. As a consequence, the organism gradually degrades over time,
becoming more susceptible to extrinsic and intrinsic risk factors, and ultimately
dies.
6
2. TOR in ageing and age-related diseases
2.1.2 The resource allocation problem
In the disposable soma theory, resource allocation is the key problem as resources
are limited and maintenance is costly. In an organism, these resources are al-
located among the physiological functions of growth, maintenance and repair,
storage and reproduction [Kirkwood, 2008] (see Figure 2.1B). At the level of the
organism, resource allocation is partially regulated by growth factors and nutri-
ents, as variability in these two players significatively affects size and reproduction
in Caenorhabditis elegans, Drosophila melanogaster and mice [Bass et al., 2007;
Holzenberger et al., 2001; Selman et al., 2009; Walker et al., 2005; Zid et al., 2009].
Similarly, at the level of the cell, resource allocation is regulated by growth fac-
tors, amino acids and energy [Laplante and Sabatini, 2012; Russell et al., 2011;
Sengupta et al., 2010; Zoncu et al., 2011]. In the cell, a key protein responsible
for orchestrating resource allocation is the target of Rapamycin (TOR). Through
resource availability, recognised by the cell as growth factors, nutrients and en-
ergy, TOR promotes cellular growth and proliferation, improves mitochondrial
function increasing the amount of cellular energy, and inhibits conservative or
recycling processes such as cell cycle arrest or autophagy [Dunlop and Tee, 2009;
Inoki and Guan, 2006; Stanfel et al., 2009; Yang and Guan, 2007; Zid et al., 2009]
(see Figure 2.1C). Therefore, understanding the regulation of TOR and its in-
teracting partners represent a crucial step in furthering our knowledge of ageing
and uncovering potential therapies for extending healthspan and lifespan.
2.1.3 Links between TOR, mitochondria and ROS
In response to growth factors and nutrients TOR regulates protein translation
and mitochondrial function [Finley and Haigis, 2009; Kaeberlein, 2010; Kaeber-
lein et al., 2007; Stanfel et al., 2009]. TOR can affect mitochondria in multiple
ways. TOR can directly inhibit mitochondrial autophagy (mitophagy) imped-
ing the degradation of dysfunctional mitochondria [Lee et al., 2012]. Conversely,
TOR also regulates global mitochondrial function through mitochondrial biogen-
esis [Hock and Kralli, 2009].
There is substantial evidence on the link between mitochondria and reactive oxy-
gen species (ROS). The majority of cellular ROS are generated as a by-product
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of ATP production by the mitochondrial electric transport chain (ETC) during
oxidative phosphorylation [Murphy, 2009]. The ETC activity can be measured
by the mitochondrial membrane potential (see Figure 2.2). Interestingly, ROS are
responsible for the damage of mitochondrial DNA (mtDNA) subunits [Shokolenko
et al., 2009] which would lead to a gradual dysfunction of the mitochondria ETC
mechanism [Turrens, 2003]. Mitochondrial function would therefore enter a sub-
optimal state characterised by low energy production (ATP) and high ROS gen-
eration. The establishment of this vicious cycle between ROS production and
mitochondrial ETC activity may lead to catastrophic dynamical changes inside
a cell [Turrens, 2003].
From this prospective, it is clear that the insulin/TOR signalling regulation of
mitochondrial function is essential to understand in order to selectively intervene
for improving cellular functions and health.
2.2 TOR-dependent interventions for extending
lifespan
This section discusses two of the most well-known interventions for increasing
lifespan in a TOR-dependent manner: caloric restriction and selective perturba-
tion of TOR-dependent downstream partners.
2.2.1 Caloric restriction
Caloric Restriction (CR), defined as a reduction in calories without malnutrition,
is the most well known nutritional intervention that leads to lifespan extension
and prevention from various chronic diseases in protected environments [Gredilla
and Barja, 2005; Kapahi et al., 2010]. Although most studies report a positive
effect for CR there are notable exceptions. In fact, CR was not found to extend
lifespan or reduce the incidence of cancer in wild mice [Harper et al., 2006] or
rhesus monkeys [Mattison et al., 2012]. Mutations in the insulin and insulin-like
signalling pathway were the first genetic interventions confirmed to extend life in
animals [Kenyon, 2010]. Both insulin signalling and amino acids activate TOR,
and reduced TOR activity increases lifespan [Evans et al., 2010; Kaeberlein and
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Kapahi, 2009; Kapahi et al., 2004; Laplante and Sabatini, 2012]. In yeast, both
replicative1 and chronological2 lifespans increase when TOR1 and TOR2 genes
are deleted or pharmacologically inhibited. In general, reduced TORC1 activ-
ity has been demonstrated to increase lifespan in several organisms including
single-celled budding yeast Saccharomyces cervisiae [Wanke et al., 2008], inver-
tebrate nematode Caenorhabditis elegans and fruit fly Drosophila melanogaster
[Zid et al., 2009], mice [Anisimov et al., 2010; Harrison et al., 2009] and rhesus
monkeys [Colman et al., 2009]. The effects of CR in the mTOR pathway are a
progressive reduction of the IGF/PI3K/Akt/mTOR signalling, and an increase in
AMPK [Jiang et al., 2008]. This results in an enhancement of autophagy activity
which could therefore limit the progression of age-related diseases and promoting
lifespan [Ravikumar et al., 2010].
2.2.2 Intervention on TOR downstream targets
Another way to extend lifespan is by the regulation of TOR downstream targets
or substrates, such as p70 ribosomal S6 kinase 1 (p70-S6K1) [Selman et al., 2009]
and 4E-binding protein 1 (4E-BP1) [Zid et al., 2009]. These substrates promote
the production of ribosomal proteins and ribosome biogenesis and a reduced pro-
duction is associated with increased lifespan. In addition to the regulation of
mRNA translation, ageing is also modulated by autophagy [Blagosklonny, 2010;
Blagosklonny and Hall, 2009; Cuervo, 2008; Hansen et al., 2008]. A reduction
in TOR activity obtained by Rapamycin-induced inhibition or CR, stimulates
the autophagy process. Through autophagy [Alvers et al., 2009], non-vital and
damaged components are destroyed and transformed into nutrients, extending
lifespan. It is worth noting that, in contrast to yeast, in mammals TOR can be
regulated in different ways in different tissues and thus, it is also important to
understand the consequences of TOR inhibition within a specific tissue. In fact,
inhibition of TORC1 may be beneficial in some tissues, but in contrast, may be
detrimental to others [Russell et al., 2011].
1Replicative lifespan counts the number of daughter cells generated by a mother cell prior
to senescence [Mortimer and Johnston, 1959].
2Chronological lifespan measures the amount of time a cell can survive within the G0 phase
(quiescence) of the cell cycle [MacLean et al., 2001].
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2.3 TOR in age-related diseases
In this section, the role of TOR in the most significant age-related diseases is
outlined to provide an overview on the impact that TOR research could have on
society by increasing both lifespan and healthspan.
2.3.1 Cancer
Mutations of important cell check-point proteins, such as the tumour suppressor
PTEN or the oncogene protein Akt/PKB, as well as an elevated mTOR activity,
are often discovered in many cancers. The interest of cancer research in mTOR is
also related to the effects of the natural drug Rapamycin [Bjornsti and Houghton,
2004], which has been shown to extend lifespan in cancer-prone mice [Anisimov
et al., 2010]. Following Rapamycin treatment, cells tend to arrest their life-cycle
at G1 phase because of insufficient cell growth input [Bjornsti and Houghton,
2004]. A pure Rapamycin treatment in cancer does not provide significant im-
provements because the drug only partially inhibits mTORC1 and does not af-
fect mTORC2 [Janes and Fruman, 2010]. However, the adoption of radiotherapy
or chemotherapy drugs administered in combination with Rapamycin has been
shown to be more effective in cancer treatment [Rosner et al., 2008]. Due to the
limitation of Rapamycin, interest has increased in the study of cancer treatments
by more specific TOR inhibitors, such as Torin and PP242 [Feldman et al., 2009;
Janes and Fruman, 2010; Laplante and Sabatini, 2012; Liu et al., 2011]. mTOR
is also responsible for the activation of the Vascular Endothelial Growth Factor
(VEGF), a signalling pathway related to vasculogenesis, process in which new
blood vessels are created, and angiogenesis, which is the growth of blood vessels
from existing ones [Treins et al., 2002]. This stimulation is essential for cancer
maintenance and development of metastasis.
2.3.2 Diabetes and Obesity
Diabetes is a serious age-related disease and is affected by age-related increase
in obesity. There are two forms of diabetes, Type 1 and Type 2, and both in-
volve the mTOR signalling pathway. In the former, the destruction of pancreatic
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β-cells leads to insufficient insulin production. As a consequence, glucose levels
increase in blood and urine and patients need repeated administration of insulin,
typically by injection [Lehuen et al., 2010]. Type 2 diabetes is mostly connected
to caloric excess and lack of physical activities, which are both associated with
the elderly. Type 2 diabetes is associated with over activation of the mTOR
pathway and the consequent insulin resistance and deficiency. One feature is an
upregulation of mTOR due to amino acids which leads to a sustained p70-S6K-
dependent negative feedback activation and consequent constitutive degradation
of insulin receptor substrate (IRS1) [Dann et al., 2007; Laplante and Sabatini,
2012; Tremblay et al., 2007] (see Figure 3.2 for a conceptual map of the TOR net-
work). Conversely, inhibition of mTORC1 activity with Rapamycin reduces the
p70-S6K activity restoring the normal sensitivity of the IRS1/PI3K/Akt path-
way. Type II diabetes is usually linked to obesity and TOR is also an important
regulator of lipid synthesis [Laplante and Sabatini, 2012; Rosner et al., 2008]. In
hepatic cells mTOR exerts a role in the lipogenic gene expression by regulating
the transcription factor sterol regulatory element binding protein 1c (SREBP-1c)
[Peterson et al., 2011]. Amino acids represent a key regulator of both mTORC1
and SREBP-1c. Recently, SREBP-1c has been found to be activated by protein
kinase C β (PKCβ) [Yamamoto et al., 2010], which is stabilised and phospho-
rylated by mTORC2 [Ikenoue et al., 2008]. Therefore, a long-term continuous
activity of mTORC1 and mTORC2 can determine insulin resistance and hepatic
steatosis through IRS1 degradation and SREBP-1c activation.
2.3.3 Neurodegeneration
The mechanisms by which neurons lose their functionality are not yet completely
understood. Interestingly, CR and inhibition of mTOR signalling have been pro-
posed as possible candidates in order to protect neurons and reduce neuronal loss
during ageing by promoting autophagy. These effects could limit and also reduce
damage causing neurological disorders such as Alzheimer’s, Parkinson’s, Hunt-
ington’s, Creutzfeldt-Jakob’s and dementia diseases [Rosner et al., 2008]. These
neurodegenerative diseases are characterised by an accumulation of aggregated
mutant proteins in the intracellular space. For example, Huntington’s disease
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presents polyglutamine (polyQ) expansion repeats; mutant forms of τ , a protein
thought to contribute to neurofibrillary tangles, are discovered in Alzheimer’s dis-
ease; whereas α-synuclein and β-amyloid mutants accumulate Parkinson’s disease
[Glick et al., 2010; Levine and Kroemer, 2008]. Autophagy can potentially benefit
these diseases by removing these aggregates. Rapamycin or Metformin treatment
could be used to inhibit mTORC1 signalling and increase autophagy levels [Hara
et al., 2006; Komatsu et al., 2006]. The role of autophagy in neurodegenerative
diseases is also highlighted by the fact that, mice with deficiency of autophagy-
related 5/7 proteins (Atg5, Atg7) increased the accumulation of mutant proteins
in neurodegenerative diseases [Hara et al., 2006; Komatsu et al., 2006]. Finally,
other important neuropsychiatric disorders, such as autism, epilepsy and mental
retardation, are often linked to mutations of TSC genes, upstream of mTORC1
[Gomez et al., 1999; Tee et al., 2002]. Thus, an inhibition of mTOR may improve
the impact of these diseases in affected patients.
2.3.4 Hamartoma syndromes
The Hamartoma syndromes represent genetic diseases characterised by benign
tumours which grow in brain and various organs such as lungs, kidneys, skin
and heart. Hamartoma syndromes include: tuberous sclerosis complex syndrome
(TSCS), Cowden syndrome (CS) and Peutz-Jeghers syndrome (PJS) [Inoki et al.,
2005]. TSC syndrome is due to a mutation of either TSC1 or TSC2 which disrupts
TSCs complex hyperactivating mTORC1. This hyperactive mTORC1 promotes
cell over-growth and tumour formation in TSC patients [Umeoka et al., 2008]. In
CS patients, a mutated PTEN leaves activated PIP3 hyperstimulating mTORC1.
As a consequence, PIP3 hyperactivates Akt/mTORC1 causing a dysregulation
of cellular growth and proliferation [Pilarski, 2009]. A similar effect can be ob-
served in PJS patients, due to a mutation of the protein LKB1 [Beggs et al.,
2010]. A mutation of LKB1 prevents the formation of AMPK and leaves acti-
vated mTORC1 even though in hypoxia conditions [Krymskaya and Goncharova,
2009]. Cells induced by a hyperactive mTORC1 grow larger, faster and with
different structure than normal cells, increasing susceptibility to tumourigenesis.
Rapamycin can be used for reducing tumour size by inhibiting mTORC1. To
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reduce the risk of malignancy progression, it is also important to restrict the ac-
tivity of the PI3K/Akt pathway directly by using PI3K inhibitor drugs, such as
LY294002 or Wortmannin. Due to the crucial role of mTORC2 in the phospho-
rylation of Akt, new TOR specific inhibitors could improve the treatment of the
Hamartoma syndromes.
2.4 Figures
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Figure 2.1: Disposable soma theory, resource allocation and TOR. (A) Lifespan differences
between wild and protected environments. Adapted from [Kirkwood, 2008, Fig. 1]. (B) Re-
sources allocation in the disposable soma theory of ageing [Kirkwood, 1977, 1981, 2008]. In this
theory, the problem of resource allocation is crucial since resources are limited and maintenance
is costly. Adapted from [Kirkwood, 2008, Fig. 3]. (C) TOR in ageing. In response to stimuli
such as insulin or growth factors, amino acids, energy and stress, Target of Rapamycin (TOR)
kinase governs numerous age-related cellular processes regulating the allocation of resources.
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Figure 2.2: ROS production and mitochondrial dysfunction. Mitochondrial DNA (mtDNA) in
combination with nuclear DNA encode proteins building the mitochondrial electron transport
chain (ETC), whose activity can be measured by mitochondrial membrane potential. Through
ETC, molecules of adenosine triphosphate (ATP) are synthesised and utilised by the cell as an
energy supply. Aside from ATP production, mitochondrial ETC also produces reactive oxygen
species (ROS) as a waste product. ROS accumulation, due to a lack of ROS detoxification,
severely damages mtDNA subunits, establishing a vicious circle which decreases mitochondrial
function, energy levels within the cell, and increases ROS production and mutated mtDNA.
Adapted from [Tsutsui et al., 2009, Fig. 1].
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Chapter 3
mTOR network: an overview
TOR kinase is centrally located in a complex signalling network that responds
to the availability of cellular resources. TOR is positively regulated by growth
factors, nutrients and energy uptake. Through these signals, the kinase activates
protein translation initiation and elongation mechanisms, regulates cell growth
and metabolism, improves mitochondria function and transmits signals for cell
survival. TOR-activated downstream targets inhibit apoptosis, autophagy and
cell cycle arrest. Conversely, nutritional or energetic stress conditions negatively
control TOR activity. The TOR network is further complicated by several feed-
back mechanisms that work at different time-scales and hamper a full understand-
ing. This chapter presents details of TOR kinase and the two protein complexes
containing TOR in mammals (mTOR) to place TOR in the network of related
upstream and downstream signals.
3.1 mTOR, Rapamycin and AGC kinases
This section introduces the mammalian TOR kinase from a biochemical point
of view and the first natural drug found to partially inhibit the kinase. A short
introduction of the mTOR-dependent AGC kinases is also presented as useful
background to understanding the complexity of mTOR network.
3.1.1 mTOR: kinase and complexes
The protein TOR was discovered in the early 1990s in genetic screens in yeast for
the resistance to Rapamycin [Heitman et al., 1991]. TOR1 and TOR2 in yeast
and the single mammalian homolog mTOR which are present in two multi-protein
complexes, mTORC1 and mTORC2, integrate upstream signals to regulate sev-
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eral downstream processes.
The mammalian TOR, mTOR, is a serine/threonine protein kinase which belongs
to the phosphatidylinositol kinase (PIKK) family in which the catalytic domain
presents significant homology to that of other phosphoinositide 3-kinases (PI3Ks)
although mTOR has protein rather that lipid targets. The protein mTOR is
composed of five important components. From its N-terminus: a tandem HEAT
domain involved in substrate binding; a FAT domain whose function is currently
unknown; an FRB domain which provides a docking site for the ligand FKBP12;
finally, there are the fundamental mTOR kinase domain and the FATC (FAT
C-terminus) domain [Hay and Sonenberg, 2004; Wullschleger et al., 2006]. The
details of the FATC domain activity are still unknown.
The mTOR kinase represents a central regulator of eukaryotic growth and cell
division when stimulated by nutrients and growth factors, energy signals and cel-
lular stresses. mTOR was found to exist in two complexes named mTOR Com-
plex 1 (mTORC1) and mTOR Complex 2 (mTORC2) which are structurally and
functionally different (see Figure 3.1).
Whenever stimulated by amino acids and growth factors such as insulin, mTORC1
controls multiple cellular processes such as autophagy inhibition, mRNA transla-
tion, ribosome biogenesis, lipid storage and cell cycle progression. mTORC2 re-
sponds only to growth factors and serves to regulate actin polymerisation and pro-
motes the phosphorylations of Akt/PKB and serum- and glucocorticoid-inducible
kinase 1 (SGK1). In contrast to mTORC1, the role and the interactions of
mTORC2 within the cell still remains mostly unknown.
3.1.2 The natural drug Rapamycin
Rapamycin was discovered in Easter Island and is an immunosuppressant drug
used to prevent organ rejection in transplants [Saunders et al., 2001]. It is the
first drug to have been shown to extend lifespan in a mammal [Harrison et al.,
2009]. Also, it has been shown to have significant anti-proliferative properties
which made it an interesting drug candidate in cancer research [Rao et al., 2004;
Vignot et al., 2005].
Rapamycin binds with a protein named FK506-binding protein 12 kDa (FKBP12)
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[Choi et al., 1996] which associates directly with TOR, altering its normal kinase
activity, ultimately resulting in cell growth arrest [Evans et al., 2010]. When
bound to the FRB domain of mTOR by FKBP12 protein, Rapamycin blocks
some of the physiological functions of mTOR by inhibiting part of the mTOR
autophosphorylation. This intrinsic mTOR activity is fundamental for mTOR
to modulate signals to its substrates. Interestingly, the activity of both mTOR
and Rapamycin are highly preserved among eukaryotes. Of particular interest
in ageing is the fundamental role of TOR in the regulation of autophagy, a key
process responsible for the degradation of cytosolic components.
3.1.3 mTOR-dependent regulation of AGC kinases
The mTOR network contains several important kinases belonging to the AGC
family of approximately 60 kinases. In the context of the mTOR network, the
most important AGC kinases are PDK1, Akt/PKB [McManus et al., 2004; Mora
et al., 2004], p70 ribosomal S6 kinase (p70-S6K) [Volarevic and Thomas, 2001],
p90 ribosomal S6 kinase (RSK) [Williams et al., 2000], serum- and glucocorticoid-
inducible kinase (SGK1) [Jacinto and Lorberg, 2008] and protein kinase C (PKC)
[Newton, 2003]. AGC kinases are characterised by three important phosphoryla-
tion sites, whose activation provides differential functionality. A partial activation
of the kinase is achieved by phosphorylation at the activation loop, also called T-
loop, in the kinase domain. This phosphorylation enables conformational change
in the protein structure which exposes the kinase hydrophobic motif (HM), lo-
cated in a C-terminal tail region, on the protein surface. Phosphorylation at this
region determines a full activation of the AGC kinase and further functionality
[Pearce et al., 2010]. The third and least characterised phosphorylation site or
region is the turn motif phosphate which is also located in the protein tail. Its
function is to stabilise the phosphorylation of the kinase by sheltering the hy-
drophobic motif from dephosphorylation [Hauge et al., 2007; Pearce et al., 2010].
18
3. mTOR network: an overview
3.2 Upstream signalling pathways of mTOR
Multiple signalling pathways have a regulatory influence on the mTOR Complexes
1 and 2. This section presents the four major inputs of mTOR: growth factors,
amino acids, energy and hypoxia. The most important cross-talks from these
signals to other pathways are also mentioned.
3.2.1 The insulin insulin-like signalling pathway
Insulin and insulin-like signalling (IIS) is mediated at the cell membrane by a
specific insulin receptor (IR). In the presence of insulin molecules on the external
membrane surface, the insulin receptor is auto-phosphorylated at several tyrosine
residues transmitting the signal in the internal membrane surface. Among several
proteins activated by IR, the insulin receptor substrate (IRS) is crucial in the IIS
pathway. The IRS binds with phosphoinositide 3-kinase (PI3K) forming a com-
plex which enables the production of phosphatidylinositol (3,4,5)-trisphosphate
(PI(3,4,5)P3) from phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2) or phos-
phatidylinositol (3,4)-bisphosphate (PI(3,4)P2) through phosphorylation at the
membrane surface [Polak and Hall, 2009]. The activity of PtdIns(3,4,5)P3 is
negatively controlled by phosphatase and tensin homolog (PTEN) and SH2-
containing inositol phosphatase (SHIP), which convert the PI(3,4,5)P3 in the
form of PI(4,5)P2 and PI(3,4)P2 respectively. Upon insulin or insulin-like stim-
uli, phosphoinositide-dependent kinase-1 (PDK1) and Akt, also known as Protein
Kinase B (PKB), relocalise from the cytoplasm to the membrane surface and
their Pleckstrin Homology (PH) domain binds with PI(3,4,5)P3 molecules [Po-
lak and Hall, 2009]. This binding exerts a conformational change in Akt/PKB
which is necessary to enable PDK1 to phosphorylate Akt at T308 at the T-loop
[Biondi, 2004; Garcia-Martinez and Alessi, 2008; Kobayashi and Cohen, 1999;
Mao et al., 2008a; McManus et al., 2004; Mora et al., 2004; Toker and Newton,
2000]. Once phosphorylated at T308, Akt affects the integrity of the tuberous
sclerosis complex (TSC1/TSC2) by phosphorylating TSC2 at S924 and T1518
[Inoki et al., 2002; Potter et al., 2002]. Whereas TSC1 mainly serves for the
stabilisation of the TSC1/TSC2 complex, TSC2 presents a GAPase Activating
Protein (GAP) domain which controls GTPase activity of mTORC1 activator
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Ras-homolog enriched in brain (Rheb). Therefore, TSC2 switches off Rheb by hy-
drolysing Rheb activator guanosine-5’-triphosphate (GTP) to guanosine diphos-
phate (GDP), whereas guanine nucleotide-exchange factors (GEFs) reverse this
reaction by freeing GDP molecules from the GTPase and thus promoting GTP
formation and consequent GTP-bound Rheb activation. Whenever TSC1/TSC2
complex is disrupted, GTP-bound Rheb is free to bind with mTOR Complex 1
(mTORC1) at the lysosomal surface, mediating the insulin signalling [Huang and
Manning, 2008]. Regarding mTORC2, it is known that the complex is sensitive
to growth factors, such as insulin, but little is known about how this activation
happens. Insulin stimulation has been shown to be responsible for the phosphory-
lation of Rictor at T1135, even when Rictor is not associated with mTOR, as this
phosphorylation was inhibited upon Wortmannin treatment [Boulbes et al., 2010].
Recent studies have shown the presence of a positive feedback from TSC1/TSC2
to mTORC2, whereas a direct association between the dimer and mTORC1 is
not known. These authors showed that the heterodimer could positively regu-
late mTORC2 in a Rheb-independent manner [Huang et al., 2008; Rosner et al.,
2008; Sparks and Guertin, 2010]. These studies used Akt-S473 (see Section 3.4.1),
which is dependent on the p70-S6K-dependent negative feedback loop (see Section
3.3.2), as a marker of mTORC2, instead of a specific direct readout of mTORC2
activity. Although several speculations of mTORC2 activation have been pro-
posed, a comprehensive study of the modalities of mTORC2 activation has yet
to be conducted and this will be the subject presented in Section 5 (see Figure
3.2).
3.2.2 The amino acids signalling pathway
Amino acids such as Leucine, Tryptophan and Phenylalanine [Christie et al.,
2002; Taylor, 2009; Thedieck and Hall, 2009] play a crucial role in regulating the
mTOR network and mTORC1 activation, although surprisingly the mechanisms
are still mostly unknown. Recent studies have revealed the presence of new Rag
proteins which are necessary for the mTORC1 activation by amino acids [Kim
et al., 2008] (see Figure 3.2). Rag proteins are a family of four small GTPases,
RagA, RagB, RagC and RagD, belonging to the Ras family. Rags associate as
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heterodimers formed by RagA or RagB, with RagC or RagD [Kim et al., 2008;
Sancak et al., 2008]. mTORC1 and Rags associate in the presence of amino
acids, in particular leucine. Rags do not directly activate mTORC1, but allow
mTORC1 to bind with Rheb which is necessary for mTORC1 activation. Inter-
estingly, a more recent study [Sancak et al., 2010] based on mass spectrometry
analysis, has discovered the presence of a complex named Ragulator. Whenever
stimulated by amino acids, Ragulator is responsible for the mTORC1 transloca-
tion to the lysosomal surface and the subsequent association between mTORC1
and the heterodimer Rags. Once mTORC1 localises to the lysosomal surface, an
insulin stimulation can enhance mTORC1 activation by promoting the binding
between GTP-bound Rheb and mTORC1. This synchronised confluence of the
insulin and amino acids signalling pathways on the lysosomal surface could ex-
plain why insulin/IGF stimulation without amino acids is not sufficient for the
activation of mTORC1 [Drummond et al., 2008; Sancak et al., 2010]. Conversely,
in the absence of amino acids mTORC1 localises to the cytoplasm [Kalender
et al., 2010]. Therefore, amino acids are essential for activating Ragulator which
transfers mTORC1 to the lysosomal compartment and binds it with its activator
Rheb.
Little information is known about how amino acids regulate the Rag GTPase
proteins. Dura´n et al. [2012], from the lab of Hall, recently focused on glutamine,
an amino acid involved in cell growth and metabolised through glutaminolysis
to produce α-ketoglutarate. The authors reported that glutamine combined with
leucine activated Rag GTPase complex and promoted lysosomal translocation and
activation of mTORC1 by enhancing glutaminolysis and α-ketoglutarate produc-
tion. Another recent study showed that SH3 domain-binding protein 4 (SH3BP4)
negatively regulates Rag GTPase complex by binding to the inactive form of the
complex under amino acids starvation conditions. Once bound to SH3BP4, Rag
GTPase complex is unable to switch state and therefore to interact with and
activate mTORC1. This leads to an inhibition of mTORC1 activity in a Rag
GTPase-dependent manner [Kim et al., 2012].
Amino Acids were also shown to partially activate mTORC2 and its readout Akt-
S473 indirectly via class I PI3K [Jacinto et al., 2004; Tato et al., 2011] although
the detail of this connection is still unclear.
21
3. mTOR network: an overview
3.2.3 The energy signalling pathway
Another important regulator of mTOR is the energy signalling pathway [Thedieck
and Hall, 2009]. The main component of this signalling cascade is Adenosine
Monophosphate-activated Protein Kinase (AMPK). AMPK is a trimeric com-
plex formed by α, β and γ subunits, which are necessary to maintain protein
stability and function. AMPK is directly regulated by the tumour suppressor
Liver Kinase B1 (LKB1). LKB1 is activated under energy or nutrient stress con-
ditions and acts as a growth and proliferation suppressor. In adipocyte cells,
LKB1 is negatively regulated via the androgen receptor, whereas positively via
oestrogen receptor alpha [McInnes et al., 2012]. When in a complex with the
proteins STRAD and MO25, active LKB1 phosphorylates the AMPK-α subunit
activation loop under conditions of energy stress, and this is sufficient for AMPK
activation [Shackelford and Shaw, 2009]. LKB1 is of clinical importance as it
plays a key role in maintaining cell polarity and lack of LKB1 is associated with
Peutz- Jeghers syndrome and other forms of cancer.
AMPK is an energy level sensor. Whenever the number of AMP molecules is
much greater than ATP, the cell is in a low-energy status. In response to en-
ergy stress, AMPK becomes active in order to maintain energy homoeostasis in
cell metabolism. Under such energy-stress conditions, the γ subunit of AMPK
binds directly with AMP molecules and undergoes a conformational change, be-
coming activated. Once activated, AMPK phosphorylates the unit TSC2 of the
TSC1/TSC2 complex at T1271 and S1387, increasing the dimer GTPase ac-
tivity [Inoki et al., 2005, 2003]. In addition, active AMPK phosphorylates the
mTORC1 scaffold protein Raptor at S722 and S792, inhibiting it [Gwinn et al.,
2008]. Therefore, AMPK negatively controls mTORC1 through TSC1/TSC2 up-
regulation and Raptor inhibition (see Figure 3.2).
3.2.4 The hypoxic signalling pathway
Hypoxia, which is referred to as a condition of low levels of oxygen, plays a
role in the TOR network. Activated mTORC1 promotes the transcription of
Hypoxia-inducible factor 1 (HIF-1) heterodimeric complex (see Figure 3.2). HIF-
1 is differentially regulated depending on hypoxic or normoxic conditions in the
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cell. Under hypoxic conditions HIF-α binds with HIF-β and the dimer then
migrates from the cytosol to the nucleus and induces transcription of genes re-
quired for cellular adaptive response to hypoxic stress [De´ry et al., 2005], such
as erythropoietin (EPO), p300 and POLII [Maxwell, 2005]. HIF-1 also promotes
glucose metabolism [Huang et al., 2004; Ke and Costa, 2006] and angiogenesis by
activating the Vascular Endothelial Growth Factor (VEGF) pathway [Gray et al.,
2005; Klimova and Chandel, 2008]. Interestingly, HIF-1 activates the transcrip-
tion of the two genes Redd1 and Redd2 which inhibit mTOR in a TSC1/TSC2-
dependent manner [Brugarolas et al., 2004; McCarthy, 2004], thereby providing
a negative feedback loop. citetBrugarolas2004 showed that Redd1/2 is required
for down-regulating mTORC1 by promoting TSC1/TSC2 activity in a hypoxia-
dependent and energy-independent manner. The hypoxic signalling pathway
through mTORC1 also involves the protein Bnip3 which has been shown to be
enhanced by HIF-1α subunit, under hypoxia conditions [Wouters and Koritzin-
sky, 2008]. Bnip3 inhibits the GTP form of Rheb, directly reducing mTORC1
activation. In addition, Bnip3 was demonstrated to positively regulate autophagy
[Bellot et al., 2009]. Instead, in case of normoxic conditions, HIF-1 is rapidly hy-
droxilated by EGLN1/PHD1 and EGLN2/PHD2 at several prolines. Once HIF-1
is hydroxilated, the interaction with Von Hippel-Lindau (VHL) is facilitated, in-
creasing HIF-1 ubiquitination and proteasomal degradation [De´ry et al., 2005;
Maxwell, 2005].
3.2.5 Other signalling pathways
In addition to mTOR other kinases in the network have an important role. Among
these, Akt and IRS are potentially the two most important examples. Akt plays
a direct role in glucose metabolism by phosphorylating and inhibiting Glycogen
Synthase Kinase 3 (GSK-3). GSK-3 phosphorylates and inhibits Glycogen Syn-
thase (GS), which is involved in the synthesis of glycogen from glucose [Embi
et al., 1980]. Akt also controls other cellular processes, such as cell survival
and proliferation. Through phosphorylation, Akt enhances the oncogene protein
murine double minute 2 (MDM2), an E3 ubiquitin ligase and the main repressor
of p53, and deactivates FoxO. By inhibiting FoxO and p53 activity, the apoptotic
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signalling cascade composed of Bim-Bcl-2-Bax is repressed, thereby favouring cell
survival. Akt deactivates several genes, such as Wee1, p27Kip1, p21Cip, which
are involved in cell cycle arrest. Through these inhibitions, Akt promotes cell
proliferation.
IRS has multiple activity when stimulated by growth factors. Besides propagat-
ing the insulin signalling by binding with PI3K (see Section 3.2.1), IRS binds to
Growth factor receptor-bound protein 2 (GRB2) and GRB10, which are involved
in the Epidermal Growth Factor (EGF) pathway. In more detail, GRB2 and
GRB10 activate the signalling cascade SOS-Ras-MEK1/2-Erk, which has several
crosstalk connections with the insulin signalling pathway (see Figure 3.2).
3.3 Interacting partners of mTORC1
Several signalling pathways have been shown to interact with mTORC1 and our
expanding knowledge of the mTOR network is uncovering new modalities of in-
tervention in ageing and age-related diseases. In this section, the most important
interacting partners and downstream target kinases of mTORC1 are presented.
3.3.1 Rheb, FKBP38 and PRAS40
Rheb is a small GTPase protein belonging to the Ras superfamily of G-proteins.
Rheb is activated (GTP-bound Rheb) by GEFs and inactivated (GDP-bound
Rheb) by TSC2 GAPase domain [Huang and Manning, 2008]. Rheb is funda-
mental to provide a full activation of mTORC1 and thus to activate cell growth
mechanisms. Moreover, Rheb over-expression was found to correlate with an in-
crease in p70-S6K1 and 4E-BP1 phosphorylation in Drosophila [Stocker et al.,
2003], which indicates that mTORC1 activity is connected to an activated Rheb.
FKBP38, or FKBP8, is a member of the FK506-binding protein (FKBP) family
which includes FKBP12. FKBP12 binds to Rapamycin, interacts with the FRB
domain of mTOR within the complex mTORC1 and leads to inhibition. FKBP38
is a mitochondrial membrane protein which associates with mTORC1 in a similar
way to that of the complex FKBP12 and Rapamycin. Unlike FKBP12, FKBP38
does not require Rapamycin in order to form a complex with mTORC1. After
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binding with FKBP38, mTORC1 is not able to propagate signals to its down-
stream targets. In-vitro assays demonstrated that FKBP38 competed with the
complex FKBP12-Rapamycin for binding with the FRB domain of mTOR in
mTORC1 [Bai et al., 2007]. Like the complex FKBP12-Rapamycin, FKBP38
only interacts with mTORC1 and does not show any binding with mTORC2.
Furthermore, it was shown that the activated GTP-bound form of Rheb de-
creased the binding of FKBP38 with mTOR in mTORC1 in vitro, thus relieving
the inhibition of mTORC1.
The Proline-rich Akt Substrate of 40 kDa (PRAS40) is a protein able to bind
to the Raptor subunit of mTORC1. PRAS40 is directly phosphorylated by
Akt/PKB at T246 and by mTORC1 at S183, S202/3, S212, S221. The phos-
phorylation by Akt/PKB results in a conformational change in mTORC1-bound
PRAS40 which enables mTORC1 to subsequently phosphorylate PRAS40 and
disrupt the complex [Nascimento and Ouwens, 2009; Nascimento et al., 2010;
Thedieck et al., 2007; Wang et al., 2007]. The dissociation of PRAS40 and
mTORC1 permits mTORC1 to interact with the GTP form of Rheb, becoming
activated. Therefore, the insulin pathway acts as a double activator of mTORC1
firstly by activating Rheb and secondly by separating mTORC1 from its inhibitor
PRAS40 [Thedieck and Hall, 2009; Thedieck et al., 2007; Wang et al., 2007].
3.3.2 The downstream substrate p70-S6K
Among the numerous mTORC1 substrates, the two best studied are the kinase
p70-S6K1 (p70-S6 kinases) and the 4E-binding protein 1 (4E-BP1). Following
stimulation by growth factors and amino acids, mTORC1 phosphorylates p70-
S6K1 which phosphorylates its numerous substrates, inducing protein translation.
Among these substrates are the Programmed Cell Death 4 (PDCD4), the S6 ribo-
somal protein [Heinonen et al., 2008], the eukaryotic Initiation Factor 4B (eIF4B)
which is known to associate with eIF3 and the eukaryotic Elongation Factor-2
Kinase (eEF2K) which activates its substrate eEF2, promoting the elongation
phase of protein synthesis. A reduced p70-S6K1 activity has been shown to ex-
tend lifespan in mice [Selman et al., 2009].
p70-S6K1 belongs to the AGC protein kinases family and has several phospho-
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rylation sites [Jacinto and Lorberg, 2008]. mTORC1 phosphorylates p70-S6K1
at T389 and S371. In order to become fully activated, p70-S6K1 requires an
additional phosphorylation at T229 by PDK1. p70-S6K1 plays an important role
in the mTOR signalling pathway not only as translation promoter, but also as
an inhibitor of the insulin receptor substrate 1 (IRS1) which by phosphorylation
at S636/639 [Dann et al., 2007; Tremblay et al., 2007] favours its degradation
and blocks the insulin signal. This pathway is referred to as p70-S6K1-induced
negative feedback towards IRS1. Recently, p70-S6K1 was also shown to phospho-
rylate Rictor at T1135, regulating the mTORC2 activity negatively [Julien et al.,
2010; Treins et al., 2010]. Thus, p70-S6K1 interrupts Akt function by negative
feedbacks to IRS1 and mTORC2. These negative feedbacks arrest the pathways
which determine the Akt phosphorylation at T308 and S473, respectively [Foster
and Fingar, 2010].
3.3.3 The downstream substrate 4E-BP1
The 4E-binding protein 1 (4E-BP1) is another well studied mTORC1 substrate.
When unphosphorylated, 4E-BP1 forms a complex with eukaryotic Initiation
Factor 4E (eIF4E) acting as a translation repressor. The phosphorylation of
4E-BP1 by mTORC1 disrupts the complex and frees it from eIF4E [Dann and
Thomas, 2006]. Thus eIF4E associates with a specific complex represented by
the initiation factors eIF4G and eIF4A, forming the new complex eIF4F. eIF4G
is known to be the mediator for this binding [Gingras et al., 1999]. Therefore,
mTORC1 regulates cell growth and proliferation by disabling 4E-BP1 activity and
enhancing cap-dependent mRNA translation mediated by eIF4F. By regulating
4E-BP1 phosphorylation by inhibiting mTOR, it is possible to extend lifespan
[Zid et al., 2009].
3.3.4 Roles of mTORC1 and AMPK in autophagy
mTORC1 and AMPK play an opposite role in autophagy1, which is the pro-
cess by which a cell is able to degrade and recycle useless or damaged organelles
1In this context, autophagy is meant as macroautophagy
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under nutrients or energy stress conditions, through direct phosphorylation of
ULK1 [Kim et al., 2011; Lee et al., 2010a] in response to glucose. Under high
levels of glucose, AMPK is inactive and mTORC1 is active. Active mTORC1
phosphorylates ULK1 at S757, inhibiting autophagy. Conversely, active AMPK
inhibits mTORC1 and phosphorylates ULK1 at S317 and S777, promoting au-
tophagy [Kim et al., 2011]. Once autophagy is activated, new amino acids are
produced through the degradation of organelles by autophagy. This presence of
amino acids in the cytoplasm is able to restore mTORC1 activity through the
amino acids pathway after 6-8 h of autophagy activation in mice [Yu et al., 2010].
A functional balance between AMPK and mTORC1 is fundamental to maintain
cell homoeostasis and healthy cellular function. Therefore, controlling and opti-
mising this interplay, potentially through pharmacological intervention, may have
beneficial consequences in lifespan and healthspan.
3.3.5 A novel substrate: DAP1
mTOR regulates the activity of a large number of substrates in addition to p70-
S6K and 4E-BP1. The function for many of them is still unknown and in need
of further study, but of those known, Death-Associated Protein 1 (DAP1) may
have particular relevance to ageing and cancer.
Contrary to ULK1 and Atg13 which are positive regulators of autophagy, DAP1
is the first mTORC1 substrate found to inhibit autophagic flux upon amino acid
starvation [Koren et al., 2010]. Under nutrient-rich conditions, active mTOR di-
rectly phosphorylates DAP1 at S3 and S51, silencing DAP1-dependent inhibition
of autophagy. Conversely, during amino acids starvation, the mTOR pathway
is reduced and DAP1 remains unphosphorylated, inhibiting autophagy. Further-
more, Koren et al. [2010] found that DAP1 did not feed back on mTORC1, since
DAP1 knock down increased autophagy levels but did not affect mTORC1. The
authors explained this result by speculating a mTOR-governed buffering mecha-
nism which would prevent autophagy hyperactivation under nutrient deprivation
[Koren et al., 2010]. In conclusion, this new apparently contradictory signalling
pathway suggests that much knowledge on mTOR regulation of autophagy is
still missing and that new combinatorial drug-intervention are required to clarify
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these potential discrepancies.
3.4 Downstream targets of mTORC2
In contrast to mTORC1 there is little knowledge about the substrates and down-
stream signalling of mTORC2. Although the complex was found to be an impor-
tant regulator of AGC kinases, such as Akt, SGK1 and PKC, a comprehensive
investigation of the roles and interactions as well as a delineation of an exhaustive
signalling network of mTORC2 are still at an early stage of research. In this sec-
tion, three important substrates of mTORC2 are presented. Particular emphasis
is attributed to FoxO, a key target downstream of Akt, and its role in ageing.
3.4.1 Akt-S473
Akt is a central regulator in the TOR network and its double regulation as an
AGC kinase makes its functional mechanism difficult to understand. As an AGC
kinase, Akt can be further phosphorylated at S473 on its hydrophobic motif
(HM), after being phosphorylated at T308 on its T-loop. Several kinases have
been found to regulate the phosphorylation at the hydrophobic motif of Akt.
Historically, these proteins have been called PDK2 candidates in order to high-
light the necessity of PDK1 in the Akt switch mechanism. Among these PDK2
candidates, one of the most important is mTORC2 [Copp et al., 2009; Sarbassov
et al., 2006, 2005]. Interestingly, the S473 phosphorylation is not required to
phosphorylate TSC2 [Jacinto et al., 2006]. Therefore, although Akt can act down-
stream of mTORC2, but upstream of mTORC1, mTORC2 cannot be considered
an mTORC1 activation upstream through Akt. The double phosphorylation at
T308 and S473 permits Akt to phosphorylate other proteins and to promote sur-
vival signals. Among these proteins are the subclass O of the Forkhead family of
transcription factors (FoxO).
3.4.2 FoxO transcription factors
The Forkhead box (Fox) proteins are a family of transcription factors controlling a
multitude of genes implicated in cellular differentiation, glucose metabolism, cell
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growth, cell death, DNA repair, ROS detoxification and cell cycle. Among the
several genes belonging to the Fox family, the subclass O has attracted particular
interest in ageing research since it was found that Daf-16, the homologue gene
of mammal FoxO3, extended lifespan in C. elegans [Lehtinen et al., 2006; Libina
et al., 2003; Lin et al., 2001]. The FoxO subgroup of the Forkhead family consists
of four members: FoxO1, FoxO3, FoxO4 and FoxO6 [Greer and Brunet, 2005].
In the absence of insulin or growth factors, FoxO localises in the nucleus and
targets genes regulating cell cycle arrest (e.g. GADD45, p27), stress resistance
(e.g. MnSOD) and cell death (e.g. Bim). In the presence of insulin or growth
factors, fully activated Akt phosphorylates FoxO3, predominately at S253, which
results in the translocation of the transcription factor from the nucleus to the
cytoplasm where it is sequestered by the protein 14-3-3. Notably, elevated Akt
activity is often found in malignant tumour cells [Hara et al., 2005], whereas FoxO
up-regulation was shown to increase lifespan [Kenyon, 2011; Willcox et al., 2008].
Under oxidative stress conditions, c-Jun N-terminal kinase (JNK) is activated and
phosphorylates FoxO. This phosphorylation forces the localisation of FoxO to the
nucleus, over-riding previous phosphorylation by Akt [Chaanine et al., 2012; Greer
and Brunet, 2005]. Whether FoxO play different roles in the nucleus in absence
of insulin or growth factors, or under oxidative stress conditions has not yet been
clarified. Besides phosphorylation, FoxO can also be regulated by acetylation
by NAD-dependent deacetylase sirtuin-1 (Sirt1, Sirtuin 1) in the nucleus. Sirt1
is responsible for deacetylating FoxO at several sites, promoting oxidative stress
resistance instead of genes regulating apoptosis [Brunet et al., 2004]. FoxO also
represents an important interconnecting point in the cellular signalling network.
Under stress stimuli or nutrient starvation, FoxO was also found to associate
with p53 in the nucleus, trascribing several genes with p53 [Brunet et al., 2004].
Another important interaction is between FoxO and SMAD transcription factors,
which up-regulates p21 expression. This binding also represents a link between
IIS and Transforming Growth Factor β (TGF-β) signalling pathways [Seoane
et al., 2004].
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3.4.3 SGK1
Another important member of the AGC family is the protein Serum- and Gluco-
corticoid-induced protein Kinase 1 (SGK1). SGK1 is activated by growth factors,
such as insulin, and is responsible for the regulation of sodium channel, transport
and cellular processes such as cell growth, proliferation, survival and apopto-
sis. mTORC2 was found to phosphorylate the SGK1 hydrophobic motif at S422
[Garcia-Martinez and Alessi, 2008], which undergoes a conformational change
permitting PDK1 to further phosphorylate the kinase on its catalytic domain at
T256 [Kobayashi and Cohen, 1999; Mora et al., 2004]. As with other AGC ki-
nases, the double phosphorylation enables a full activation of SGK1 [Pearce et al.,
2010]. Some substrates are shared between SGK1 and Akt. Particularly, SGK1
activates MDM2, leading to a MDM2-dependent ubiquitination of p53 [Amato
et al., 2009]. SGK1 was also found to phosphorylate FoxO3a predominately at
S315, driving its translocation from the nucleus to the cytoplasm, interrupting
its transcription activity [Brunet et al., 2001].
3.4.4 PKC family
The family of Protein Kinase C (PKCs) contains oncogene AGC kinases involved
in cell proliferation and differentiation [Griner and Kazanietz, 2007]. As Akt,
PKC is phosphorylated at the activation loop by PDK1 and at the hydrophobic
loop by mTORC2 [Ikenoue et al., 2008]. mTORC2 is also responsible for the
phosphorylation of PKC at its turn motif, which preserves the phosphorylation
of PKC hydrophobic motif [Hauge et al., 2007; Ikenoue et al., 2008]. PKC can also
phosphorylate the TSC2 subunit, leading to the disruption of the TSC1/TSC2
complex and following activation of mTORC1. Whereas some phosphorylation
sites overlap with those targeted by Akt, others are PKC-dependent only [Tee
et al., 2003]. The authors also showed that these PKC-dependent phosphorylation
sites are also PI3K-independent, supporting the idea of multiple independent
signalling toward TSC1/TSC2 complex [Inoki et al., 2006]. Interestingly, PKC
was also shown to be involved in the transcription of IRS1 in MCF-7 breast cancer
cells [deVente et al., 1996], suggesting a positive feedback loop driven by IRS1
through mTORC2 and PKC2.
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3.5 Figures
Figure 3.1: mTOR complexes 1 and 2. In mammals, the complexes mTORC1 and mTORC2
share mTOR, the mammalian LST8/G-protein β-subunit like protein (mLST8/GβL) and Dep-
tor [Peterson et al., 2009]. mLST8/GβL likely binds to the kinase domain of mTOR regulating
its kinase activity. Deptor is known to have an inhibiting role in both complexes. A pecu-
liar characteristic of mTORC1 is the binding with Raptor (Regulatory associated protein of
mTOR). Raptor is known to be essential for the phosphorylation of mTORC1 downstream
targets p70-S6K1 and 4E-BP1. It is supposed that it binds to the HEAT repeats of mTOR
and it is sensitive to Rapamycin because it reduces its binding strength with mTOR in the
presence of the drug. mTORC2 differs by containing Rictor (Rapamycin-insensitive companion
of mTOR), the mammalian stress-activated protein kinase interacting protein 1 (mSIN1) [Frias
et al., 2006] and PRR5-L [Woo et al., 2007]. mSIN1 is necessary for the binding between mTOR
and Rictor, whereas PRR5 has not been found relevant. The detailed function of PRR5-L is
still unknown.
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Figure 3.2: The mTOR signalling network is complicated by the numerous inputs and interac-
tion between signals. In addition, the network presents several negative and positive feedback
loops and most of them are not completely understood. Understanding the relationships among
the proteins and the mechanisms by which mTOR-dependent processes are regulated is of fun-
damental importance to enable intervention on numerous age-related diseases. New systems
biology approaches, such as modelling, using phosphoproteomics data, are able to deal with the
complexity of the network and predict both qualitative and quantitative regulations. (Source:
Cell Signaling Technology R© (CST), Inc., website: http://www.cellsignal.com/; proteins are
linked to PhosphoSitePlus R© (PSP), website: http://www.phosphosite.org/ (CC BY-NC-SA
3.0) [Hornbeck et al., 2012]).
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Chapter 4
Systems biology for investigating
mTOR network in ageing
This chapter begins by presenting the main concepts of systems biology, from
parameter estimation to advanced techniques of dynamical system theory. Fi-
nally, published work on systems modelling of the mammalian TOR network are
described.
4.1 Introduction to systems biology
Understanding the connections between proteins to form networks and determin-
ing the emergent properties of dynamical interactions has been a major focus of
research in recent years. Due to the complexity of biological systems, the need
for an appropriate level of abstraction in order to characterise the key signalling
network governing cell behaviour is essential. An approach to address the prob-
lem is provided in the mathematical modelling of signalling pathways [Hughey
et al., 2010; Kolch et al., 2005]. So far, several key pathways have been mod-
elled and simulated such as the epidermal growth factor (EGF) pathway [Borisov
et al., 2009; Schilling et al., 2009; Wang et al., 2009], the insulin insulin-like path-
way [Bra¨nnmark et al., 2010; Nyman et al., 2012; Smith and Shanley, 2010] or
p53/MDM2 oscillation signalling [Geva-Zatorsky et al., 2006; Proctor and Gray,
2008]. This chapter presents a concise introduction to systems biology and other
more advanced techniques imported from dynamical systems theory with the aim
of introducing the current mathematical models of the TOR network.
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4.1.1 Why systems biology?
Before introducing the main concepts important for dynamic modelling in sys-
tems biology, I think it is reasonable to discuss what systems biology is and how
it can improve our understanding in biological studies. Systems biology is not
simply a means to replace expensive wet-experiments with dry alternatives. It
would not be very useful to consider systems biology just as an additional tool to
provide more evidence to support scientific findings. From this point of view, a
systems biology approach does not reveal much more than using wet-experimental
techniques.
The advantages of systems biology are multiple. Firstly, the system represen-
tation is an abstraction of the biological context, and therefore it is simpler to
investigate. Systems biology offers an extraordinary possibility to represent our
biological knowledge as an interconnected system using an appropriate formal-
ism. Secondly, this system can be formally analysed from multiple perspectives
using theories coming from other sciences such as mathematics and computer sci-
ence (e.g. dynamical systems, optimisation, formal methods), and statistics (e.g.
stochastic simulation of models). Thirdly, from these analyses, specific prop-
erties of the system can be extracted and formulated as modelling predictions
which can be tested in the laboratory. Systems biology permits the biologist to
selectively search those predictions (e.g. systematic sensitivity analysis of sys-
tem components) as well as provides the user with new non-trivial results (e.g.
system bifurcations at specific protein amounts). Moreover, the feasibility of ob-
taining these predictions is mainly due to fast numerical computing tools, which
allows the user to perform high-throughput tasks which would be impossible for
wet-experimentalists.
4.1.2 Model definition
Over the last 20 years, the necessity of creating a standard language for systems
biology models has emerged. Systems Biology Markup Language (SBML) [Hucka
et al., 2003] was developed as an XML standard aimed at porting systems biology
models amongst different platforms and therefore increasing systems biology in-
teroperability. In the field of molecular systems biology, a model is described as:
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(1) a set S of species (e.g. unphosphorylated or phosphorylated proteins, com-
plexes), (2) a set R of reactions between species (e.g. phosphorylation, binding),
(3) a set I of inputs (e.g. insulin stimuli), and (4) a set C of compartments (e.g.
cytoplasm, nucleus). These biological models can be graphically represented us-
ing CellDesigner1 [Funahashi et al., 2008, 2003]. Although this representation can
be user-friendly, it hides the real representation of a model from a mathematical
point of view. Instead, a mathematical representation explicitly offers the details
for dealing with tasks such as parameter estimation and model quality analysis.
A biological model can be described as follows:
~˙xt,θ = ~f(~xt,θ, ~ut,θ, θ), ~xt0,θ = ~x0,θ (4.1)
~yt,θ = ~g(~xt,θ, θ) + ~ (4.2)
where 4.1 is a system of Ordinary Differential Equations (ODEs) and 4.2 describes
the model observable variables. The ODE-based model is characterised by n
species ~x (e.g. protein concentrations), whose dynamics are dependent on l input
functions ~u (e.g. constant or impulse stimulation) and j model parameters θ =
{θ1, . . . , θj} (e.g. protein initial concentrations, kinetic rates constants, scaling
factors) over time t = {0, . . . , T}. The species in ~x which can be experimentally
measured (e.g. by immunoblotting, mass spectrometry), are mapped into m
observable variables ~y by an observable function ~g and a measurement error  ≈
N(0, σ2(di,k)), where σ
2(di,k) is the variance of the i-th measurement at the time
point k.
4.1.3 Parameter estimation
The choice of the observable variables depends on the measurements that can
be feasibly measured in the laboratory. Once these are collected, the model can
be optimised in order to represent the experimental data within a certain error.
Parameter estimation is the task in which the model parameters are established
in order to reduce this error. Let di,k and yi,k,θ be the i-th data measurement and
observable at the time point k respectively, and σ(di,k) be the standard deviation
1http://www.celldesigner.org/
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for di,k, parameter estimation aims at measuring the distance between the model
observables and the experimental data:
χ2(θ) =
m∑
i=1
T∑
k=0
(
di,k − yi,k,θ
σ(di,k)
)2
(4.3)
and computing a solution, or assignment of values to the parameters θ, which
minimises such a distance:
θˆ = argmin
θ
(χ2(θ)) (4.4)
Parameter estimation is therefore a problem of minimum optimisation. Optimi-
sation algorithms can be classified into two classes: global and local algorithms.
Global optimisation algorithms aim at finding the solution of minimum cost1 in
the differential χ2 manifold2 M of the search space. Although these algorithms can
be very accurate since the performed research is more extended, they usually have
exponential time complexity. An additional problem is that they can stall on local
minima, which may not be suitable as solutions. Examples of these algorithms
are simulating annealing (SA) [Corana et al., 1987; Kirkpatrick et al., 1983], ge-
netic algorithms (GA) [Ba¨ck et al., 1997; Ba¨ck and Schwefel, 1993; Michalewicz,
1994; Mitchell, 1998] and evolutionary programming (EP) [Ba¨ck et al., 1997; Ba¨ck
and Schwefel, 1993; Fogel et al., 1991]. Local optimisation algorithms focus on
retrieving the minimum solution closest to the current assignation of parameter
values. These algorithms usually permit to calculate a solution quickly, although
this may not be optimal. Instances of this class are Trust Region (TR) [Byrd
et al., 1987; Celis et al., 1984; Yuan, 2000], Levenberg-Marquardt (LM) [Lev-
enberg, 1944; Marquardt, 1963], Steepest Descent (SD) [Fogel et al., 1991] and
Truncated-Newton (TN) [Gill et al., 1981; Nash, 1984]. A common approach
is to perform a global optimisation and then improve the solution quality by a
local optimisation. These methods are implemented in several software tools for
1Maximum cost in the case of maximum optimisation.
2An n-dimensional manifold is a topological space having the property that the neighbour-
hood of each point approximates (formally, it is homeomorphic to), the Euclidean space of
dimension n, whereas this may not hold true globally.
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calibrating and analysing systems biology models. The models presented in this
thesis were developed using Copasi1 [Hoops et al., 2006] and the Matlab tool-
boxes Potterswheel2 [Hengl et al., 2007; Maiwald and Timmer, 2008; Raue et al.,
2009] and SBToolbox23 [Schmidt and Jirstrand, 2006]. In the case of testing dif-
ferent biological hypotheses, each corresponding to a specific network structure,
parameter estimation can be used for establishing a rank within these different
networks, based on fitting quality. The χ2 measure is sufficient to define this hy-
pothesis rank if the number of parameters is the same for each model, otherwise
other measures taking into account the number of parameters, such as Akaike in-
formation criterion (AIC) [Akaike, 1973] or Bayesian information criterion (BIC)
[Schwarz, 1978], should be adopted. This hypothesis ranking can be useful as a
means to predict likely network structure and to guide further experimental test
that could discriminate between alternatives. An example of this approach can
be found in [Sonntag et al., 2012].
4.1.4 Identifiability analysis
In parameter estimation, two problems arise depending on model structure and
data availability. The former concerns model structural non-identifiability [Balsa-
Canto et al., 2010; Bellu et al., 2007; Chis¸ et al., 2011; Raue et al., 2010, 2009].
This type of non-identifiability happens when the model structure is not suffi-
ciently mapped by the available data. For instance, if a sub-graph of the network
is over-parameterised or there are not sufficient observables characterising those
dynamics, that sub-component may result structurally non-identifiable. From a
graphical point of view, structural non-identifiability is represented in the |θ|-
dimensional χ2 space as an unlimited plateau along the dimensions of the struc-
turally non-identifiable parameters. Formally, assuming absence of measurement
noise ~ = 0, a subset of parameters η ⊂ θ is structurally non-identifiable if the
overall χ2 remains constant for each assignment a ∈ A to the parameters in η:
{∀ η := a | η ⊂ θ, a ∈ A} ⇒ χ2(θ) = const (4.5)
1http://www.copasi.org/
2 http://www.potterswheel.de/
3http://www.sbtoolbox2.org/
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In other words, the parameters in θ cannot be uniquely determined due to a lack
of observable information:
~yt,η = ~g(~xt,η, η) = ~0⇒ χ2(θ) = const (4.6)
In practical terms, if a model is structurally non-identifiable, parameter estima-
tion results are inconclusive, as infinite different solutions report the same χ2.
Structural identifiability can be solved by altering the model structure or in-
creasing the numbers of observable variables for the structurally non-identifiable
sub-graph. Among the software for testing structural identifiability, the soft-
ware GenSSI1 [Balsa-Canto et al., 2010; Chis¸ et al., 2011] was used in this thesis.
GenSSI computes the successive k orders of Lie derivatives of ~g with respect to
the vector field ~f , evaluated at the initial time t = t0. In this generating series
approach, GenSSI searches for a exhaustive summary, which is a vector of the
series coefficients, evaluated at the initial conditions, that only depends on the
model parameters to estimate and identify. Then, GenSSI uses the exhaustive
summary for computing solutions for the parameters θ. If a unique solution is
found, then the parameters are structurally globally identifiable; in the case of
multiple solutions, the parameters are structurally locally identifiable. Finally, in
the case of no solution, the parameters are structurally non-identifiable.
Although a parameter is structural identifiable, it may still be practically non-
identifiable [Raue et al., 2010, 2009]. Practical non-identifiability depends on
the amount or quality of data sets used to estimate model parameters and can
therefore be solved by increasing or improving the measured data. In case of
time-course-based experiments, this means that the collected time points are not
enough in number or that their standard deviations are too big to allow the op-
timisation algorithm to infer clear time-dependent signalling trajectories. There-
fore, practical identifiability concerns the problem of assessing finite confidence
intervals for each parameter. A parameter p is practically non-identifiable when
its confidence interval is infinite, although there may exist a unique minimum
for it. Graphically, the χ2 measured as a function of p, χ2(p), is always lower
than a desired confidence threshold ∆α, in the neighbourhood of the parameter
1http://www.iim.csic.es/∼genssi/
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minimum pm:
∀ δ ∈ R+ : {χ2(p := pm) ≤ χ2(p := pm ± δ)}, (4.7)
{χ2(p := pm − δ) < ∆α ∨ χ2(p := pm + δ) < ∆α}
This results in a deficiency in estimating a valid confidence interval for p [Kreutz
et al., 2012; Raue et al., 2010, 2009; Raue and Timmer, 2011]. A problem with this
approach regards the choice of ∆α. This threshold is defined as ∆α = χ
2(α, df),
where χ2(α, df) is the χ2-distribution with confidence level α and degrees of free-
dom df which corresponds to the number of parameter estimations. Therefore,
an accurate ∆α depends on a sufficiently large number of precise parameter esti-
mations which requires a considerable time to compute.
In this thesis, the Potterswheel plugin Mean Optimal Transformations Analysis
(MOTA) [Hengl et al., 2007] was employed for detecting functionally related pa-
rameters and therefore solving structural non-identifiability issues in relation with
data sets adopted for parameter estimation, in conjunction with a structural iden-
tifiability analysis theoretically performed using GenSSI. From a fit sequence of
parameters, the MOTA algorithm returns the tuples of highly related parameters,
permitting the user to fix independent parameters and estimate the remaining
related parameters in the reduced parameter space. These iterations of parameter
estimation and fixing may eventually terminate leading to model identifiability,
decreasing the variability of estimated parameters. In order to provide the user
a graphical intuition of identifiability issue, Figure 4.1 illustrates parameter non-
identifiability through graphical χ2 landscape surface.
4.1.5 Model simulation
Before introducing a definition for simulation and describing the operations which
can be done over a simulation, it is worth formalising the concept of algorithm.
An algorithm A is a step-by-step procedure with an internal state S which receives
an input I, performs a list of instructions evolving S and returns an output O
[Cormen et al., 2009]:
A : (I, S) −→ O (4.8)
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Therefore, a simulation can be defined as the task of reproducing a real problem,
using an algorithm [Malesani, 2004]. In this context, the interest is in simulat-
ing aspects of cellular behaviour, formally represented by mathematical models,
and collecting information related to their temporal evolution. A mathematical
model can be simulated deterministically or stochastically, depending on the type
of algorithm used for reproducing its dynamical behaviour. For a certain input, a
deterministic algorithm always returns the same output, reproducing the same in-
ternal state sequence. In other words, a deterministic algorithm does not contain
any form of randomisation. An example of these algorithm is LSODA [Hind-
marsh, 1983; Petzold, 1983]. Stochastic algorithms differ as they include some
form of randomisation, defined by a specific probability distribution, in their pro-
cedure [Wilkinson, 2006]. This randomisation can be limited to the internal state
sequence only or be propagated to the output. In the former case, a stochastic
algorithm is called Las Vegas1 (LV), whereas in the latter case the algorithm is
named Monte Carlo (MC) [Cormen et al., 2009; Motwani and Raghavan, 1995].
In the context of systems biology, the stochasticity of a biological context can
be reproduced by MC stochastic algorithms, such as Gillespie [Gillespie, 1976],
Gibson-Bruck [Gibson and Bruck, 2000], Tau-Leap [Rathinam et al., 2003] or
Runge-Kutta [Kloeden and Platen, 1999]. This is of particular importance in the
case of modelling gene transcription or low levels of protein amounts, since these
systems are highly stochastic. The major drawback of stochastic simulations is
their long computation-time as compared to deterministic simulations. For this
reason, if the system stochasticity is low, a deterministic simulation may be more
convenient for representing the dynamical behaviour of the model.
4.1.6 Sensitivity analysis
In mathematical modelling, establishing the influence of the parameters on overall
behaviour is of fundamental importance to understand which of them play a more
significant role then others [Aldridge et al., 2006]. The analysis addressing this
question is called sensitivity analysis. Sensitivity analysis is particularly useful in
several areas. For instance, the detection of irrelevant parameters on the global
1An instance of this class of algorithm is Randomised-Quicksort.
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dynamics may suggest model reduction [Jia and Yue, 2008], whereas assessing
important ones may lead to new experimental design [Cho et al., 2003]. Sensitivity
analysis offers a means to explore the robustness of a system, as it shows how
the dynamics change depending on parameter perturbation. There exist two
types of sensitivity analysis: global and local. Global sensitivity analysis aims
at retrieving multidimensional sensitivity operating multiple parameter changes.
Local sensitivity analysis aims at exploring the domain of one parameter only
and analysing the effect on the others [Marino et al., 2008].
The main concepts of sensitivity analysis are presented limiting the objective to
linear models [Saltelli et al., 2005]. A linear model can be represented as
Y =
n∑
i=1
ΩiZi (4.9)
where Y is the model output, Zi are uncertain input factors chosen from a normal
distribution Zi ≈ N(0, σZi) and Ωi are the coefficients for Zi. Y is also normally
distributed Y ≈ N(0, σY ), where σY =
√∑n
i=1 Ω
2
iσ
2
Zi
. Therefore, measuring a
normalised sensitivity of Zi over Y can be defined as:
SσZi =
σZi
σY
∂Y
∂Zi
(4.10)
In case of a non-linear model, an extension of the previous calculation of sensi-
tivity analysis based on MC methods can be found in [Cho et al., 2003; Saltelli
et al., 2008, 2005].
Sensitivity analysis can be used in combination with model simulation. In fact,
model simulations become particularly interesting when the initial conditions,
such as the initial protein amounts or input stimuli, are changed. This type
of simulation can reveal specific predictions, which can then be tested experi-
mentally. For instance, reducing the amount of a protein species corresponds
to a simulated knock-down, whereas increasing it represents a simulated over-
expression. In the field of systems biology, cases of study involving this type of
approach are [Dalle Pezze et al., 2012a; Ihekwaba et al., 2004; Mahdavi et al.,
2007; Suresh-Babu et al., 2004]. In this work, the term model perturbation will be
used to refer to a generic alteration of protein amount. Model perturbations can
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be interpreted as local sensitivity analyses performed on target species by varying
their expression level. Of course, the number of protein species perturbed is not
necessarily limited to one at a time. In fact, an advantage of systems modelling
is the possibility to compute these dry-experiments relatively easily compared to
wet-experiments in a laboratory. These predictions may reveal non-trivial dynam-
ical changes at certain time points as well as at specific protein levels. Therefore,
a biologist may use this information for reducing the number of experiments, as
models can return optimal conditions for detecting differences or similarities, and
extending biological knowledge, as models can predict completely new system
behaviours.
4.2 Advanced analyses from dynamical systems
theory
Dynamical systems theory constitutes a powerful body of knowledge which can
be used to investigate dynamical properties of the model. This section presents
some of these analyses and their importance in the study of biological models.
4.2.1 Steady-state analysis
After a certain amount of time, a system may reach a state characterised by
invariability. This state is called steady state. A definition of steady state based
on [Ay et al., 2009; Garg et al., 2007] can be proposed as follows. Let S be a
set of states. ∀si ∈ S, si is steady if and only if the following two conditions are
verified:
1. Succ(S) = S (4.11)
2. ∀ si, sj ∈ S, ∀ t ∈ T | t : si → sj,
∃ n ∈ N+finite | Prob(t(n)(si) = si) = 1
which means that (1) the set of the successors of S is equal to S, and (2) for
each visited si ∈ S the probability of re-visiting si is 1 in a finite number of state
transitions.
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In other words, a steady state corresponds to a point at which the system reaches
a condition of equilibrium or a fixed point from a mathematical point of view.
This analysis is of particular interest for biological systems in order to elucidate
the temporal length of specific dynamics and investigate the conditions leading to
these steady states. Steady-state conditions also provide scientists with a starting
point for analysing system behaviour at such states as illustrated in the following
analyses.
4.2.2 Stability analysis
An interesting question arising from the discovery of steady states in a dynam-
ical model regards the system response upon a small perturbation of a steady
state. Does this perturbed state move away from or towards its previous steady
state? The analysis pertaining to this question is called stability analysis. These
sort of questions are of particular interest in biological systems [Thomson and
Gunawardena, 2009] and highly relevant in ageing. For example, a senescent cell
can be seen as a cell staying in a specific steady state. As stochasticity increases
with ageing [Bahar et al., 2006; Finch and Kirkwood, 2000; Kirkwood, 2008], the
study of stability of a senescent steady state upon stochastic perturbations may
reveal important information about the evolution of senescent cells. To provide
an intuition of this analysis in the linear case1, let us consider an n-dimensional
linear system of ODEs2 [Hirsch et al., 2004; Parks, 1992]:
dxi
dt
= fi(x1, . . . , xn), (i = 1, . . . , n) (4.12)
and assume ~s = (s1, . . . , sn) be a steady state. Therefore:
fi(s1, . . . , sn) =
dsi
dt
= 0, ∀ i ∈ [1, n] (4.13)
This system is now perturbed by a small perturbation ~ρ = (ρ1, . . . , ρn), such that
the new perturbed state is ~s∗ = (s∗1, . . . , s
∗
n) = (s1 + ρ1, . . . , sn + ρn).
1In case of non-linear systems, this linearisation technique can still be used although not
generally.
2For simplicity, the Leibniz notation of derivative is used here.
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In order to determine whether the perturbed state ~s∗ moves away from or towards
~s, it is necessary to derive the System 4.12 at the perturbed state ~s∗.
d(si + ρi)
dt
=
dρi
dt
=
ds∗i
dt
, (i = 1, . . . , n) (by Formula 4.13) (4.14)
= fi(s
∗
1, . . . , s
∗
n) (by definition)
= fi(s1 + ρ1, . . . , sn + ρn) (by substitution)
= fi(s1, . . . , sn) +
∂fi
∂x1
(s1, . . . , sn)ρ1 + · · ·+ ∂fi
∂xn
(s1, . . . , sn)ρn + T
(Taylor series expansion)
=
∂fi
∂x1
(s1, . . . , sn)ρ1 + · · ·+ ∂fi
∂xn
(s1, . . . , sn)ρn (by Formula 4.13)
where T = O(ρn1 , ρ
n
2 , . . . , ρ1 . . . ρn) are the Taylor series higher-order terms which
can be neglected as ~H is assumed a small perturbation. Therefore, the evolution
of the perturbation is determined by the following n-dimensional linear system:(
dρi
dt
)
=
(
∂fi
∂xj
(s1, . . . , sn)
)(
ρi
)
, (i, j = 1, . . . , n) (4.15)
= J~ρ
where J is the Jacobian matrix of the System 4.12 at the fixed point ~s. At this
stage, it is necessary to calculate the complex eigenvalues λ = (λ1, . . . , λn), such
that J~ρ = λ~ρ. Let T = trace(J)1 and D = det(J), the classification for the fixed
point ~s by linear stability analysis is summarised as follows:
• Unstable fixed point (repellers or sources):
T > 0, D > 0, ∀λi ∈ λ : Re(λi) > 0
• Stable fixed point (attractors or sinks):
T < 0, D > 0, ∀λi ∈ λ : Re(λi) < 0
• Unstable fixed point (saddle points):
D < 0, ∃λi ∈ λ : Re(λ) > 0
1The trace of a square matrix is the sum of the elements located on the main diagonal.
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Additional study is required for the case in which there exist at least one eigen-
value with a null real part [Hirsch et al., 2004].
4.2.3 Bifurcation analysis
Bifurcation analysis offers a way to detect and characterise qualitative behaviour
variations around a selected steady state of a model. This leads to the inves-
tigation of signal trajectory changes by systematically exploring the domain of
one or more model parameters. In conjunction with stability analysis, bifurca-
tion analysis enables one to map the possible states of a system and how this
system can switch between them [Aldridge et al., 2006]. Biological systems are
typically characterised by multiple steady states. Therefore, understanding the
conditions by which a system transits from one steady state to another one is
important, especially when investigating biological states which are apparently
irreversible. Many age-related diseases discussed in Section 2.3 are defined by a
cellular dysregulation which denies the system to restore its normal functionality.
More generally, since ageing itself has been considered an irreversible process, it
would be interesting to investigate under which conditions, a senescent pheno-
type may resume a pre-ageing phenotype or at least remain locked at the current
state. Bifurcation analysis provides an exceptional tool for treating and possibly
answering these biological questions. Due to the large body of bifurcation theory,
this section only provides an overview of it in order to give a graphical interpreta-
tion insight of the analysis without dealing with the mathematical details. More
formal introductions of this theory can be found in [Borisuk, 1997; Hirsch et al.,
2004].
The study of bifurcations concerns the individualisation of bifurcation points
which are the points corresponding to specific parameter values at which a sys-
tem undergoes a qualitative state change. A bifurcation is said to be local if
the bifurcation point is located in the neighbourhood of a fixed point, also called
steady-state, or periodic solution, otherwise it is called global. The number of
parameters which must be specified in order to detect a bifurcation is called co-
dimension. To clarify these concepts, two instances of bifurcation are graphically
represented in Figure 4.2.
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A system containing a bifurcation b can always be reduced to its normal form,
which is the simplest system preserving b. Local bifurcations requires that the
perturbation of a parameter alters the stability of a fixed point, that is that the
real part of an eigenvalue in J passes through 01. Because of this, a common
approach when working on higher dimensional models consists of calculating the
normal form of such a model and then focusing on the eigenvectors in the centre
subspace2, ignoring the stable and unstable subspaces [Borisuk, 1997; Borisuk and
Tyson, 1998]. Conversely, a pragmatic way of mapping the states of a system is
by systematically sampling the parameter space and then looking for qualitative
differences in the phase space [Araujo et al., 2007; Wang and Krueger, 2010]. Of
course this approach is only suitable for lower-dimensional models.
4.2.4 Lyapunov exponents
When studying a dynamical system, it may be of interest to investigate qualitative
behaviour changes over time [Aldridge et al., 2006]. A measure used for charac-
terising this quantity is the vector of Lyapunov exponents. This type of analysis
allows one to determine specific attractors in the system evolution as well as the
rate of these dynamical changes. Interestingly, the determination of this rate
also provides an estimation of the rate of entropy production of the system. In
a biological context, Lyapunov exponents can be used to prove whether a bio-
logical system is stable, asymptotically stable or presents some form of chaotic
behaviour. To provide an intuition of this analysis, let us consider a reduced
system composed of two points x1(t) and x2(t) in the state space of a dynam-
ical system, assuming that they are very close together at initial time t = 0.
Therefore, the objective is to study how these two points evolve over time. The
trajectories individualised by these points diverge at a rate estimated by:
|x1(t)− x2(t)| ≈ eλt|x1(0)− x2(0)| (4.16)
1This typology of fixed points are called non-hyperbolic.
2Centres are fixed points for which the eigenvalue of J are purely imaginary. For these fixed
points, the solution within their subspace do not converge to nor diverge from them.
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where λ is a Lyapunov exponent. Since this exponent, which resembles a sep-
aration rate of trajectories, depends on the considered dimensions of the phase
space, a general dynamical system evolving in an n-dimensional space Rn will be
characterised by a spectrum of Lyapunov exponents {λ1, . . . , λn}. Moreover, as
a spectrum depends on the positions of the trajectories at time t = 0, different
spectra of Lyapunov exponents can be found by changing the initial time. There-
fore, for each reached attractor, a particular spectrum can be calculated.
Among the Lyapunov exponents of a selected spectrum, the largest one, defined
using the previous example as
lim
t→+∞
1
t
ln
|x1(t)− x2(t)|
|x1(0)− x2(0)| (4.17)
permits to obtain an overview of the global behaviour of the system, whereas
the signs of all the exponents in the spectrum provides information about the
type attractor [Parks, 1992]. In more detail, assuming that a system of the first
approximation is regular1, such as systems characterised by constant or periodic
coefficients [Kuznetsov, 2008; Leonov and Kuznetsov, 2007], if all its Lyapunov
exponents are negative, then the system is asymptotically Lyapunov stable, oth-
erwise some form of chaotic behaviour occurs [Kuznetsov, 2008; Lyapunov, 1992;
Parks, 1992]. This knowledge can be important in characterising the system
in long-term dynamics. Furthermore, it may be significant to characterise the
topologies of attractors to which a system may evolve and study how these states
mutate in presence of stochasticity.
4.3 mTOR dynamical models
Interest in the mTOR network has increased in the recent years but only few,
often incomplete, models have been developed. In this section, an overview of
these existing mTOR models are presented.
1This condition is substantial [Leonov and Kuznetsov, 2007] as shown in [Perron, 1930] by
counter-example.
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4.3.1 Model of Jain and Bhalla
In [Jain and Bhalla, 2009], the authors proposed a signalling network model in-
volving growth factors such as brain-derived neurotrophic factor (BDNF) and
neurotransmitters such as glutamate to predict mTOR activity and downstream
effects. The focus was the analysis of protein synthesis in dendrites which is
fundamental for memory formation. Their model predicted levels of protein syn-
thesis from the complex formed by eiF4F and S6, which are downstream targets
of mTORC1. Three inputs were considered: a BDNF pathway which propagates
the signal to mTORC1, metabotropic glutamate which binds to its receptor and
stimulates Akt, and ionotropic glutamate and its relative calcium (Ca2+) produc-
tion. Once calcium levels are increased, the signal activates the ERK pathway by
stimulating p21/Ras protein and MAPK, and the calcium-calmodulin type III ki-
nase (CaMKIII) by inhibiting eukaryotic elongation factor-2 (eEF2). The model
was parameterised using previously published experimental data, combined with
published models of Ca2+ and MAPK signalling.
The authors found that the protein synthesis is primarily due to the BDNF signal
and that MAPK serves to increase responses further. Three positive feedbacks
related to BDNF, 40S and eEF2 were implemented. From the introduction of
positive feedback, the authors identified bistability which is however not suffi-
cient to declare that the system exhibits an inner switch-like behaviour because
the model could not show bistability when fixed fractions of the total synthesised
proteins were considered for each kind of feedback molecule.
The implemented model was based on about 130 molecular species. However,
it does not consider mTORC2 nor any negative feedbacks. Also, the mTORC1
inhibiting-substrate protein PRAS40 is not included. The model lacks negative
signals which are common in biological systems and it appears rather unlikely
that there is no negative feedback in biological neuronal systems, since neuronal
transmission is tightly controlled.
4.3.2 Model of Vinod and Venkatesh
In [Vinod and Venkatesh, 2009], a model of mTOR activated by amino acids and
insulin growth factors (IGF) was proposed. Amino acids are necessary for the
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mTOR activity and nutrient starvation is recognised to inhibit mTOR even when
stimulated by growth factors such as insulin. In the developed model, amino acids
regulate the activity of Class III PI3K or hVps34, regulating mTORC1 and p70-
S6K. The insulin pathway involves the classic IRS1/PI3K/Akt/TSCs pathway.
The model also introduces PRAS40 and FKBP38 as mTORC1 inhibitors. The
authors mentioned mTORC2 in their model, although it is not associated with
any other protein. The insulin pathway is parameterised by using data from an
earlier more specific insulin model [Giri et al., 2004]. Other parameters are taken
from literature or assumed.
The authors found that amino acids are necessary to regulate Rheb, mTORC1
and PRAS40. In the absence of amino acids, their model predicted that an
overexpression of the GTP form of Rheb is able to achieve the same effects of a
stimulation based on amino acids.
In this ODE-based model, many parameters are assumed without any connection
with experimental data and robust experimental validation and testing of the
model predictions is missing.
4.3.3 Model of Borisov et al.
The model proposed by [Borisov et al., 2009] studies the interactions between
the insulin and epidermal growth factor (IGF and EGF), comprising positive and
negative feedbacks. The PI3K/Akt pathway is activated by either IGFR directly
or by EGFR indirectly involving the phosphorylation of Grb2-associated binder 1
(GAB1). The Ras/ERK pathway is activated directly by EGFR which can either
bind with the complex Grb2-SOS or with Shc. The same pathway can also be ac-
tivated indirectly by IRS1 binding with Grb2-SOS. There are numerous positive
and negative feedbacks from IGFR and EGFR downstreams, such as mTORC1,
GSK3 and ERK. These phosphorylate and inhibit proteins such as IRS1, Akt
and GAB1 which then interrupt or increase the signal propagation. By using
an experimental parameterisation, this model shows how insulin enhances the
activation of the MAPK/ERK pathway whenever applied in combination with
EGF. This cooperation between the two pathways is demonstrated to occur both
upstream and at the level of p21/c-Raf (Ras/Raf) level.
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The model predicts that the stimulation of insulin is only a weak indirect activa-
tor of EGF pathway. However, a synergistic effect was found in the presence of a
co-stimulation of both EGF and IGF due to crosstalk interactions. This synergy
becomes insignificant at saturating EGF levels.
The model is made of nearly 80 species and 110 reactions. In order to fit and
customise the model, data from in vitro and in vivo experiments are used in com-
bination with previously published models by the same authors. All performed
simulations of the model were deterministic. Although an explicit identifiability
analysis of the estimated parameters is missing, the authors reported numerous
model predictions opportunely validated with experimental data. This contin-
uous link between in silico and in vitro experiments is of crucial importance
in systems biology in order to increase the confidence of the model predictions.
This study therefore offers a clear example of how modelling-experimental-based
approaches should work.
4.3.4 Model of Araujo et al.
In [Araujo et al., 2007], dynamical systems properties were investigated in a re-
duced model of the TOR network. In this study, a minimal model comprising of
just IRS1, Akt and mTORC1 was generated in order to determine and map dy-
namical states of the system to healthy or cancer phenotypes. A cancer phenotype
was modelled by an hyper-activated positive feedback loop driven by Akt to the
IRS1 [Gual et al., 2005]. The authors analysed the case of no-treatment versus the
cases of single inhibitory treatments of mTOR, Akt or IRS1 by gradually perturb-
ing the input signal, represented by insulin. Therefore, their approach illustrates
network behaviours under different conditions upon parameter perturbation, us-
ing techniques based on dynamical systems theory. In case of no-treatment or
inhibition of mTOR, or IRS1, the hyper-activated positive feedback loop showed
a one-way switch represented by bi-stability at low levels of input stimulus and
by a monostable high response above a critical threshold of input level. In the
case of inhibition of Akt, the one-way switch was converted to a two-way toggle
switch (for a graphical representation of these two bifurcations, see Figure 4.2),
permitting to control the positive feedback intensity by reducing the input stim-
50
4. Systems biology for investigating mTOR network in ageing
ulus. Finally, the authors showed that these dynamical switches can be removed
by a treatment inhibiting the positive interaction between Akt and IRS11. This
treatment would act to restore the functionality of the negative feedback loop,
and a response control to different stimulus levels, changing the disease pheno-
type. Recently, Wang and Krueger [2010] showed that it is highly likely that only
two dynamical states are possible for the model defined by [Araujo et al., 2007].
This result was achieved by systematically exploring the model 6-dimensional
parameter space and mapping types of signalling responses, without using any
other experimental data sets. Although such reduced model may seem too sim-
plistic to approximate the corresponding biological TOR network, it includes the
two most important components of the network and the negative feedback loop.
Therefore, the applied abstraction is correct because it contains all the necessary
information for determining TOR regulatory mechanism, conserving the network
behaviour. This study also represents a clear example of how dynamical systems
theory can provide systems biologist with new interesting insights of a case of
study, herein a simplified TOR network.
4.3.5 Model of Caron et al.
The knowledge about the mammalian TOR network has been steadily increasing
in the last few years. Caron et al. [2010] reviewed this information in Systems
Biology Graphical Notation (SBGN) [Le Nove`re et al., 2009] and SBML [Hucka
et al., 2003] using the software CellDesigner [Funahashi et al., 2008, 2003]. In
contrast to the previous models, this work does not involve any time-course ex-
perimental data, parameter estimation or model simulation. Instead, the ob-
jective was to link all the pathways interacting with the complexes mTORC1
or mTORC2 into a single network. This integrative model comprises a total
number of 777 reactions and 964 species, incorporating the upstream and down-
stream signalling of mTOR. In more detail, the included upstream signalling
modules are growth factors, nutrients, energy, hypoxia, WNT, TNF, whereas the
downstream modules comprise autophagy, protein folding, rRNA and ribosome
1IRS1 can also activate a positive feedback loop through its downstream target PKC as
shown in 3.4.4.
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biogenesis, cap-dependent translation, mitochondrial metabolism, cytoskeleton
dynamic, transcription and cell cycle. The authors also generated a simplified
network extracting the most relevant information from their extended model and
highlighting the activation and inhibition reactions. In addition, a version is
available as a web-service1 and continuously updated. This review represents the
first attempt to reproduce the TOR network on a large scale and therefore it
undoubtedly constitutes an important achievement in systems biology.
4.4 Figures
1Web-service: http://sblab.celldesigner.org/Payao10/bin/
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Figure 4.1: Graphical visualisation of parameter non-identifiability by log10(χ
2) landscape
(darker colour correspond to parameter minimum). (A) Graphical mini-model of the insulin
receptor with an additional unknown species. In this example, the only observable species is
IR beta pY1146 which is phosphorylated by Insulin. IR beta pY1146 is responsible for the
phosphorylation of unknown species, a species for which no information is available. (B) Struc-
tural non-identifiability for the parameter regulating the phosphorylation of unknown species.
This parameter is clearly structurally non-identifiable as its dynamics are not mapped by any
data. This parameter does not affect the search of solutions in the log10(χ
2) landscape. (C)
Practical non-identifiability shown as an infinite upper bound confidence interval slightly above
the parameter minimum (see blue χ2 region on the right). (D) Parameter identifiability. The
parameter is clearly identifiable showing a well defined minimum and a confidence region. White
line indicates the convergence path to a solution in the log10(χ
2) landscape.
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A B
Figure 4.2: Graphical examples of bifurcations. (A) One-way switch bifurcation. At low levels
of input stimulus, the system shows a bistable signalling response. After reaching a critical
point, or bifurcation point, Scrit, the previous response dramatically changes into a monostable
elevated response. This signalling response is characterised by two steady states (a low one
and a high one) separated by an unstable state. However, the high steady state is the only one
which persist above a certain threshold Scrit of input stimulus, since the system is not able to
restore its signalling response to the low steady-state. (B) Two-way toggle switch bifurcation.
This type of bifurcation presents two bifurcation points, called Scrit1 and Scrit2, depending on
both the strength and history of the input stimulus. This dependency of the response on the
previous and current levels of the input stimulus represents the reason why these switches are
also called hysteresis. In contrast to the previous case, this bifurcation permits to free the
system from a constitutively activated response, since this one can be reduced by altering the
signal strength. Adapted from [Tyson et al., 2003, Fig. 1].
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Chapter 5
A dynamical network model of
mTOR signalling reveals
TSC-independent mTORC2
regulation
This chapter describes a systems biology-based investigation of mTORC2 regu-
lation as described in [Dalle Pezze et al., 2012a]. The results here focus on the
modelling point of view and only include in vitro experimental work necessary
for model validation and test. All the in vitro data included in this project were
collected by Annika Sonntag, PhD student supervised by Dr Kathrin Thedieck,
Department of Bioinformatics and Molecular Genetics, Freiburg University, Ger-
many. A copy of the published work, which includes the in vitro experimental
data used for parameterising and testing the model, is attached in Appendix A.
5.1 Introduction
In this project an insulin-mTOR network model integrating both mTORC1 and
mTORC2 was built and used to investigate alternative mTORC2 activation mech-
anisms. In contrast to mTORC1, little is known about mTORC2 upstream reg-
ulation (see Section 3.2). mTORC2 is mainly regulated by growth factors (see
Section 3.2.1), but the molecular mechanism has not yet determined.
Many substrates of mTORC2 are proteins belonging to the family of AGC ki-
nases (see Sections 3.1.3, 3.4). Using these AGC kinases as indicators of mTORC2
activity, the TSC1/TSC2 complex has been implicated in mTORC2 activation
by insulin. It was found that TSC1/TSC2 inhibition reduces phosphorylation
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of Akt at S473 [Huang et al., 2008; Huang and Manning, 2009; Huang et al.,
2009; Inoki et al., 2005], which contrasted with TSC1/TSC2 inhibition increasing
mTORC1 activity [van Veelen et al., 2011]. Two models have been proposed to
explain mTORC2 regulation by TSC1/TSC2, one involving direct mTORC2 ac-
tivation by TSC1/TSC2 [Huang et al., 2008; Huang and Manning, 2009; Huang
et al., 2009], the other by an indirect mechanism through inhibition of PI3K
in response to TSC1/TSC2 ablation via mTORC1-p70-S6K-dependent negative
feedback loop (NFL) activation [Yang et al., 2006]. However, data showing that
mTORC2 contributes to proliferation in TSC2-null cells suggests that mTORC2
can be active in the absence of TSC1/TSC2 [Goncharova et al., 2011]. A third
hypothesis for mTORC2 activation is through a PI3K-independent mechanism,
which has been identified in Dictyostelium [Cai et al., 2010; Charest et al., 2010;
Kamimura et al., 2008; Lee et al., 2010b]. Interestingly, in mammals, several
cellular processes that are regulated by mTORC2 have been described as PI3K
independent [Jacinto et al., 2004; Kamada et al., 2005; Sarbassov et al., 2004;
Worthen et al., 1994; Zheng et al., 1997].
To distinguish among the possible mTORC2 activation mechanisms and to deter-
mine whether they acted independently or in combination, a dynamical model was
developed, assuming that different modes of mTORC2 regulation would result in
distinguishable, dynamical network responses. The model was parameterised
with dynamic quantitative time course data and its predictions experimentally
validated. Then, perturbations were used to simulate and experimentally test al-
ternative network structures connecting upstream insulin signalling to mTORC2.
This approach also provided the benefit of both a structural and dynamical net-
work analysis [Papin et al., 2005].
In contrast to the previous hypotheses, TSC1/TSC2 complex was found not to
be a direct activator of mTORC2 and that mTORC2 activity was insensitive to
the mTORC1-induced NFL. Although PI3K was inhibited by the NFL, activa-
tion of the NFL-insensitive mTORC2 also required active PI3K. Therefore, none
of the three literature-based hypotheses was confirmed and we proposed a new
hypothesis that insulin signalling activated mTORC2 through a PI3K that was
insensitive to the NFL. This new model fitted all our collected experimental data.
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5.2 Results
5.2.1 Development of a dynamical insulin-TOR network
model
Initially, a static network model in SBGN format [Le Nove`re et al., 2009] of
insulin-mTOR signalling was established as a means to integrate current knowl-
edge [Cybulski and Hall, 2009; Feldman and Shokat, 2010; Garcia-Echeverria,
2011; Howell and Manning, 2011; Polak and Hall, 2009; Sengupta et al., 2010;
Zoncu et al., 2011] and as a platform to chose appropriate targets for measure-
ment (Figure 5.1). It is impractical to work with such a large network, due to the
high number of parameters and the difficulty in obtaining sufficient experimental
data under reasonable time and cost. The extended model presented in Figure 5.1
was therefore abstracted by selecting (1) regulation mechanisms with an impor-
tant role in dynamical behaviour (e.g. the activation of mTOR complexes by the
presence of both amino acids and insulin, the pathways connecting these stimuli
to the mTOR complexes, and the NFL from p70-S6K to IRS), and (2) measurable
molecules and interactions distributed across the network (Y1146-phosphorylated
IR, the S636- phosphorylated IRS1, S473- and T308-phosphorylated Akt, S2448-
and S2481-phosphorylated mTOR, T246- and S183-phosphorylated PRAS40, and
T389-phosphorylated p70-S6K). These readouts are marked with an asterisk in
Figure 5.1. This simplified network shows insulin signalling propagating from the
IR through the TSC1/TSC2 complex to the mTORC1 complex and includes p70-
S6K, PRAS40, and Akt. In addition, mTORC1 induction by amino acids was
included. At this stage, no upstream pathway regulating mTORC2 was assumed
(see Figure 5.2).
Studies suggesting that TSC1/TSC2 regulates mTORC2 commonly used Akt
phosphorylated at S473 (Akt-pS473) as an mTORC2 readout. However, Akt ac-
tivity depends on PI3K-dependent relocalisation to the plasma membrane and
subsequent phosphorylation at T308 by PDK1 and at S473 by mTORC2 [Pearce
et al., 2010]. PI3K and Akt are inhibited in the absence of the inhibitory
TSC1/TSC2 complex, due to mTORC1 and NFL hyperactivation. Consequently,
under conditions of TSC1/TSC2 deficiency and NFL activation, monitoring Akt-
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pS473 does not distinguish between PI3K, PDK1, and mTORC2 activity, and
therefore may not be a suitable readout to investigate the mode of mTORC2 reg-
ulation by TSC1/TSC2 [Huang and Manning, 2009]. Other AGC kinases that are
targeted by mTORC2 (SGK and PKC) have similar issues [Bruhn et al., 2010;
Jacinto and Lorberg, 2008]. In this study mTOR-S2481 was used as a direct
marker of mTORC2 activity in addition to using Akt-S473. Details about the
specificity of mTOR-S2481 as an mTORC2 readout for HeLa cells can be found
in [Copp et al., 2009] and in [Dalle Pezze et al., 2012a,b].
5.2.2 Parameterisation of the network model
Immunoblot-based phosphorylation time-courses for network components along
the signalling cascade were generated to parameterise the model depicted in Fig-
ure 5.2. Data were collected from HeLa cells under amino acids/insulin starvation
and restimulation conditions and quantified from 1 min up to 2 hours post in-
duction with amino acids/insulin. The model parameters were estimated using
the mean time course, computed from four time-course repetitions (Figure 5.3).
The initial concentrations of the species in their non-phosphorylated state were
determined directly from these semi-quantitative data (see Section 5.4.1). For all
other species, the initial concentrations were set to 0.
Due to the known difficulty in calibrating a large number of parameters from the
data [Chen et al., 2010; Moles et al., 2003; Zhan and Yeung, 2011], in this case
kinetic rate constants, parameter estimation was divided into calibration phases
(see Figure 5.4). In Phase 1 of the parameter estimation, isolated modules that
could be calibrated independently within the network, were identified. Because
the IR regulation was not affected by the rest of the network, the 3 parame-
ters governing the kinetics of IR activation by insulin, dephosphorylation to a
refractory state and transition to a receptive state could be isolated and inde-
pendently calibrated. In Phase 2, due to the lack of knowledge about mTORC2
upstream, a model that was independent of the pathway by which mTORC2 was
activated, was generated. The regulation of the mTORC2 substrate Akt-S473
and mTORC2 component mTOR-S2481 were temporarily modelled with two
auto-activation mechanisms, which were then calibrated using Akt-pS473 and
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mTOR-pS2481 experimental datasets. This guaranteed to reproduce Akt-pS473
activation while maintaining mTORC2 isolated from the network. During Phase
2, a total of 24 reaction rate constants were estimated using eight experimental
readouts. Finally, in Phase 3, the autoactivation mechanism of Akt-pS473 was re-
placed with a phosphorylation mediated by mTORC2-pS2481. Because the initial
induction of Akt-pS473 occurred before mTOR-pS2481 was induced (see Figure
5.3), mTORC2-pS2481 alone could not completely reproduce the dynamics of
the experimental data for Akt-pS473. mTORC2 is not the only PDK2 candidate
that may phosphorylate Akt-S473; therefore, an additional PDK2 species was
introduced and parameters governing the phosphorylation of Akt-S473 under the
influence of the two kinases, were re-estimated. In this phase, three kinetic rate
constants were estimated using the Akt-pS473 experimental data.
Each of these phases was resolved using an iterative procedure (see Figure 5.5).
This procedure is summarised by the following steps:
1. The initial values of the parameters that needed optimisation were assigned
by random generation;
2. the calibration was repeated until a set of parameters with consistent values
was identified;
3. this set of parameters was fixed and the remaining free parameters were
calibrated again by repeating the process.
Once this process of parameterisation was complete, the simulated time courses
matched the experimental data for all the analysed mTOR network readouts
(Figure 5.3). The ordinary differential equations (ODEs) and estimated parame-
ters for the general model are provided in Tables 5.1-5.2. Identifiability analysis,
which indicates whether the parameters can be estimated with confidence from
the available data, and sensitivity analyses, which indicates how sensitive model
behaviour is to variation in each parameter, for the general model are shown
in Figures 5.6-5.7. Importantly, the identifiability analysis did not show high
correlation between estimated parameters indicating that they could indeed be
identified.
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5.2.3 Validation of the mTORC1 branch
If a parameterised model correctly represents the biological mTOR network dy-
namics in response to amino acids/insulin, model simulations must accurately
reflect the dynamics of known network responses to a gradual perturbation. To
validate the mTORC1 branch of the model, the network was perturbed by gradu-
ally inhibiting mTORC1 first in silico, and then experimentally by Raptor knock
down (shRaptor). The model was used to simulate the effect of gradual mTORC1
inhibition on the activation dynamics of the direct mTORC1 substrate p70-S6K-
pT389, at several time points after induction with amino acids/insulin.
The model predicted a constant increase in p70-S6K-pT389 signal from 10 min
to 2 hours after induction. Furthermore, the model also predicted that p70-S6K-
pT389 would decrease starting 10 minutes after induction in a near linear manner
in response to gradual Raptor (mTORC1) inhibition, whereas there should be no
detectable increase or Raptor-dependent change in p70-S6K-pT389 below 5 min
after induction (see Figure 5.8A). This simulated quantitative p70-S6K-pT389
response upon gradual mTORC1 inhibition (see Figure 5.8B) was experimentally
validated (see Figure 5.8, C and D) at 3, 20 and 45 min, also indicated in the
simulation in Figure 5.8A by the green lines. The simulations (Figure 5.8B) and
the experimental results (Figure 5.8D) monitoring p70-S6K-pT389 activity in re-
sponse to gradual Raptor inhibition at 20 and 45 min after induction with amino
acids/insulin consistently showed an overall increase in signal at 45 min and no
signal at 3 min after induction.
Therefore, the model accurately reproduced the dynamic behaviour of the mTORC1
substrate p70-S6K-T389 upon gradual mTORC1 inhibition.
5.2.4 Alternative models of mTORC2 regulation by TSC1/-
TSC2
Two alternative mechanisms of TSC1/TSC2-dependent regulation of mTORC2
have been suggested: either direct activation or indirectly through mTORC1 and
NFL [Huang et al., 2008, 2009; Yang et al., 2006]. Since the different suggested
molecular mechanisms by which TSC1/TSC2 regulates mTORC2 should result
in mechanism-specific changes in the dynamics of the mTORC2 readouts, the
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response of the readouts to network perturbations should be predictable and
distinguishable through dynamical modelling.
On the basis of the existing literature, we postulated three different hypotheses
for the molecular connection, or lack thereof, between TSC1/TSC2 and mTORC2
(see Figure 5.9):
Hypothesis 1 (TSC-dependent): TSC1/TSC2 directly activates mTORC2 in
response to insulin, and has opposite effects on mTORC1 and mTORC2
Hypothesis 2 (NFL-dependent): mTORC2 is activated by insulin through
PI3K, but independently of Akt and TSC1/TSC2, however mTORC2 ac-
tivity can be inhibited indirectly by TSC1/TSC2 ablation through NFL-
mediated inhibition of PI3K;
Hypothesis 3 (PI3K-independent): mTORC2 is activated by insulin in a
manner that is independent of both TSC1/TSC2 and PI3K.
These hypotheses were directly implemented into the established model, re-using
the same kinetic parameters. To keep the hypotheses as comparable as possible,
each hypothesis shared the network topology of this general model but assumed
a specific mTORC2 upstream regulator according to each hypothesis (see Figure
5.9). These kinetic parameters regulating mTORC2 were re-estimated according
to each hypothesis (see Tables 5.1, 5.3). The total goodness-of-fit for the general
model and each hypothesis showed that no model could be statistically rejected
(see Table 5.4), in accordance with the following:
Lemma 1. Let M be a model correctly parameterised with some data1 and s a
species in M. If a modifier f directly upstream of s is selected and re-calibration
solely of the dynamics of s maintains a close fit between the simulated time course
for s and the experimental data for s, then all the time course curves downstream
of s will continue to fit their corresponding data.
Proof. Let U be the set of the upstream species of f (U = {upstream species(f)})
and D be the set of the downstream species of d (D = {downstream species(s)})
1This assumes that the model parameters are structurally and practically identifiable (see
Section 4.1.4).
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by applying a cut of the feedback loops. Depending on the existence of a feedback
loop connecting an arbitrary species d ∈ D to an arbitrary species u ∈ U , there
exist two cases.
Case 1: @ d → u | d ∈ D, u ∈ U . After model re-calibration, the time-course of
f remains unchanged and the time-course of s is not affected by the dynamics of
the network. Since the simulated time course of s still fits the experimental data
for s by hypothesis, the signalling cascade from s does not significantly differ,
maintaining the fitting of the species in D with their corresponding experimental
data.
Case 2: ∃ d → u | d ∈ D, u ∈ U . In this case, the time-course of f is also
modulated by some d ∈ D and s dynamics are therefore affected by the network.
However, f can be interpreted as downstream target of s beyond the application
of the cut. Thus, for the previous case, the simulated time course of f maintains
the fit with its corresponding experimental data.
For each hypothesis, time course simulations and experimental validation for
the mTORC2 readouts mTOR-pS2481 and Akt-pS473, the PI3K readout Akt-
pT308, and the mTORC1 substrate p70-S6K-pT389 (see Figure 5.10) were per-
formed. The curves for all other analysed network components are provided in
Figure 5.11. The simulations matched the experimental time courses, indicating
that the hypotheses were compatible with the observed dynamics for mTORC2
activation and more generally for the mTOR signalling network. Further experi-
mental validation of these models for the mTORC1 branch, monitoring p70-S6K-
pT389 can be found in [Dalle Pezze et al., 2012a, Fig. 7A]. Identifiability and
sensitivity analyses for the three models representing each hypothesis are shown
in Figures 5.12-5.17.
5.2.5 Perturbations of alternative models of mTORC2 reg-
ulation
As independent parameter estimation for the three models could not clearly reject
any of the previous hypotheses, gradual network perturbations of TSC1/TSC2,
the NFL (through perturbation of mTORC1), or PI3K were computationally
applied and then experimentally tested. The idea was that the hypotheses might
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have been rejected by first perturbing the respective upstream modulators of
mTORC2 as determined for each hypotheses for each model and then finding
experimental inconsistencies with the predicted perturbations. In formal terms:
Definition 1. Let t : f → s | f, s ∈ Species be a connection. Then, t is
said correct if it can be experimentally proved. t is said incorrect if it can be
experimentally negated.
Lemma 2. Let us assume the conditions established in Lemma 1 and that all
the connections besides the connection t : f → s for a model M correctly param-
eterised with some data, are experimentally correct. If the introduced upstream
connection t is correct then the model output following perturbation of f will nec-
essarily maintain a fit with the corresponding data. Instead, if t is incorrect, then
the model output following perturbation of f will not necessarily maintain a fit
with the corresponding data.
Proof. This lemma shows a semi-decidability property for model rejection.
Case 1: t is correct. Then, a simulated perturbation of f is consistent with the
corresponding data upon experimental perturbation of f , since the model was
correctly parameterised.
Case 2: t is incorrect. Then, a simulated perturbation of f may or may not be
consistent with the corresponding data upon experimental perturbation of f . In
fact, if this is not consistent, then the network can be clearly rejected. Instead,
if the prediction is still consistent, then nothing can be asserted with such a
simulated perturbation and further testing is required. Instances of this case can
arise due to model abstraction or multiple input besides f to s.
From Lemma 2, a tool for rejecting a model was formalised in case of detection
of model inconsistency with some data upon perturbation.
In this study, the connection t referred to as the link from a kinase regu-
lating mTORC2 and mTORC2 itself. For each of the three perturbations and
each of the three hypotheses, the dynamical network response of the readouts
of mTORC2-pS2481 activity (see Figure 5.18), Akt-pS473 activity (see Figure
5.19), Akt-pT308 activity (see Figure 5.20), and p70-S6K-pT389 activity (see
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Figure 5.21) were detected. These simulated perturbations unambiguously distin-
guished network behaviour, indicating specific experimental testing treatments,
and highlighted time points in which these differences occurred (see green lines
in Figures 5.18-5.19).
5.2.6 Predictions and experimental testing of mTORC2
regulation
Prediction and testing for Hypothesis 1
The models predicted that for gradual TSC1/TSC2 inhibition, if Hypothesis 1 was
correct, then the abundance of mTOR-pS2481 would be affected by TSC1/TSC2
inhibition in a linear manner down to minimum levels (Figure 5.18). In contrast,
for Hypothesis 2, simulated mTOR-pS2481 dynamics were only slightly affected
by TSC1/TSC2 inhibition, and for Hypothesis 3, mTOR-pS2481 was not affected
(Figure 5.18). For Akt-pS473 dynamics, the phosphorylation should only be af-
fected after 5-10 minutes since the PDK2 candidates are modelled as independent
of TSC1/TSC2. If Hypotheses 2 or 3 are correct, then Akt-pS473 should exhibit
a gradual decrease starting 10 min after induction for the rest of the time course
(Figure 5.19). For Hypothesis 1, the model predicted a stronger reduction of Akt-
pS473 in response to TSC1/TSC2 inhibition, compared to the reduction predicted
for Hypothesis 2 or 3. Thus, these simulation results indicated that observation of
mTOR-pS2481 in response to gradual TSC1/TSC2 inhibition should effectively
distinguish Hypothesis 1 from the two other hypotheses.
Quantifications for Akt-pS473 and mTOR-pS2481 at 60 min after amino acids/
insulin induction are shown for the simulations of the three hypotheses, and
for the experimental data in Figure 5.22A. The time course analysis on Akt-
pS473 suggested that Hypothesis 2 or 3 may be correct. Hypothesis 1 (direct
TSC1/TSC2 activation of mTORC2) was clearly excluded because the reduction
in mTOR-pS2481 activity upon TSC2 inhibition was not statistically significant.
For experimental details, see [Dalle Pezze et al., 2012a, Fig. 6].
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Prediction and testing for Hypothesis 2
For gradual mTORC1 inhibition and consequent NFL inhibition, the models pre-
dicted an increase of Akt-pS473 with decreasing mTORC1 activity (Figure 5.19).
The simulations also predicted that mTOR-pS2481 would remain unaffected in
Hypotheses 1 and 3, and would gradually increase in response to mTORC1 inhi-
bition in Hypothesis 2 starting 40 min after induction with amino acids/insulin
(Figure 5.18). This effect should be clearly experimentally visible at 100 min
after induction with amino acids/insulin and this paradigm could be used to dis-
tinguish Hypothesis 2 from the other hypotheses.
Quantifications for Akt-pS473 and mTOR-pS2481 in response to gradual Raptor
inhibition are shown in Figure 5.22B. The time course analysis on Akt-pS473
suggested that all three hypotheses may be correct. Hypothesis 2 (indirect
TSC1/TSC2 activation of mTORC2 by NFL) was clearly excluded because no
increase in mTOR-pS2481 activity upon Raptor inhibition was detected as sta-
tistically significant. For experimental details, see [Dalle Pezze et al., 2012a, Fig.
7].
Prediction and testing for Hypothesis 3
For gradual PI3K inhibition, all the three models predicted strong reduction in
Akt-pS473 levels (Figure 5.19). In contrast, the models predicted that mTOR-
pS2481 (Figure 5.18) would remain either unaffected by PI3K inhibition (Hy-
pothesis 1, 3), or to decline with decreasing PI3K starting 20 min after induction
(Hypothesis 2).
Quantification for Akt-pS473 and mTOR-pS2481 at 30 min after induction with
amino acids/insulin are shown in Figure 5.22C). The time course analysis on
Akt-pS473 suggested that all the three hypotheses may be corrected. Hypothesis
3 (PI3K-TSC1/TSC2-independent activation of mTORC2) was excluded since
mTORC2 was inhibited by the PI3K inhibitor Wortmannin. For experimental
details, see [Dalle Pezze et al., 2012a, Fig. 8].
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5.2.7 A novel hypothesis of mTORC2 activation
The results reported in Section 5.2.6 showed that mTORC2 was not regulated by
TSC1/TSC2 or the NFL, whereas it was activated by insulin in a PI3K-dependent
manner. Since mTORC2 regulation was independent of NFL, the PI3K involved
in mTORC2 activation had to be IRS1 independent. It is well known from lit-
erature that several isoforms of PI3Ks exist and only some of them bind with
IRS1. Therefore, it is reasonable that a PI3K isoform independent of IRS may
be responsible of mTORC2 regulation. This new hypothesis, referred to as Hy-
pothesis 4, was implemented into a model (see Figure 5.23). This model did not
require recalibration, because the new branch for mTORC2 activation by insulin
was similar to the PI3K-independent Hypothesis 3, but contained the new pro-
posed PI3K, which is sensitive to Wortmannin and independent of the NFL.
The simulated time courses of this new model matched all the available exper-
imental data presented in this study (see Figure 5.24A for mTOR-pS2481 and
Akt-pS473 and Figure 5.25A for all other readouts). For each of the three net-
work perturbations (gradual TSC1/TSC2, mTORC1, or PI3K inhibition), the
predictions for all readout dynamics (see Figures 5.24A-D, 5.25B) matched the
experimental data (Figures 5.22). Additional model validation for mTORC2 ac-
tivity was performed by mTORC2 and mTORC1 knock down, experimentally
obtained by Rictor and Raptor knock down respectively, at 20 minutes after
amino acids/insulin induction, showing a close match with the experimental data
(see Figure 5.26). This last result was published in [Dalle Pezze et al., 2012b].
Identifiability and sensitivity analyses for Hypothesis 4 are shown in Figures
5.27-5.28. The identifiability analysis reports low correlation between the esti-
mated parameters, indicating that the parameters can be identified. Thus, the
new model representing mTORC2 induced by a PI3K-variant species indepen-
dent of NFL and IRS1 accurately predicted the responsiveness of mTORC2 to
PI3K inhibition, and mTORC2 insensitivity to gradual TSC1/TSC2 or mTORC1
inhibition.
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5.3 Discussion
This work presents the development of a computational model of the TOR net-
work, whose parameters were estimated by immunoblot-based semi-quantitative
time-course data. From this model, three hypotheses of mTORC2 activation
based on literature were investigated: (1) mTORC2 was directly activated by
complex TSC1/TSC2; (2) mTORC2 was indirectly activated by complex TSC1/TSC2
through the NFL; (3) mTORC2 activation was independent of complex TSC1/TSC2
and NFL. This current confusion in the literature concerning the modalities of
mTORC2 activation was mainly due to the use of mTORC2 substrate Akt-S473
as readout of mTORC2 activity [Huang et al., 2008, 2009; Yang et al., 2006]. How-
ever, Akt is involved in the NFL induced by p70-S6K to IRS1 and therefore it is
not a reliable candidate for monitoring mTORC2 activity. In this study we used
mTOR-S2481 in addition to Akt-S473, as readouts of mTORC2 activity. mTOR-
S2481 was previously shown to be a specific marker for mTORC2 activity [Copp
et al., 2009] and we also validated it in this study [Dalle Pezze et al., 2012a,b].
For each hypothesis, a dynamical model was derived from the generic one (see
Figures 5.2, 5.9). Since the parameter estimation for each derived-model does not
allow rejection of any hypothesis, model perturbation analysis was conducted by
varying the levels of mTORC2 input candidates. Perturbations of TSC1/TSC2,
mTORC1 and PI3K were selected for predicting differential network behaviours
and the specific time points at which these differences were maximised. These
predictions clearly indicated experimental modes of intervention for testing the
three hypotheses. By experimental testing of the model predictions, all three hy-
potheses were rejected. Surprisingly, the PI3K inhibitor Wortmannin was found
to inhibit mTORC2. Since mTORC2 was proved independent of the NFL in test-
ing Hypothesis 2, and mTORC2 levels were reduced less than Akt levels upon
Wortmannin treatment, it appeared that mTORC2 could be activated in an NFL-
independent and PI3K-dependent manner. This new pathway (Hypothesis 4) was
implemented in a new model which was shown to be consistent with all the gen-
erated experimental data.
Dynamical modelling has been used extensively in the study of cell signalling
networks, yielding many important insights related to cellular behaviour [Kholo-
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denko, 2006]. Here we use dynamical modelling to discriminate among alternative
network structures, in particular alternative modes of mTORC2 regulation. Oth-
ers have used similar approaches to study the possible network structures for the
segment polarity gene network [von Dassow et al., 2000] and the extracellular
signal-regulated kinase pathway [Xu et al., 2010]. Although network testing can
be performed using a Bayesian statistical approach [Xu et al., 2010], we chose to
perform experimental testing to distinguish among the proposed network topolo-
gies, because our simulated conditions and outputs were experimentally tractable.
This work differs from earlier studies [Huang et al., 2008; Huang and Manning,
2009; Huang et al., 2009] due to the inclusion of a direct readout for mTORC2 ac-
tivity (mTOR-S2481) and in using a combined modelling-experimental approach.
The modelling enabled us to predict network hypothesis dynamics and define a
precise experimental plan to test these predictions. Through this methodology of
hypothesis-modelling and experimental testing, a new PI3K-mTORC2 pathway,
which was not previously discovered, was hypothesised and confirmed by several
experimental tests.
In the tasks of data collection and parameter estimation, Akt regulation showed
a high degree of complexity which is largely overlooked in other insulin signalling
modelling studies. Model parameterisation revealed more complex dynamics for
mTORC2’s target site S473 in the AGC kinase Akt than for S2481 in mTOR,
and this could not be explained exclusively by mTORC2 activation. To integrate
Akt-pS473 dynamics into the dynamic network model, a second PDK2 that ac-
counted for the early peak of Akt-pS473 at 3 min after induction with amino
acids/insulin (Figure 5.3) was considered. This need arose since, in addition to
mTORC2, various other PDK2 candidates for Akt have been reported, including
DNA-PK [Bozulic et al., 2008; Feng et al., 2004], ILK [Troussard et al., 2003],
ATM [Viniegra et al., 2004], MAPKAPK-2 [Rane et al., 2000], PKC [Kawakami
et al., 2004; Partovian and Simons, 2004], Pak1 [Mao et al., 2008b], and even Akt
autophosphorylation [Toker and Newton, 2000], any of which may contribute to
Akt-pS473 dynamics under different metabolic conditions.
This model implements the NFL as induced by p70-S6K which phosphorylates
and degrades IRS. However, this is not the only negative feedback in the insulin-
TOR signalling. For example, mTORC1 activation leads to GRB10-dependent
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IR inhibition [Hsu et al., 2011; Yu et al., 2011]. Although the identification of
GRB10 as a contributor to the NFL is mechanistically relevant, the effect is the
same, namely the inhibition of IRS in response to mTORC1 activity, and is read-
ily detected by the reduction of Akt-pT308 upon high mTORC1 activity. Given
the need to reduce the complexity of our model to enable parameterisation, we
did not introduce such mechanisms separately into our model, but combined them
into one step.
In this work, a new PI3K, independent of IRS and NFL, was found to mediate the
insulin signalling from the insulin receptor to mTORC2. Interestingly, previous
studies detected PI3K activity in cells lacking IRS [Myers, Jr et al., 1994; Peruzzi
et al., 1999], or PI3K activation in part by direct binding with the insulin receptor
[Horn et al., 1994]. Therefore, it could be that an IRS-independent PI3K may
be responsible for propagating alternative insulin signalling in order to activate
mTORC2. In this study, a maximum Wortmannin concentration of 100nM was
used to inhibit PI3K and this level was reported to inhibit class I PI3Ks only
[Brunn et al., 1996]. Particularly, we showed that a Wortmannin concentration
of 20nM was sufficient to inhibit mTOR-pS2481 and this furthermore confirmed
mTORC2 dependency on class I PI3K, in agreement with other studies [Peterson
et al., 2000; Soliman et al., 2010]. Despite the identification of class I PI3Ks, for
this class, there are at least seven alternative regulatory subunits and four alterna-
tive catalytic subunits, and specific combinations of these subunits may mediate
different physiologic outputs. Therefore, the existence of an NFL-independent
class I PI3K is conceivable and requires further investigation.
In conclusion, the discovery of mTORC2 activation by an IRS-independent PI3K
means that a new perspective of the insulin signalling network is required. This
study is also of importance for developing new drugs in cancer and ageing re-
search. Due to the complexity of the TOR network, this work showed the high
impact that mathematical modelling can have on biology by formalising hypothe-
ses, predicting outcomes and offering modalities of interventions to test these
predictions. Importantly, despite being an abstraction of the insulin-TOR net-
work, model simulations mathematically showed that the simplified system was
sufficient to explain the experimental observations. Finally, the model provides a
resource for future work and other modelling efforts can extend and build upon
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it, as well as provide a framework on which pharmacological interventions can be
tested.
5.4 Materials and methods
5.4.1 Modelling
CellDesigner 4.2 [Funahashi et al., 2008, 2003] was used to construct the model
network topology in SBGN [Le Nove`re et al., 2009]. COPASI 4.7.34 [Hoops et al.,
2006] was used for all deterministic simulations, parameter estimations, param-
eter scanning and sensitivity analysis. The deterministic simulation algorithm
(LSODA) was configured with parameters: Duration (1440), Interval Size (1),
Intervals (1440), Integrate Reduced Model (0), Relative Tolerance (1e-06), Ab-
solute Tolerance (1e-12), Max Internal Steps (10000). The algorithm used for
parameter estimation was Simulated Annealing [Corana et al., 1987; Kirkpatrick
et al., 1983], configured with parameters: Start Temperature (1), Cooling Factor
(0.85), Tolerance (1e-06), Random Number Generator (1), Seed (0). The param-
eter estimation weight method was Mean Square and the experiment type was
Time Course. The initial concentration of the species in non-phosphorylated state
was fixed to the maximum intensity of the third quantile time course, computed
from the four experimental datasets, of the corresponding experimental phospho-
rylated protein. This ensured that the modelled kinases did not saturate their
substrates and that the level of concentration of the substrates remained small.
The initial concentration of the species in any other state was fixed to 0. The
initial concentration of PDK2 was assumed equal to the concentration of the beta
subunit of the IR because the two species are directly connected in the model. In
the absence of experimental data for the TSC complex, the initial concentration
was assumed to be 10. The models were formalised using only mass action reac-
tions. For each phase, the kinetic rate constants were estimated by running 350
independent calibrations, each initialised with a random initial configuration of
the parameters. The parameter values were constrained within the interval [1e-
04, 1], except for the Akt parameters, which were constrained within the interval
[1e-04, 10]. For each calibration phase (F ), the solutions of the estimations con-
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sistent with the data and achieving the lowest root mean square error (RMSE)
were selected as the best solutions set (BS). Among these, the solution closest
to the centroid of the BS cluster in the parameter space was selected using the
following formula:
argmin
S∈BSF
N∑
i=1
(S(pi)− µi)2 (5.1)
with:
BSF =
{
x | ∀y ∈ AllSolutions,
RMSE(Model(x), Data) ≤ RMSE(Model(y), Data)
}
where pi, is the i
th estimated parameter in S, µi is the i
th parameter mean com-
puted from BSF and N is the number of estimated parameters.
Model identifiability based on correlation analysis of sensitivity trajectories was
calculated using SBToolbox2 and SBPDToolbox [Schmidt and Jirstrand, 2006]
for MATLAB. SBMLToolbox 4.0.1 [Keating et al., 2006] was used to import our
SBML [Hucka et al., 2003] models into SBToolbox2. Identifiability analysis tables
for the general model and the four hypotheses models are depicted in Figures 5.6,
5.12, 5.14, 5.16 and 5.27.
All parameter values for the final models are given in Tables 5.2-5.3. The sensi-
tivity analysis algorithm was configured for time series with parameters: Delta
Factor (0.001) and Delta Minimum (1e-12) (Figures 5.7, 5.13, 5.15, 5.17, 5.28).
Models were exported in SBML Level 2 Version 4 using Copasi and CellDesigner.
The latter was used to generate the extended mTOR network model in SBGN
graphical notation.
5.4.2 Statistics
The statistical and programming language R v.2.12.1 [R Development Core Team,
2010] was used to calculate the statistics and generate the plots of this study.
The Standard Error of the Mean (SEM) was chosen to estimate the statistical
variability of the measured samples of experimental time course. Model goodness-
of-fit was defined by computing Akaike information criterion [Akaike, 1973] and
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χ2 calculated as in Formulae 4.3 and 4.4. For the general model and the four
hypotheses, χ2 and Akaike information criterion measures are provided in Ta-
ble 5.4. Tukey’s Honest Significant Differences (HSD) test, in conjunction with
one-way analysis of variance (ANOVA), was used as statistical test for multiple
comparisons among groups of experimental data.
5.5 Figures and tables
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Figure 5.1: A static network model of TOR signalling stimulated by amino acids plus insulin is
shown in SBGN notation. This model integrates the current knowledge and guided our decision
on appropriate targets for measurement. The selected targets are marked with an asterisk.
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Figure 5.2: An insulin/mTOR network graphical model. Reduced graphical model of the mTOR
network activated by amino acids/insulin (see Figure 5.1 for the extended graphical model).
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Figure 5.3: Development of a dynamic insulin/mTOR network model. Comparison between
the simulated time courses of the general model (solid lines) and the experimental time courses
(points, dotted error bars) within [0, 120] min. For each curve, the χ2 computed over n
time points, is reported as goodness-of-fit measure. Experimental data based on quantitative
immunoblotting time course by measuring phosphorylation dynamics of central network com-
ponents (four replicates). In vitro experiments were performed by Annika Sonntag, Freiburg
University, Germany.
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Figure 5.4: Phases of the calibration process. The approach for defining our model was hierar-
chical and structured in two main parts. Part 1 (Phases 1-3) was the development of a general
model without regulation of mTORC2 and Part 2 (Phases 4-7) was the introduction of specific
hypotheses for regulation of mTORC2. In Phase 1, the kinetic rate constants of the insulin
receptor were calibrated independently because the insulin receptor module was not regulated
by the rest of the network. In Phase 2, the kinetic rate constants for the model representing the
entire network without PDK2 were calibrated, assuming that the phosphorylation dynamics of
mTOR-S2481 and Akt-S473 dynamics were regulated by autoactivation. In Phase 3, PDK2
was added to the network and the autoregulation mechanism controlling phosphorylation of
Akt-S473 was replaced with the regulation by both mTORC2 and PDK2. Part 2 (Phases 4-
7) of the calibration process concerned the introduction of the three hypotheses (Hypothesis
1,2, and 3) for mTORC2 activation from the general model defined in Part 1 (Phase 3). The
development and calibration of these hypotheses only required substitution of the mTORC2
dynamics of the general model with the specific regulation of the corresponding hypothesis and
then recalibration of these new kinetic parameters. In Phase 7, Hypothesis 4 was obtained
from the PI3K-independent model by transforming the unknown kinase into one dependent on
Wortmannin, which did not involve further calibration.
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Figure 5.5: Detail of a calibration phase. The flow chart shows the details of the parameter
calibration procedure. The procedure began with the selection of the set of parameters to
estimate. After completing the calibrations, the procedure selected the subset of the solutions
that obtained the minimum root mean square error (best solutions). The closest solution to
the centroid of the best solution cluster was selected and the values common to all the solutions
were fixed. All the parameters that were not fixed were selected for the next step of calibration.
The procedure terminated when there were no further parameters to calibrate. In the model
calibration, all the parameters were identified in only one iteration step.
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Figure 5.6: Identifiability analysis for the general model. Parameter identifiability is based on
sensitivity analysis and parameter correlation as computed by SBPD Matlab Toolbox. The
symmetric matrix shows the parameter correlation in absolute values. High parameter corre-
lations suggest potential issues in identifying the corresponding parameters independently (the
elements on the diagonal obviously have correlation equal to 1). Conversely, low parameter
correlations indicate that the corresponding parameters can be identified independently. Our
experimental data were used in computing the reported identifiability analysis.
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Figure 5.7: Sensitivity analysis for the general model. The top plot illustrates the sensitivity
analysis of the model by row, in response to the perturbations of the kinetic rates constants
shown in columns. The bottom plot shows the model sensitivity analysis of the initial con-
centrations of the modelled species by row with perturbations shown in columns. Values were
normalised in the range [-1, 1]. Positive values (red squares) represent positive regulation;
negative ones (white-blue squares) represent inhibition.
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Figure 5.8: Validation: dynamic response of p70-S6K-pT389 to gradual Raptor inhibition. (A)
Model predictions for p70-S6K-pT389 dynamics in response to a perturbation of mTORC1.
The curves show the simulated response to gradual mTORC1 inhibition starting at 5-10 min-
utes after induction with amino acids/insulin. The model was simulated with both mTORC1
overexpression and knockdown conditions. Time points for experimental validation are indi-
cated by green lines. (B) Simulated and quantified relative amounts of p70-S6K-pT389 under
conditions of mTORC1 reduction (0, 25, 50, 75, 100 %) at selected time points after induction
with amino acids/insulin. (C) Experimental validation of the effect of gradual Raptor knock-
down (shRaptor) on p70-S6K phosphorylation in starved cells induced with amino acids/ins for
the indicated times. Data are representative of 3 experiments. d = days. (D) Experimentally
determined and quantified p70-S6K-pT389 amounts at the indicated times after induction with
amino acids/insulin in cells in which Raptor was knocked down. Data are the average and SEM
of 3 experiments. * P < 0.05, ** P < 0.01; low Raptor levels compared to high Raptor
levels after 20 min and 45 min induction, 20 min compared to 45 min induction. Differences
in p70-S6K-pT389 were significant. In vitro experiments were performed by Annika Sonntag,
Freiburg University, Germany.
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Figure 5.9: Three different hypotheses on mTORC2 regulation by insulin (graphical model).
Reduced graphical network model including the three hypotheses (1, 2, 3, indicated by the
dotted lines), translated into different network structures.
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Figure 5.10: Three different hypotheses on mTORC2 regulation by insulin (dynamical mod-
els). Comparisons of simulated time courses, calibrated for each hypothesis, with experimental
data. Data shown are for mTORC2 readouts (mTOR-pS2481, Akt-pS473), the PI3K read-
out Akt-pT308, and the mTORC1 readout p70-S6K-pT389 (see Figure 5.11 for curves of all
other readouts). In vitro experiments were performed by Annika Sonntag, Freiburg University,
Germany.
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Figure 5.11: Comparison between the simulated and experimental time-courses for Hypothesis
1, 2, and 3 for readouts of the mTOR network. The three hypotheses were consistent with each
other for all the readouts indicating that introducing each hypothesis into the general model
did not perturb the network. NFL = Negative Feedback Loop. In vitro experiments were
performed by Annika Sonntag, Freiburg University, Germany.
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Figure 5.12: Identifiability analysis for Hypothesis 1: TSC1/TSC2-dependent mTORC2 reg-
ulation. Parameter correlation matrix for TSC1/TSC2-dependent hypothesis is shown. See
Figure 5.6 for details.
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Figure 5.13: Sensitivity analysis for Hypothesis 1: TSC1/TSC2-dependent mTORC2 regula-
tion. The sensitivity analyses of the three hypotheses (see Figures 5.15 and 5.17) showed a
similar sensitivity analysis excluding the sensitivity for the parameters characterizing each spe-
cific hypothesis. This provided evidence that the proposed general model (common to the three
hypotheses) behaved in a consistent manner following introduction of the three hypothetical
models and, therefore, the three models were comparable. See Figure 5.7 for details of the top
and bottom plots.
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Figure 5.14: Identifiability analysis for Hypothesis 2: NFL-dependent mTORC2 regulation.
Parameter correlation matrix for NFL-dependent hypothesis is shown. See Figure 5.6 for details.
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Figure 5.15: Sensitivity analysis for Hypothesis 2: NFL-dependent mTORC2 regulation. Sen-
sitivity analysis for the initial concentrations and the kinetic rates parameters for the NFL-
dependent hypothesis is shown. See Figure 5.7 for details of the top and bottom plots.
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Figure 5.16: Identifiability analysis for Hypothesis 3: PI3K-independent mTORC2 regulation.
Parameter correlation matrix for PI3K-independent hypothesis is shown. See Figure 5.6 for
details.
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Figure 5.17: Sensitivity analysis for Hypothesis 3: PI3K-independent mTORC2 regulation.
Sensitivity analysis for the initial concentrations and the kinetic rates parameters for the PI3K-
independent hypothesis is shown. See Figure 5.7 for details of the top and bottom plots.
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Figure 5.18: Simulations of network perturbations at several levels and differential dynami-
cal network responses for the three different hypotheses (mTOR-pS2481 readout). Simulated
mTOR-pS2481 response upon amino acids/insulin induction in systems with the indicated
perturbations: TSC1/TSC2 (experimental equivalent: gradual TSC2 knockdown), mTORC1
(experimental equivalent: gradual Raptor knockdown), and PI3K (experimental equivalent:
gradual PI3K inhibition with Wortmannin) for Hypothesis 1, 2, and 3. The time points that
were experimentally tested are indicated with green lines.
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Figure 5.19: Simulations of network perturbations at several levels and differential dynamical
network responses for the three different hypotheses (Akt-pS473 readout). Simulated Akt-
pT308-pS473 response for each of the three hypotheses upon amino acids/insulin induction in
systems with perturbations of TSC1/TSC2, mTORC1, and PI3K. The time points that were
experimentally tested are indicated with green lines.
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Figure 5.20: The influence of perturbations of TSC1/TSC2, mTORC1, or PI3K on the phos-
phorylation of Akt-T308 for the three hypotheses. The three hypotheses did not show any
difference in the dynamics of Akt-T308 phosphorylation when varying the amounts of PI3K
and mTORC1. A small difference was observed for TSC1/TSC2 perturbation where the
TSC1/TSC2-dependent hypothesis showed a slight increase in Akt-T308 phosphorylation when
TSC1/TSC2 activity was reduced. In the TSC1/TSC2-dependent hypothesis, the mTORC2
activity is reduced when the amount of TSC1/TSC2 is reduced.
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Figure 5.21: The influence of perturbations of TSC1/TSC2, mTORC1, or PI3K on the phos-
phorylation of p70-S6K-T389 for the three hypotheses. The effect of each perturbation on the
networks representing each hypothesis for the phosphorylation of p70-S6K-T389, which is a
readout for mTORC1 activity, is shown.
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Figure 5.22: Quantitative representations of simulated and experimentally determined Akt-
pS473 and mTOR-pS2481. (A) mTOR-pS2481 is not affected in response to a gradual TSC2
knock down for 60 min after induction with amino acids/insulin. (B) mTOR-pS2481 is not
affected by the NFL in response to Raptor knock down for 100 min after induction with amino
acids/insulin. (C) mTOR-pS2481 is sensitive to the PI3K inhibitor Wortmannin (Wmn) for 30
min after induction with amino acids/insulin. Data are the average and SEM computed from
3 repeats. * P < 0.05, ** P < 0.01, *** P < 0.001, n.s. not significant. d = days, Hypo
= hypothesis. In vitro experiments were performed by Annika Sonntag, Freiburg University,
Germany.
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Figure 5.23: A new hypothesis and network structure for mTORC2 regulation by insulin.
Schematic representation of the pathway for Hypothesis 4: Insulin induction of mTORC2 by
a PI3K (red) that is insensitive to TSC1/TSC2 and to the S6K to IRS-mediated NFL. This
hypothesis was equivalent to Hypothesis 3 (PI3K and TSC1/TSC2-independent activation),
assuming that the mTORC2 activator was sensitive to Wortmannin.
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Figure 5.24: A new hypothesis and network structure for mTORC2 regulation by insulin. (A)
The model simulation data for Hypothesis match the experimental dynamical phosphorylation
data. The simulated and experimentally measured dynamics are shown for the mTORC2 read-
outs mTOR-pS2481 and Akt-pS473 (see Figure 5.25 for all other readouts). (B) Predictions for
mTOR-pS2481 and Akt-pS473 upon gradual TSC1/TSC2 knock down match the experimen-
tal data, which is presented in Figure 5.22A. Whereas at 60 min after induction Akt-pS473 is
gradually reduced by TSC2 inhibition, mTOR-pS2481 is TSC2-insensitive. See Figure 5.25 for
Akt-pT308 and p70-S6K-pT389. (C) Predictions for mTOR-pS2481 and Akt-pS473 readouts
upon gradual Raptor knock down match the experimental data, which is presented in Figure
5.22B. Whereas at 100 min after induction Akt-pS473 is gradually induced by Raptor inhibition,
mTOR-pS2481 is Raptor-insensitive. See Figure 5.25 for Akt-pT308 and p70-S6K-pT389. (D)
Predictions for mTOR-pS2481 and Akt-pS473 readouts upon gradual PI3K inhibition match
the experimental data, which is presented in Figure 5.22C. Both Akt-pS473 and mTOR-pS2481
are gradually reduced by Wortmannin at 30 min after induction. See Figure 5.25 for Akt-pT308
and p70-S6K-pT389. In vitro experiments were performed by Annika Sonntag, Freiburg Uni-
versity, Germany.
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Figure 5.25: Simulation and perturbations for the new network structure based on Hypothe-
sis 4: PI3K-dependent, NFL-independent regulation of mTORC2. (A) Comparison between
the simulated and experimental time courses for Hypothesis 4 shows that the simulated time
courses match the experimental readouts. (B) The influence of perturbations of TSC1/TSC2,
mTORC1, or PI3K on the dynamics of phosphorylation of Akt-T308 and p70-S6K-T389 for
Hypothesis 4. In vitro experiments were performed by Annika Sonntag, Freiburg University,
Germany.
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Figure 5.26: Validation Hypothesis 4 by Rictor and Raptor knock down. (A) Simulation of
mTOR-pS2481 dynamic in response to addition of amino acids and insulin when Rictor or
Raptor is knocked down (KD). (B) Quantifications of the simulations and experimental data for
mTOR-pS2481 upon Rictor or Raptor knock down 20 min after amino acids/insulin induction.
* P < 0.01; n.s., not significant; Student’s t-test. In vitro experiments were performed by
Annika Sonntag, Freiburg University, Germany. (See [Dalle Pezze et al., 2012b, Fig. 1]).
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Figure 5.27: Identifiability analysis for Hypothesis 4: PI3K-dependent, NFL-independent reg-
ulation of mTORC2. Parameter correlation matrix for Hypothesis 4 is shown. See Figure 5.6
for details.
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Figure 5.28: Sensitivity analysis for Hypothesis 4: PI3K-dependent, NFL-independent regu-
lation of mTORC2. Sensitivity analysis for the initial concentrations and the kinetic rates
parameters for Hypothesis 4 is shown. See Figure 5.7 for details of the top and bottom plots.
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Table 5.1: Ordinary differential equations of the general model and the models representing
Hypothesis 1, 2, and 3 for mTORC2 activation. List of kinetic rate constants and ordinary
differential equations (ODEs) for the general model (A) and the Hypotheses 1, 2, and 3 (B).
Each hypothesis is derived from the general model by replacing the mTORC2 ODEs, shown in
the box, with those corresponding to the hypothesis.
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Table 5.2: Parameter values of the general model. The general model was fully parameterised by
three steps. Phase 1, 3 kinetic rate constants of the insulin receptor (IR-beta) were determined.
Phase 2, the general model without PDK2 was obtained by parameterising 24 kinetic rate
constants. In this phase, Akt-S473 activation is modelled as autoregulation, independent of
mTORC2 and PDK2. Phase 3, PDK2 dynamics were added to the system and the 3 parameters
regulating Akt-S473 phosphorylation were calibrated by substituting the previously introduced
autoregulatory mechanism (parameters values shown in red) of Akt. For each phase, 350
independent calibrations, starting from random initial configurations of the parameters, were
executed and the best solution set fitting the data was selected. Phase 1 and 3 converged to
a single solution set. Phase 2 converged to two solutions sets of which one was discarded as
inconsistent with the experimental data (shown for phosphorylated Akt-S473 and IRS1-S636
readouts). For each phase, the mean and standard deviation of the estimated parameters were
computed from the selected solution set. The solution closest to the centroid of the selected
solution cluster was chosen for fixing the parameter values. In vitro experiments were performed
by Annika Sonntag, Freiburg University, Germany.
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Table 5.3: Parameter values of Hypotheses 1, 2, and 3. For each hypothesis, the estimated
parameters were calibrated using the same protocol provided in Table 5.2. For each hypothesis,
all the corresponding calibrations converged to a single solution set.
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Table 5.4: Summary of model goodness-of-fit. The total χ2 and Akaike Information Criterion
(AIC) measures are reported for the general model and the four hypotheses. Both the mea-
sures slightly penalise the TSC1/TSC2-dependent hypothesis. AIC also penalises the PI3K-
independent and the fourth hypotheses due to the higher number of parameters in these two
models. However, these differences are not statistically significant for rejection of any model.
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Chapter 6
A modelling-experimental
approach reveals IRS dependent
regulation of AMPK by insulin
This chapter describes a systems biology-based investigation of AMPK regulation
as described in [Sonntag et al., 2012]. The results here focus on the modelling
point of view and only include in vitro experimental work necessary for model val-
idation and test. All the in vitro experimental data included in this project were
collected by Annika Sonntag, PhD student supervised by Dr Kathrin Thedieck,
Department of Bioinformatics and Molecular Genetics, Freiburg University, Ger-
many. A copy of the published work, which includes the in vitro experimental
data used for parameterising and testing the model, is attached in Appendix B.
6.1 Introduction
After generating an insulin-mTOR dynamical model and determining mTORC2
induction by a distinct PI3K which is insensitive to the NFL [Dalle Pezze et al.,
2012a], the upstream regulation of both mTOR Complex 1 and 2 was elucidated
and implemented. The next step was to add the energy signalling pathway, as
represented by the AMPK module, into the model.
The choice of AMPK reflected the fact that this trimeric complex not only rep-
resents one of the most well known energy-dependent regulators within the cell
[Thedieck and Hall, 2009], but also promotes, whereas mTORC1 inhibits, au-
tophagy through ULK1 phosphorylation [Kim et al., 2011; Lee et al., 2010a] (see
Section 3.3.4). Under low energy conditions, AMPK directly phosphorylates and
increases TSC2 GAPase activity [Inoki et al., 2003], thereby inhibiting mTORC1.
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In addition, AMPK phosphorylates the mTORC1 scaffold protein Raptor on two
serine residues [Gwinn et al., 2008]. This phosphorylation induces 14-3-3 bind-
ing to Raptor and is required for mTORC1 inhibition by energy deprivation.
Therefore, the inclusion of AMPK into the model is essential for achieving a
computational framework for both studying molecular mechanisms and achiev-
ing simulated drug interventions with the ultimate aim of extending lifespan.
Further details concerning the biology of the energy signalling pathway can be
found in Section 3.2.3.
In the process of data collection, we found that AMPK not only responds to
energy deprivation but is also strongly activated by insulin within 3 minutes post
induction, and is further induced in Raptor deficient cells. Although it was al-
ready shown that AMPK can be regulated by insulin [Aguilar et al., 2007; Polak
et al., 2008; Suzuki et al., 2004], the mechanism involved in this regulation has not
yet been clarified. The immunoblot-based AMPK-mTOR dynamical model was
employed for generating a quality-of-fit based ranking of hypotheses of AMPK
activation. This prediction using this procedure indicated that the most probable
point in the network at which the insulin and AMPK signalling forked was at
the level of IRS and that AMPK was dependent on the negative feedback loop
(NFL). This was experimentally tested and confirmed in LKB1-deficient and -
functional cells lines. In summary, this study shows that AMPK is positively
regulated initially by IRS and inhibited by the NFL.
6.2 Results
6.2.1 An insulin-TOR-AMPK model
AMPK is another important mTOR regulator that suppresses mTORC1 activity
in response to energy deprivation [Mihaylova and Shaw, 2011]. A new dynamical
mTOR-AMPK model was generated including AMPK signalling to the earlier
mTOR model as developed in [Dalle Pezze et al., 2012a] which only assumed
insulin and amino acids as mTORC1 regulators. This new model implemented
AMPK inhibition of mTORC1 through promotion of TSC1/TSC2 complex activ-
ity only. We chose not to include direct phosphorylation of Raptor by AMPK for
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two reasons: first, the AMPK functional regulation on mTORC1 was still main-
tained, since these two pathways both contributed to mTORC1 inhibition; sec-
ond, the inclusion of a regulatory mechanism of Raptor and 14-3-3 was out of the
scope of this project. The following new connection was added into the model pre-
sented in [Dalle Pezze et al., 2012a]: AMPK phosphorylation at T172 allows active
AMPK to phosphorylate TSC2 at S1387 (species TSC1/TSC2) which leads to
TSC1/TSC2 activity enhancement and subsequent inhibition of mTORC1 [Inoki
et al., 2005, 2003; Mihaylova and Shaw, 2011]. Conversely, the phosphorylation
of TSC2 at T1462 (species TSC1/TSC2) by Akt-pT308 inhibits the TSC1/TSC2
complex, activating mTORC1 [Inoki et al., 2002]. Finally, the species Akt-pS473,
PRAS40-pT246 and PRAS40-pS183 were defined as supplementary readouts for
mTORC2, Akt, and mTORC1, respectively.
Although AMPK is known to be induced by energy depletion [Mihaylova and
Shaw, 2011], AMPK was described to be induced in Raptor deficient cells [Aguilar
et al., 2007; Polak et al., 2008] and also gradually induced in gradual Raptor
knock down HeLa cell line upon amino acids/insulin after only 20 min post in-
duction (p.i.) (see [Sonntag et al., 2012, Fig. 1A]). Surprisingly, we found that
insulin alone was able to strongly induce AMPK-pT172 and its readout TSC2-
pS1387 already at 3 min p.i. and that these phosphorylations decreased over
time. Although it has been described previously that AMPK is induced by IGF-
1 [Suzuki et al., 2004], this signalling connection has to date only been poorly
explored. Therefore, in the present study, the possible AMPK-activators in the
insulin-mTORC1 signalling were systematically investigated. The AMPK activa-
tor candidates were selected among the upstream species of mTORC1 because:
(1) mTORC1 is maximally induced at 30 - 45 min p.i. [Dalle Pezze et al., 2012a],
(2) AMPK induction by insulin peaked already as early as 3 min p.i., and (3)
AMPK was induced by Raptor knockdown (e.g. mTORC1 inhibition). Therefore,
we focused on the following AMPK activator candidates:
Hypothesis 1 (Insulin) where insulin is considered as a constant and direct
input to AMPK;
Hypothesis 2 (IR beta pY1146) reflecting IR activation;
Hypothesis 3 (IRS1 p) reflecting IRS1 activation by insulin receptor;
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Hypothesis 4 (mTORC2 pS2481) reflecting mTORC2 activation by amino
acids/insulin;
Hypothesis 5 (Akt pT308) reflecting Akt activation downstream of PI3K;
Hypothesis 6 (TSC1 TSC2 pT1462) reflecting TSC1/TSC2 deactivation by
Akt.
A graphical representation of this insulin-mTOR-AMPK model depicting our six
alternative hypotheses of AMPK activation is provided in Figure 6.1. In order
to add and calibrate the AMPK module, time course data for AMPK-pT172 and
TSC1/TSC2-pS1387, monitoring the activity of AMPK and its readout TSC2,
were acquired under serum and amino acids starvation followed by induction by
insulin and amino acids, the same conditions used for calibration of the dynamic
mTOR network model [Dalle Pezze et al., 2012a]. All signal intensities were
quantified, and descriptive statistics were computed over three replicates. The
experimental mean time courses were used to calibrate the model parameters.
6.2.2 Parameter estimation and identifiability
A specific model was instantiated for each hypothesis and calibrated using the
same data sets and using the Matlab Toolbox PottersWheel [Maiwald and Tim-
mer, 2008]. Before calibrating the models, structural identifiability analysis was
performed using the software GenSSI [Chis¸ et al., 2011]. This software calcu-
lated the symbolic solution of the problem computing Lie derivatives for each
hypothesis confirming structural global identifiability for all six models. For the
IRS1-induced AMPK model, structural identifiability analysis is reported in Fig-
ure 6.2A, showing that all the parameters were structurally identified in the first
(blue circles) or second (magenta circles) order identifiability tableau.
To calibrate the models, experimental time course data upon amino acids/insulin
induction for nine readouts (IR-beta-pY1146, IRS1-pS636, Akt-pT308, Akt-pS473,
mTORC1-pS2448, mTORC2-pS2481, p70S6K-pT389, PRAS40-pT246, PRAS40-
pS183; data set 1) in wild type cells along the insulin-mTOR signalling axis were
used in combination with time course data under gradual mTORC1 inhibition
(Raptor knock down; data set 2) in wild type cells, as measured previously [Dalle
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Pezze et al., 2012a]. Furthermore, in order to calibrate the species AMPK-pT172
and TSC1/TSC2-pS1387, the five time points (0, 3, 20, 45, and 100 min. p.i.;
[Sonntag et al., 2012, Fig. 1A]) without knock down induction, i.e. corresponding
to wild type, were added as an additional data set (data set 3).
Parameter estimation was executed for each model independently over multiple
data sets in order to reduce the bias of the solution and therefore overfitting.
However, the addition of data sets used to calibrate a model can lead to a se-
rious increment of variance, particularly due to the increase in intrinsic noise in
experimental data, which does not permit to estimate the model correctly. Our
second data set was characterised by three different levels of Raptor knock down,
obtained by doxycycline treatment for 1, 2 or 3 days respectively (subsets 1-3). A
satisfactory bias-variance trade off was found by combinatorially and singularly
testing these three subsets and eventually selecting only the subset of Raptor
knock down induced by doxycycline treatment for 3 days (subset 3). Subset 3
was selected as it represented the strongest signal reduction and consequently
novel information with respect to wild type time courses (data set 1) for cali-
brating the model. Moreover, the readouts in our data sets (data set 1, data set
2-subset 3, data set 3) were scaled in order to have species time course profiles
of comparable intensity. This evenly distributes the cost of the solution over the
simulated time course profiles approximating the data, avoiding an implicit pref-
erence ranking of calibration.
For calibrating the models, only the kinetic rate constant parameters were es-
timated, whereas the species protein concentrations were determined from im-
munoblot time course data sets by selecting the corresponding readout maximum
intensity plus two standard deviations measured at that time point. The ad-
dition of two standard deviations to the maximum signal peak guaranteed to
avoid species protein saturation conditions. The kinetic rate constants regulating
PI3K-variant dynamics were fixed a priori assuming a time course similar to the
insulin receptor. In fact, no experimental data is available for this PI3K insensi-
tive to the negative feedback loop and it is more likely that it follows the IR-beta
receptor than other curves. Furthermore, fixing these parameters led us to a full
structural identifiability of the model.
A posterior identifiability analysis was performed using Mean Optimal Transfor-
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mation Approach (MOTA) plugin [Hengl et al., 2007; Maiwald and Timmer, 2008]
after selecting 50% of the best fits (shown in Figure 6.2B for the IRS1-induced
AMPK model). This analysis revealed that high parameter correlations had co-
efficient of variation (CV) lower than 0.05 for all our models except for the IR
-beta-induced AMPK model (Hypothesis 2; Figure 6.3). For this model, MOTA
analysis highlighted high correlation and CV for the pair of parameters regulating
AMPK dynamics. Model identifiability was obtained after fixing one of the two
parameters and recalibrating the remaining one in a second round of calibration.
In combination with the previous analysis, parameter non-identifiability was also
checked by directly analysing the estimated percentage of standard deviations of
the parameters, computed over the 50% best fits, and considering non-identifiable
the parameters with standard deviations higher than a threshold of 5%. Table
6.1 presents the estimated parameters values with mean, standard deviations and
CV for the IRS1-induced AMPK model showing parameter identifiability. Sensi-
tivity analysis for the same model is provided in Figure 6.4, showing a balanced
sensitivity among the parameters and that all of them were required.
In summary, six models sharing the main network structure and differing in
AMPK activation were independently calibrated. The next step was therefore
to find at which level in the network AMPK is induced by insulin.
6.2.3 Hypotheses ranking and testing of AMPK activa-
tion by insulin
Once parameter estimation was achieved, the simulated time courses for the read-
outs AMPK-pT172 and TSC1/TSC2-pS1387 of each model were compared with
the corresponding experimental time courses (see Figure 6.5). Surprisingly, the
readouts AMPK-pT172 and TSC1/TSC2-pS1387 for the IRS1-induced AMPK
model (Hypothesis 3) were found to fit the data with high accuracy, whereas the
goodness-of-fit decreased for species downstream of IRS1 (Akt and TSC1/TSC2;
Hypotheses 5 and 6) and upstream of IRS1 (Insulin, IR-beta; Hypotheses 1 and
2), as indicated by the measure χ2. Furthermore, the two readouts fitted worse
for the mTORC2-induced AMPK model (Hypothesis 4).
At this point, the question was whether these local differences could lead to a
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possible ranking of the overall models. In order to achieve this, several additional
likelihood-based statistical criteria, such as Akaike Information Criterion (AIC,
AICc) [Akaike, 1973] and Bayesian Information Criterion (BIC) [Schwarz, 1978],
were used besides the total χ2, to estimate the goodness-of-fit calculated over
the entire models. Through these estimations a ranking of the hypotheses in
according to the goodness-of-fit was established (see Table 6.2). All these mea-
sures were consistent between them in selecting the IRS1-induced AMPK model
(Hypothesis 3) as the most probable model. The remaining simulated versus ex-
perimental time courses for IRS1-induced AMPK model are reported in Figure
6.6. An SBML model is provided for the IRS1-induced AMPK hypothesis.
In order to test hypotheses ranking and specifically Hypothesis 3 validity, four ex-
perimental tests were conducted: IRS over-expression, PI3K inhibition by Wort-
mannin, PTEN over-expression and myristoylated Akt. Schematic diagrams illus-
trating these tests are provided in Figure 6.7. These tests consistently confirmed
the predicted validity of Hypothesis 3, rejecting all the other hypotheses and
are in line with the observed AMPK induction in mTORC1 deficient cells (see
[Aguilar et al., 2007; Polak et al., 2008]). Moreover, since HeLa cells do not
express AMPK upstream kinase LKB1 [Sun et al., 2007; Suzuki et al., 2004],
this mechanism of AMPK induction by insulin was also tested and confirmed
in C2C12 cell line, which is LKB1 functional. Experimental testing details can
be found in [Sonntag et al., 2012, Fig. 4]. A graphical representation of the
IRS1-induced AMPK model (Hypothesis 3) in SBGN notation is given in Figure
6.8.
6.3 Discussion
In the present study, amino acids/insulin was observed to induce AMPK, confirm-
ing a previous report [Suzuki et al., 2004]. Here, we showed that this induction
happened already at 3 minutes post treatment with amino acids/insulin and in-
creased under Raptor inhibition. The dynamical model developed in [Dalle Pezze
et al., 2012a] was employed and extended with an AMPK module. This work sys-
tematically explored which component in the IIS-TOR signalling pathway was the
most likely candidate activator of AMPK. Applying a hypothesis ranking based
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on quality-of-fit between the model and experimental data sets, a signalling fork
was predicted at the level of IRS (Hypothesis 3), one fork leading to the canonical
insulin signalling pathway, another one to AMPK. This prediction was experi-
mentally confirmed in LKB1-deficient (HeLa) and -functional (C2C12) cells lines.
Besides confirming this hypothesis, experimental tests also rejected all the other
hypotheses, which were already considered less probable by our predictions due
to poor fitting with the data. These results showed that AMPK induction was
dependent on IRS and was therefore sensitive to the NFL, in agreement with our
previous finding that Raptor inhibition increased AMPK activation.
From a modelling point of view, a comprehensive mTOR network has been stud-
ied statically [Caron et al., 2010] and parts of the mTOR network have been
modelled dynamically [Borisov et al., 2009; Dalle Pezze et al., 2012a; Faratian
et al., 2009; Jain and Bhalla, 2009; Kiselyov et al., 2009; Kuepfer et al., 2007;
Sedaghat et al., 2002; Vinod and Venkatesh, 2009]. The network presented in this
study is the most extensive mTOR-AMPK model, incorporating AMPK as di-
rectly regulated by amino acids/insulin. Six models were defined and calibrated
using our experimental data. The models shared the main network structure,
but differed for the AMPK activation mechanism. After repeating cycles of pa-
rameter calibration and identifiability for each model, likelihood-based statistical
measures were used to estimate a model ranking, based on the goodness-of-fit
between each model and the experimental data.
Interestingly, other studies reported that AMPK inhibits IRS by phosphorylation
of IRS1 at S794 [Jakobsen et al., 2001; Ning and Clemmons, 2010; Tzatsos and
Tsichlis, 2007]. What is the meaning of this inhibition along with the activa-
tion mechanism reported in this study? May this be an additional mechanism to
switch off the insulin signalling analogous with the canonical IIS-TOR signalling
and the p70-S6K-induced negative feedback loop? A possible explanation of this
redundancy may be to increase the robustness of the cellular system upon insulin
stimulation. Certainly, further investigation on the dual regulation of AMPK and
IRS is required in order to better characterise the role of IRS and the meaning
of its downstream effect on AMPK.
In this study, we found that AMPK activation was dependent on IRS in HeLa
cells, which are known to be LKB1-deficient, and confirmed this results in C2C12
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cells line, which are LKB1-functional cells. Another study reported that IGF1
could induce AMPK in LKB1-functional PANC1 cells, besides HeLa cells [Suzuki
et al., 2004]. Therefore, the activation of AMPK at the level of IRS, presented
in this work, could be conserved in other cells in addition to HeLa, C2C12 and
PANC1.
Finally, linking AMPK with IRS1 and the NFL is a crucial aspect in drug in-
tervention, since the positive effects of AMPK activity can be maximised by
mTOR-inhibitors [Garcia-Echeverria, 2011]. In this context, model simulations
of drug treatments can offer a parsimonious and rapid methodology for predict-
ing best protein-dependent drug intervention and administration in preventing or
treating metabolic and tumour diseases.
6.4 Materials and methods
6.4.1 Modelling
The illustrated graphical model in SBGN graphical notation [Le Nove`re et al.,
2009] were designed using CellDesigner 4.2 [Funahashi et al., 2008, 2003]. The
Matlab Toolbox PottersWheel [Maiwald and Timmer, 2008] was used for design-
ing and calibrating the models. The parameters for each of the models were
estimated by 1000 fits with parameter disturbance noise of 0.4 using the best fit
as starting value. For each fit a maximum of 250 iterations with χ2 and parame-
ters tolerances of 1e-07 were run using the optimisation algorithm TrustRegion.
To reduce the computation time, CVODES integrator was selected and config-
ured with the following parameters: maximum number of steps = 1500, relative
tolerance = 1e-06, absolute tolerance = 1e-08. The reactions representing the
dynamics of the models were described by mass action laws. Only the kinetic
rate constants were estimated and the interval [1e-06, 1e+04] was selected as a
constraint for each parameter. The initial protein concentrations were directly
determined from our experimental data and scaled to distribute the fitting qual-
ity over the model. Experimental error bars indicate standard error of the mean
(SEM). The dynamics for the species PI3K-variant were assumed by reproducing
the dynamics of the insulin receptor, whereas its initial concentration was the
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same as IRS1 species.
Structural identifiability was calculated a priori with GenSSI [Chis¸ et al., 2011].
The model in Potterswheel format was exported in SBML and converted to Oc-
tave format using The System Biology Format Converter (SBFC)1. Then the
model in Octave format was adapted for the software GenSSI. Symbolic solutions
for each model were computed setting 10 as maximum number of iterations. After
executing each sequence fits, parameters were considered non-identifiable when
their coefficients of variance (CV), measured in the best 50% fits of the calibration
sequence, were higher than 5%. In combination to this preliminary analysis, the
PottersWheel plugin MOTA was used to confirm the parameter non-identifiability
and to assess the relations between the target parameter and the others.
3D Sensitivity analysis was performed using PottersWheel and provided in Figure
6.4. Models were exported in SBML [Hucka et al., 2003] Level 2 Version 4 using
PottersWheel.
6.4.2 Statistics
The Standard Error of the Mean (SEM) was chosen to estimate the statistical
variability of the measured samples of experimental time course. The goodness-of-
fit statistical measures χ2 [Maiwald and Timmer, 2008], AIC, AICc [Akaike, 1973]
and BIC [Schwarz, 1978] were used in order to rank the hypotheses. All these
measures were directly computed using PottersWheel Toolbox. The statistical
and programming language R v. 2.13.1 [R Development Core Team, 2010] was
selected for the graphic representation of the identifiability matrix computed with
MOTA and for all the computed statistics.
6.5 Figures and tables
1Software available from http://sourceforge.net/
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Figure 6.1: Graphical insulin-mTOR-AMPK model. This model integrates the insulin-mTOR
model presented in [Dalle Pezze et al., 2012a] with AMPK regulation. Six hypotheses of AMPK
activation are investigated (blue dotted lines). Except for the Insulin- and IR-beta-induced
AMPK hypotheses, all the others implicitly assume AMPK being dependent on the p70-S6K-
negative feedback loop.
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Figure 6.2: Identifiability analysis for IRS1-induced AMPK model (Hypothesis 3). (A) Struc-
tural identifiability analysis was performed with the software GenSSI a priori. In the reduced
identifiability tableau, blue circles indicate the parameters detected directly as structurally
globally identifiable at the first order tableau, whereas magenta circles highlight the parame-
ters detected as structurally globally identifiable at the second order tableau after computing
the symbolic solution. (B) MOTA identifiability analysis was executed using the 50% of the
best fits of the calibration fits sequence. A correlation among a set of parameters is indicated
by the tuple of correlated parameters, their correlation coefficient (r2), coefficient of variation
(CV ) and the number of times this correlation is identified by varying the parameters of the
tuple (#). Even though there are high correlations among some parameters, the corresponding
coefficient of variation was lower than 0.002, which can be explained as numeric approximation
error in the fit sequence calibration process. (*) r2 > 0.9 & CV > 0.1 (**) r2 > 0.9 & CV > 0.1
& #> 1.
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Figure 6.3: Identifiability and parameter estimation for IR-beta-induced AMPK model (Hy-
pothesis 2). (A) Identifiability analysis for the IR-beta-induced AMPK model indicated non
identifiability issues for the parameters regulating AMPK dynamics (p7, p8). (B) Correlation
plot between the two parameters (p7, p8) confirms non-identifiability of the parameters. (C)
Finally, the first round of the parameter estimation reported a standard deviation percentage
higher than 5% for the two parameters. p8 was further recalibrated in a second round in which
it was correctly identified. (*) r2 > 0.9 & CV > 0.1 (**) r2 > 0.9 & CV > 0.1 & #> 1.
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Figure 6.4: Sensitivity analysis for IRS1-induced AMPK model (Hypothesis 3). (A) 2-
dimensional sensitivity analysis between the estimated kinetic rate constants versus the protein
concentrations. The table shows that all the parameters are essential for describing the model
and the IRS1-p regulation is the most important as it mediates the insulin signalling as well
as the p70-S6K-negative feedback loop. Colours indicate sensitivity levels. (B) 3-dimensional
sensitivity analysis as normalised in [0,1]. Colours distinguish different estimated kinetic rate
constant parameters.
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Figure 6.5: Prediction of the intersection between insulin and AMPK signalling. Simulated time
courses (red lines) versus experimental data (blue points) for AMPK-pT172 and its downstream
readout TSC1/TSC2-pS1387 (columns) shown for the six hypotheses: Insulin-, IR-beta-, IRS-,
mTORC2-, Akt-, TSC1/TSC2-induced AMPK (rows). These predictions suggest that AMPK
could be regulated by kinases downstream of the insulin receptor. The IRS-induced AMPK
model (Hypothesis 3) fitted experimental data best. Experimental data error bars indicate
standard error of the mean (SEM) calculated from three repetitions. Goodness-of-fit χ2 is
reported for each plot along with the number of measured time points. In vitro experiments
were performed by Annika Sonntag, Freiburg University, Germany.
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Figure 6.6: Additional simulated versus experimental additional time courses for IRS1-induced
AMPK model (Hypothesis 3). (A) Main data set used for parameter estimation. Simulated
(red lines) versus experimental data (blue points) are plotted for nine wild type (WT) readouts
along the insulin-TOR network upon amino acids/insulin induction. (B) Additional data set
used for parameter estimation. Experimental data for seven readouts for a Raptor knock down
(KD) upon amino acids/insulin induction. Experimental data error bars indicate standard error
of the mean (SEM) calculated from four repetitions. Goodness-of-fit χ2 is reported for each
plot along with the number of measured time points. In vitro experiments were performed by
Annika Sonntag, Freiburg University, Germany.
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Figure 6.7: Schematic diagrams for testing hypotheses ranking. (A) IRS overexpression induced
AMPK and TSC1/TSC2 activity directly and indirectly by inhibiting the negative feedback
loop (NFL). In addition, AMPK was also positively regulated by either inhibiting PI3K with
Wortmannin or overexpressing PTEN. (B) Constitutively active Akt inhibited AMPK by hy-
peractivating the NFL. Wmn: Wortmannin. Figures adapted from [Sonntag et al., 2012, Fig.
5A].
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Figure 6.8: IRS is required for AMPK induction by insulin (Hypothesis 3). Graphical model
of the insulin induced mTORC1 pathway in SBGN notation, including IRS dependent AMPK
induction. Importantly, the negative feedback loop (NFL) via IRS targets not only PI3K but
also AMPK.
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Table 6.1: Parameter table for the IRS1-induced AMPK model (Hypothesis 3). The estimated
kinetic rate constants together with the species concentrations are provided. The mean, stan-
dard deviations and percent of standard deviation over the mean, computed over the 50% of the
best fits, are also indicated. These statistics shows that all the 24 estimated parameter could
be fixed at the first round of calibration. Scaling factor parameters and observable variables
are also indicated.
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Table 6.2: Statistical ranking of the models. Quality of fitting measures were used to determine
a ranking of the investigated models. IRS1-induced AMPK model (Hypothesis 3) showed the
lowest χ2 value, indicating that this model was the most probable. AIC, AICc and BIC values
are reported as additional measures.
124
Chapter 7
A dynamical mTOR-ROS model
for irradiation-induced cellular
senescence
This chapter describes a systems biology-based investigation on cellular senes-
cence. The presentation focuses on the modelling point of view and only include
in vitro experimental work necessary for model validation and test. All the in
vitro experimental data included in this project were collected by Dr Glyn Nelson,
supervised by Professor Thomas von Zglinicki, Institute for Ageing and Health,
Newcastle University, United Kingdom.
7.1 Introduction
Cellular senescence is a phenomenon characterised by loss of mitosis and the dys-
regulation of multiple cellular processes. Ageing is associated with a progressive
accumulation of DNA damage and reactive oxygen species (ROS) are a major
cause of this damage [Finkel and Holbrook, 2000]. ROS are mostly generated as
a by-product of mitochondrial activity in supplying cells with energy [Turrens,
2003]. ROS are highly reactive and can cause severe damage to macromolecules
and organelles, leading to loss of function. As most ROS are generated from the
mitochondria, it is not surprising that mitochondrial DNA (mtDNA) is partic-
ularly vulnerable and damage leads to impaired mitochondrial function [Passos
et al., 2007; Shokolenko et al., 2009]. Recent studies also showed that telomere
dysfunction can compromise mitochondrial function through activation of p53
and consequently repression of PGC-1α/β [Sahin et al., 2011]. The result is a
viscous cycle whereby ROS cause mitochondrial dysfunction which leads to fur-
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ther increases in the level of ROS.
DNA damage and oxidative stress initiate a multitude of signalling pathways
which may, in the case that damage is unrepaired, be reinforced through signalling
feedback loops. Under such chronic conditions the downstream consequences may
ultimately impair cellular function as is the case with the inflammatory response
[Passos et al., 2010]. Oxidative stress also activates c-Jun N-terminal kinases
(JNK), which is responsible for FoxO3 translocation to the nucleus through phos-
phorylation [Greer and Brunet, 2005, 2008]. Oxidative stress promotes SIRT1-
dependent deacetylation of FoxO3 favouring the transcription of genes controlling
cell cycle arrest [Brunet et al., 2004; Greer and Brunet, 2005]. Moreover, nuclear
FoxO3 induces autophagy by expressing autophagic genes LC3, Gabarapl1 and
Atg12 [Sengupta et al., 2009; van der Vos et al., 2012].
In recent years, interest has increased on the roles of the insulin/TOR signalling
pathway in the mechanisms regulating ageing processes. Its importance was
first recognised in worms where inhibition of insulin signalling, particularly Akt
activity, leading to enhanced transcriptional activity of Daf-16, the homologue
of FoxO3a in humans, was shown to extend lifespan [Lee et al., 2003; Murphy
et al., 2003]. In agreement with this, TOR inhibition by caloric restriction or Ra-
pamycin treatment, or AMPK activation by resveratrol or metformin treatment,
increases autophagy [Kim et al., 2011; Lee et al., 2010a] and SIRT1 activity [Canto´
et al., 2009; Lagouge et al., 2006; Rodgers et al., 2005]. In turn, SIRT1-dependent
deacetylation activity was shown to suppress p53 [Vaziri et al., 2001] and increase
transcriptional activity of FoxO3a and activity of PGC-1α/β [Canto´ et al., 2009;
Lagouge et al., 2006; Rodgers et al., 2005]. As a consequence, autophagy and
mitochondrial biogenesis are promoted, whereas ROS levels are reduced.
The network arising from these signalling pathways is clearly complex, especially
due to the numerous signalling pathways and regulatory feedbacks. Moreover,
it appears that the cellular transition from normal to senescence involves inter-
nal dynamical changes which need to be carefully investigated. In this study,
we used a systems biology approach to develop the first dynamical model for
irradiation-induced cellular senescence as a means to unravel the main processes
governing the transition from a healthy to a senescent cell. We used this model
to study FoxO3a-dependent mechanisms of regulating mitochondrial fusion and
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membrane potential. We provide evidence for the importance of two nuclear
states of FoxO3a: unphosphorylated and JNK-dependent phosphorylated. The
former predominantly triggered Mfn2 and improved mitochondrial membrane
potential. The latter mostly acted in response to DNA-damage and oxidative-
stress, and promoted cell cycle arrest through p21 signalling which contributes
to ROS production. This dual role of FoxO3a was critical for determining cellu-
lar senescence progression and consolidation. Also, this work showed that new
drug-interventions aimed at preventing cellular senescence, should include com-
binatorial inhibition of the insulin/TOR pathway and JNK/ROS oxidative-stress
response.
7.2 Results
7.2.1 A dynamical model for cellular senescence
The model presented in Figure 7.1 aimed to integrate five key regulators of age-
ing: insulin-TOR, FoxO3a, DNA damage, reactive oxidative species (ROS), mi-
tochondrial function. The insulin-TOR network was abstracted in order to repro-
duce Akt, mammalian TOR Complex I (mTORC1) and the mTORC1-p70-S6K-
induced negative feedback loop. Akt was responsible for FoxO3a translocation
from the nucleus to the cytoplasm and this migration was overridden by JNK
activity [Brunet et al., 2004; Greer and Brunet, 2005, 2008]. This resulted in two
nuclear FoxO3a states for which no specific assumption was made on their respec-
tive downstream activity. Since PGC-1α/β is linked to FoxO3a and activated by
AMPK, PGC-1α/β-dependent mitochondrial biogenesis signalling was embedded
within FoxO3a-AMPK-Mfn2 signalling, where Mfn2 is indicative of mitochondrial
fusion (mitofusin2) [Koshiba et al., 2004], mitochondrial metabolism [Bach et al.,
2003] and herein mitochondrial biogenesis through PGC-1β [Liesa et al., 2008;
Soriano et al., 2006]. Therefore, global mitochondrial function was improved by
Mfn2, abstracting PGC-1α/β activity. Three states of mitochondrial membrane
potential (high, low, null) were assumed. Each state contributed to ROS pro-
duction and total ROS was responsible for mitochondrial membrane potential
decrement. ROS also increased DNA damage levels and induced the oxidative
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stress response through JNK, which promoted FoxO3a translocation from the cy-
toplasm to the nucleus. Both nuclear FoxO3a states and DNA damage triggered
p21 signalling, which led to an increase in ROS production [Passos et al., 2010].
p53 was not directly included into the model because its time-course was similar
to DNA damage H2A.X foci marker. Finally, p27 and GSK3α activities were
monitored as additional readouts.
7.2.2 Time-course analysis upon irradiation-induced senes-
cence
In vitro experimental time course data were collected in MRC5 fibroblast cells for
13 experimental readouts in the network up to 21 days post 20 Gy X-ray irradi-
ation. The in vitro data and model simulation upon X-ray irradiation are shown
in Figure 7.2. Following irradiation, in vitro and in silico data showed a dra-
matic increase in DNA damage and oxidative stress responses, and a consequent
decrease in mitochondrial membrane potential. Immediately following cellular
damage, an Mfn2 response was observed indicative of unphosphorylated nuclear
FoxO3a activity combined with AMPK. The increasing levels of AMPK should
result in an increase in the levels of PGC-1α/β, which in turn should promote
mitochondrial biogenesis. However, the mitochondrial membrane potential was
not restored, despite AMPK activity. The model parameter estimation explained
this conflict by attributing differential roles to the two nuclear FoxO3a pools
(see graphical model in Figure 7.1 and predicted nuclear FoxO3a time courses
in Figure 7.3A). The JNK-phosphorylated nuclear FoxO3a played a more mi-
nor role in activating the processes of mitochondrial fusion and biogenesis than
the unphosphorylated-state nuclear FoxO3a. In fact, high JNK levels indicated
that FoxO3a mainly resided in the nucleus and was phosphorylated on its JNK-
dependent sites. However, JNK-phosphorylated FoxO3a interaction with AMPK
was reduced in promoting Mfn2, and consequently mitochondrial membrane po-
tential levels were maintained low and unaffected by JNK activity. Interestingly,
although ROS levels were maximised and were maintained stable, JNK was only
at half of its maximal observed activity and was gradually increasing, highlighting
that other factors, such as chronic inflammation as regulated by other pathways,
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may be responsible for further JNK activation.
This consideration provided a preliminary understanding about how a senescent
state was driven and consolidated. Firstly, DNA damage and ROS production
would be responsible for loss of mitochondria function. Secondly, the system
would enter a point of no return, due to mitochondrial fusion and biogenesis fail-
ure, which in this framework was explained by a shift of FoxO3a activity due to
JNK high levels. Therefore, JNK-phosphorylated FoxO3a would not respond to
AMPK and potentially would not mediate signals with PGC-1α/β to correctly
activate the processes of mitochondrial fusion and biogenesis.
7.2.3 JNK inhibition promotes cytoplasmic FoxO3a mi-
gration and Mfn2
To better formalise and test this hypothesis, we perturbed JNK levels in the
model at day 0 and then analysed the effects on FoxO3a and FoxO-downstream
proteins. These predictions were tested experimentally in vitro.
As a first step, the model predicted that a JNK inhibition of 25-50% applied at
day 0 would correspond to a reduction in JNK-pT183 levels to 48-73% at 10 days
post irradiation. To experimentally test this prediction, cells were treated with
1µM of the JNK inhibitor SP600125 at day 0. Consistent with this prediction,
in vitro JNK inhibition measured at 10 days post irradiation showed a reduction
in JNK-pT183 levels to 68%. Thus, this preliminary result indicated that our in
vitro JNK inhibition at day 0 was between 25 and 50% of total JNK level (see
Figure 7.3B and C). Since JNK constrains FoxO3a to reside inside the nucleus,
inhibition of JNK would have allowed FoxO3a translocation to the cytoplasm.
The model predicted an increment in cytosolic/nuclear FoxO3a ratio between
117% and 152% at 10 days post irradiation upon 25-50% in silico JNK inhibi-
tion applied at day 0. This result was experimentally confirmed in vitro showing
an increase in cytosolic/nuclear FoxO3a ratio of 140% (see Figure 7.3B and C).
Cytosolic FoxO3a levels were increased as Akt-pS473 induced FoxO3a transloca-
tion from the nucleus to the cytoplasm and this translocation was opposed by
JNK-pT183. A reduction in JNK-levels thereby released the JNK counter-effect
of Akt.
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We then investigated downstream of FoxO3a detecting the levels of mTOR-
pS2448, which reflects the activation of mTORC1 through Akt, and Mfn2 upon
the same JNK inhibition treatment. The model predicted an increase in both
mTOR-pS2448 and Mfn2 levels with respect to the control after 3-5 days post
irradiation (see Figure 7.3D). In addition, the simulation showed that these levels
could stabilise if JNK was inhibited by more than 50%. This prediction was ex-
perimentally verified in vitro (see Figure 7.3E). Under JNK-inhibition treatment,
mTOR-pS2448 and Mfn2 levels were significantly higher than the corresponding
control levels. Moreover, these curves gradually decreased after 9-11 days, which
was predicted by the model when JNK was inhibited at approximately 50%.
These predictions and in vitro confirmations indicated that nuclear FoxO3a acted
differently depending on whether it was phosphorylated by JNK in response to
oxidative stress. Mfn2 levels remained sensitive even after 9-11 days post irra-
diation upon JNK inhibition treatment. See Figure 7.4 for model predictions of
AMPK-pT172, FoxO3a-pS253, JNK-pT183 and mitochondrial membrane poten-
tial upon JNK gradual perturbation. Interestingly, the mitochondrial membrane
potential increased upon gradual inhibition of JNK, although the original levels
at day 0 were not restored.
7.2.4 ROS inhibition improves mitochondrial membrane
potential
As ROS is a central driver for mitochondria dysfunction we gradually perturbed
the variable ROS in the model at day 0 and analysed the effects on mitochondrial
membrane potential along the time course.
At 15 days post irradiation, model simulation predicted an increase in mitochon-
drial membrane potential up to 154% upon ROS scavenging from day 0 (see
Figure 7.5A). This prediction was experimentally tested in vitro by measuring
the TMRM/MTG ratio. The mitochondrial membrane potential increased to
149% with respect to the control. As the model predicted that an increase to
154% was obtained by reducing the total ROS amount to 50% at day 0, we could
infer that the in vitro experimental test scavenged approximatively 50% of ROS
(see Figure 7.5B and C).
130
7. A dynamical mTOR-ROS model for irradiation-induced cellular
senescence
In addition to these prediction-test results, we also theoretically predicted the
effects on Akt-pS473, mTOR-pS2448, Mfn2 and AMPK-pT172 upon ROS grad-
ual perturbation (see Figure 7.6). ROS inhibition was responsible for increas-
ing mTOR-pS2448 and consequently decreasing AMPK-pT172, Akt-pS473 and
Mfn2. Intriguingly, Mfn2 was again confirmed to lose sensitivity after 9-11 days
post irradiation upon ROS scavenging treatment. This result highlighted the fact
that, despite ROS inhibition, the levels of Mfn2 were not restored after 9-11 days,
suggesting that a ROS inhibition treatment alone was not sufficient.
7.2.5 Combinatorial intervention for improving both Mfn2
and mitochondrial membrane potential
By applying a JNK gradual inhibition, we predicted and tested an increase in
Mfn2 and cytoplasmic FoxO3a levels. Since FoxO3a translocation to the cy-
toplasm depends on Akt-pS473, the model predicted that an intervention for
increasing Mfn2 levels and mitochondrial membrane potential could be a com-
bined JNK-Akt perturbation. In fact, this intervention allowed us full control
over the nuclear states of FoxO3a and therefore its downstream signals (see Fig-
ure 7.7A). Figure 7.7B shows the levels of cytoplasmic FoxO3a-pS253, Mfn2 and
mitochondrial membrane potential at day 10 upon combined JNK-Akt perturba-
tion applied at day 0. Cytoplasmic FoxO3a-pS253 levels notably increased upon
gradual inhibition of JNK and gradual overexpression of Akt. As our focus was
to maintain FoxO3a predominantly in the nucleus and we have showed a ben-
eficial effect upon JNK gradual inhibition, we considered the area of JNK-Akt
inhibition (see white square marked by *) as a region of study. Interestingly, the
model predicted that Mfn2 levels significantly increased up to 166% by reduc-
ing the levels of JNK and Akt in combination to 60% (see arrow inside square).
The mitochondrial membrane potential was also predicted to increase to 133% by
applying the same combined inhibition, although it showed dependency on Akt
only when the activity of this protein was reduced.
The next step was therefore to use this new information together with the previous
prediction-test that ROS inhibition improved mitochondrial membrane potential
(see Section 7.2.4). The idea was to use the benefits of the predicted output for
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FoxO3a and Mfn2 upon combined JNK-Akt perturbation (see Figure 7.7B) as
an input for a combined Mfn2-ROS perturbation (see Figure 7.7C). From Figure
7.7B, we found a way to increase Mfn2 levels by decreasing both JNK and Akt.
Therefore, in a combined Mfn2-ROS perturbation we could simply consider the
area of Mfn2 hyperactivation (Mfn2 >100%) (see Figure 7.7D). This area could
be further reduced by two reasons:
R1. Cytoplasmic FoxO3a-pS253 levels should be at the basal level of 1 (see Figure
7.7B and D, magenta/dark blue colour for FoxO3a-pS253);
R2. ROS levels should be maintained as low as possible, since ROS inhibition
increases mitochondrial membrane potential (as shown in Figure 7.5).
From Figure 7.7B, reduced levels of FoxO3a-pS253 (bottom-right) determined
low levels of Mfn2 (bottom-right), since FoxO3a acted upstream of Mfn2. There-
fore, the region could be safely limited along the threshold 1 of FoxO3a (see
magenta/dark blue colour for FoxO3a-pS253) which interestingly corresponded
to 50% of ROS levels in agreement with Figure 7.5 (see regions indicated by **
in Figure 7.7D). Accordingly with Figure 7.5 and R1, a decrease in ROS lev-
els also determined a significative increase in mitochondrial membrane potential
upon a combined Mfn2-ROS perturbation. At this point, we investigated the
effect on mitochondrial membrane potential at day 10, upon combined ROS-
Mfn2 perturbation applied at day 0, on the correspondent region (marked by **).
In agreement, we again found a significant increase to 133% in mitochondrial
membrane potential. This predictive result indicated that Mfn2 levels and mito-
chondrial membrane potential could significantly increase by applying a targeted
triple inhibition of Akt, JNK and ROS. In contrast to the application of a com-
bined JNK-Akt inhibition, this intervention had the additional benefit that the
network was not unbalanced by oxidative stress signals, as ROS levels were main-
tained low. Moreover, mitochondrial activity promotes ROS production, which
can in turn re-activate JNK and decrease membrane potential. Therefore, it was
crucial to limit the levels of ROS in order to avoid losing the achieved benefit.
Furthermore, the simulated single perturbation of Mfn2 at day 0 along the time
course was also investigated (see Figure 7.8). Interestingly, by reducing Mfn2,
the mitochondrial membrane potential decreased accordingly. Therefore, since
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the AMP/ATP ratio increased, activated AMPK negatively regulated mTOR-
pS2448. In addition, Mfn2 inhibition produced a moderate ROS reduction, caused
by a decrease in mitochondrial membrane potential.
7.2.6 Time course analysis of combined TOR-ROS per-
turbation
In the previous section, we outlined an intervention for increasing both Mfn2
levels and mitochondrial membrane potential by applying a triple inhibition of
Akt, JNK and ROS. However, it is well known that TOR plays a crucial role in
the regulation of autophagy [Kim et al., 2011; Lee et al., 2010a] and Akt-pS473
[Sarbassov et al., 2006, 2005]. Therefore it was of interest to study the effect of
a combined TOR-ROS perturbation, applied at day 0, on Mfn2 and mitochon-
drial membrane potential. Moreover, it may be that this new double intervention
would be able to restore the mitochondrial membrane potential to its original
level and avoid potentially toxic high Mfn2 levels.
Perturbation of mTORC1 alone produces serious undesired effects in the in-
sulin/TOR signalling pathway. In fact, mTORC1 inhibition reduces mTORC1-
p70-S6K-dependent negative feedback to the insulin receptor substrate (IRS) and
therefore hyper-activates Akt [Harrington et al., 2004; Shah et al., 2004]. A
cleaner approach was to perturb both the complexes simultaneously by inter-
acting with TOR kinase directly. In the model mTORC2 was abstracted since
Akt-pS473 was dependent on both insulin and mTORC1-p70-S6K-negative feed-
back loop, whereas mTORC2 was sensitive to insulin but not to the negative
feedback loop [Dalle Pezze et al., 2012a]. Nevertheless, we could still approxi-
mate a TOR kinase perturbation by adjusting a global percentage of the initial
protein levels for mTORC1 and Akt at the same time. Therefore, the initial lev-
els of the two protein variables, Akt and mTORC1, were increased or decreased
together, simulating a TOR kinase inhibition or over-expression, equivalent to
affecting both mTORC1 and mTORC2 in the cell (using a TOR inhibitor, such
as Torin [Liu et al., 2011], treatment).
In simulating a double perturbation of the main TOR kinase and ROS, we de-
tected a non-linear qualitative change along the time course of Mfn2 (see Figure
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7.9A, column 1). Two days after irradiation, Mfn2 was predominantly regulated
by ROS levels, with little sensitivity to TOR inhibition. At the same time, mi-
tochondrial membrane potential was affected almost equally by both ROS and
TOR at lower levels (<100% TOR, ROS), whereas slightly more by ROS at
higher levels (>100% TOR, ROS) (see Figure 7.9A, column 2). As time pro-
gressed, Mfn2 levels decreased and became more affected by TOR perturbation
rather then ROS. Meanwhile, mitochondrial membrane potential maintained a
combined sensitivity to TOR and ROS, although gradually reduced to low levels
along the time course. At days 15-21, TOR and ROS perturbation split the Mfn2
response into two activation states. One state (S1) was characterised by low levels
of ROS (<75% at day 15), the other (S2) by high levels of ROS (>100% at day
15). Whereas ROS divided the space of Mfn2 response, TOR shaped the bound-
aries of these two states. In S2, the Mfn2 response maintained an equilibrium
by increasing ROS and TOR in combination. This state space was thus concave
with respect to the two parameters within the explored boundaries. In S1, the
Mfn2 response vanished by increasing TOR levels. Therefore, TOR was respon-
sible for the S1 convex space. Interestingly, the S1 state gradually diminished
along the time course. Hence, we simulated the Mfn2 response to TOR and ROS
perturbations up to 40 days post irradiation, in order to study the evolution of
S1. As shown, at day 40 this second state is almost lost due to the extremely low
levels of Mfn2. Moreover, in the extreme regions outside of these two states, Mfn2
levels were either very high (<10% of TOR) or very low (<10% of ROS) (see left
or bottom of the plot). This could be explained because ROS-JNK-dependent
oxidative stress response antagonises Akt-dependent translocation of FoxO3a to
the cytoplasm, and therefore promotes fusion.
The prediction of these two time-dependent states indicated two modalities of
intervention to increase Mfn2 levels: one by increasing ROS levels, the other one
by reducing them. Since mitochondrial membrane potential was maximised at
low levels of ROS, we experimentally tested the model prediction of Mfn2 and mi-
tochondrial membrane potential upon inhibition of TOR, ROS or TOR-ROS. At
day 15, the model predicted a similar Mfn2 response upon inhibition of TOR (to
10-25%) or TOR-ROS (to 10-25% and to 45-55%, respectively). This similarity
was also found at day 21 (see Figure 7.9B). These predictions were experimen-
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tally tested in vitro by inhibiting TOR (to 10-25%) or TOR-ROS (to 10-25%
and to 45-55%, respectively) (see Figure 7.9C). We were not able to test the non
linear response of Mfn2 upon combined perturbation of TOR and ROS at day
21, as the predicted signal differences along the sigmoid curves were too small
(<20%). At day 12 the model predicted no significant response of mitochondrial
membrane potential upon TOR inhibition (to 10-25%) or ROS inhibition (to 45-
55%), although both these inhibitions showed a statistically significant increase
in membrane potential with respect to the control. In the case of a TOR-ROS
combined inhibition (to 10-25% and 45-55%, respectively), the model predicted
a significant increase in membrane potential with respect to the control or to
the single inhibition treatments (see Figure 7.9D). These predictions were experi-
mentally tested in vitro (see Figure 7.9E), and confirmed the beneficial effect of a
double inhibition and the prevailing role of ROS over TOR at low medium doses
of treatment.
These results show that TOR inhibition is sufficient for increasing Mfn2 and mi-
tochondrial membrane potential levels, but a combined TOR-ROS treatment is
more effective for restoring mitochondrial membrane potential.
7.3 Discussion
In the present work, a dynamical model was employed for investigating the dy-
namical process of irradiation-induced cellular senescence and studying modali-
ties of combined drug interventions in order to reduce progression of ageing in the
middle and long term. We hypothesised that FoxO3a existed in the nucleus in
at least two states, unphosphorylated FoxO3a and JNK-phosphorylated FoxO3a,
and that these two states mediated distinct cellular processes. Nuclear unphos-
phorylated FoxO3a was mainly responsible for Mfn2 activation and partially for
cell cycle arrest, whereas JNK-phosphorylated FoxO3a was mostly responsible
for cell cycle arrest. DNA damage and oxidative stress response activated the
inflammatory system through JNK and gradually shifted the FoxO3a nuclear
system from the unphosphorylated state to the JNK-phosphorylated state. In
addition to the initial establishment of positive feedback loops which systemati-
cally increased ROS production, DNA damage and dysfunctional mitochondria,
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this state transition of FoxO3a also had the adverse effect of arresting Mfn2 and
strengthening cell cycle arrest. As a consequence, this state transition had the
effect of switching off these positive feedbacks maintaining the system in an un-
proliferative and low energy state.
Why would FoxO3a disregard Mfn2 when phosphorylated by JNK? A possible
explanation is that progressive mitochondrial dysfunction would cause a drastic
loss of energy in the cell. In conditions of low energy availability and high lev-
els of damage, the cell would promote cheaper austerity forms for limiting the
seriousness of the problem (DNA damage, ROS, mitochondrial dysfunction) and
resources deployment (energy). It would broadly limit all expensive processes,
such as cellular proliferation, cell growth (through TOR) and finally mitochon-
drial biogenesis. In fact, these processes are expensive and it is reasonable to
think that in the presence of high levels of damage and low levels of energy, the
benefit of promoting anabolic programs is little compared to its cost. In this con-
text, JNK would be responsible for shifting FoxO3a activity towards more severe
processes, such as cell cycle arrest and apoptosis, rather than investing energy in
mitochondrial fusion and biogenesis. The choice of limiting mitochondrial fusion
and biogenesis would have opposing effects. On one side, it would increase the
total number of dysfunctional mitochondria and this would reduce energy levels
further. On the other side, this energy reduction would gradually weaken the
existing positive feedback loops. As consequence, the cell would enter a pseudo
steady state, which would slowly lose intensity due to progressive lack of energy.
Despite its power, the presented model misses important components. The most
important is the inflammatory system as controlled by NF-κB, TNF-α and TGF-
β signalling pathways. This inflammatory response is heavily abstracted in this
model by JNK through ROS regulation. The inflammatory system has important
positive feedback loops that may develop independently and may therefore be re-
sponsible for permanent activation of JNK, despite ROS signalling stabilisation.
Although the abstraction applied in this study is sufficient for the conclusions
provided, the inclusion of an inflammatory system would give important insights
about other persistent mechanisms of positive feedback loop initiation and con-
solidation as well as potential drug interventions.
An explicit signalling pathway governing mitochondrial biogenesis through FoxO3a,
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AMPK, mitophagy was discarded since the mechanism through mitochondria fu-
sion and biogenesis (Mfn2) had the same beneficial effect on mitochondria: the
increase in total membrane potential. However, a precise analysis of the roles
of these two distinguished pathways and their effect on mitochondrial mass may
unravel important questions concerning the role of TOR in middle and late senes-
cence.
In conclusion, aside from caloric restriction, multiple interventions for limiting the
progression of senescence are theoretically possible and include down regulation
of ROS and mTOR. Due to the high number of regulatory feedback loops, these
interventions should focus on the reduction of these senescence-positive feedback
loops. Conversely, it is important that these combinatorial interventions applied
to reverse senescence, do not negatively affect the senescent beneficial effect of
preventing cancer diseases, by inducing dysregulated cell proliferation.
7.4 Materials and methods
7.4.1 Mathematical model
The ODE-based mathematical model consisted of 30 dynamical variables cov-
ering 5 cellular modules: DNA-damage, oxidative stress, FoxO, IIS-mTOR and
mitochondria. These model variables were regulated by 3 inputs: insulin, amino
acids and irradiation. 13 observables were used to link the model to experimental
data. The initial amount of each dynamical variable in inactive state was fixed
to the maximum measured intensity of the associated experimental signal plus
two times the standard deviation at that time point. For dynamical variables
in active state related to DNA-damage or oxidative stress responses, the initial
amounts were fixed to 0. For all the other variables in active state, the initial
amount was fixed to 1, approximating the basal level of the proteins upon insulin
and amino acid stimuli. The dynamical variables were connected by 39 reac-
tions expressed as mass action kinetics. 37 kinetic rate constant parameters were
estimated using Potterswheel Matlab Toolbox [Maiwald and Timmer, 2008] by
executing 4 rounds of parameter estimation and identifiability as shown in Ta-
ble 7.1. Parameters were calibrated using trust region algorithm (MaxIter: 250;
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TolFun: 1e-07; TolX: 1e-07) and cvodes integration algorithm (AbsTol: 1e-08;
RelTol: 1e-06; MaxNumSteps: 1500). For each round, a sequence of 1000 fits was
computed by setting the highest possible strength of disturbance (Value: 1) over
the parameters initial value in order to extensively explore the parameter space.
Parameters were fitted among the interval [1e-08, 1e+05]. Nonlinear MOTA iden-
tifiability analysis, as implemented in PottersWheel [Hengl et al., 2007; Maiwald
and Timmer, 2008], identified tuples of related parameters as well as the sets of
parameters which could be identified at each calibration round. A threshold of
35% was applied for selecting the best fits before computing linear and nonlinear
MOTA analysis. Model simulation and perturbation were performed using Co-
pasi [Hoops et al., 2006]. The complete tables of model parameters comprising
the details of parameter estimation rounds, model ODEs and sequence fit selec-
tion are reported in Tables 7.1-7.4 and Figure 7.10. Identifiability analysis, as
performed for each parameter estimation round, is provided in Figures 7.11-7.15.
Deterministic simulations used LSODA algorithm (RelTol: 1e-06; AbsTol: 1e-12;
MaxIntSteps: 1e+04). Stochastic simulations used Direct method (MaxIntSteps:
1e+06; UseRandomSeed: 0; RandomSeed: 1). Simulated stochastic simulation
performed up to 50 days post irradiation indicated model steady state after 20-
25 days for all the measured readouts (see Figure 7.16). Model 2D sensitivity
analysis for model observables was computed at days 1, 10 and 20 by perturbing
the kinetic rate constant values (see Figure 7.17). Double perturbations data
were computed using Copasi by varying each of the two parameters from 0%
to 300% by step 0.25%. Double perturbation plots were achieved using Matlab.
Plots related to parameter estimation and identifiability analysis were generated
by Potterswheel. Model structure was graphically represented using CellDesigner
[Funahashi et al., 2008, 2003] and exported to SBML [Hucka et al., 2003] Level
2 Version 4 using Potterswheel. The statistical and programming language R v.
2.14.1 [R Development Core Team, 2010] was selected for the graphic representa-
tion of the identifiability matrix computed with MOTA and single perturbation
plots.
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7.4.2 Statistics
The programming language R was used for computing time course mean and
standard deviation of 5 independent in vitro time-course measurements. Mean
and standard deviation values were then used for calibrating the model observ-
ables. The goodness-of-fit statistical measures χ2 [Maiwald and Timmer, 2008],
AIC, AICc [Akaike, 1973] and BIC [Schwarz, 1978] were used to assess the quality
of fit of the model at each calibration round. All these measures were directly
computed using PottersWheel Toolbox.
7.5 Figures and tables
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Figure 7.1: A dynamical model for irradiation-induced cellular senescence. Graphical model
integrating the insulin-TOR (IIS-TOR) signalling pathway (left, black reactions), the oxidative
stress response (right, blue reactions), FoxO3a regulation (top), nuclear DNA damage (centre,
magenta reaction) and mitochondrial phenotype (bottom, red reactions).
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Figure 7.2: In silico versus in vitro time courses. The model (red lines) was calibrated over
experimental time course data (see blue points) collected for 13 readouts in the network up to
21 days. The inputs are amino acids/insulin (constant inputs) and irradiation (pulse input of
5 min which simulates 20 Gy X ray irradiation over 5 min). Experimental time points (blue
points) are mean +/- 1 standard deviation collected from 5 repetitions. In vitro experiments
were performed by Dr Glyn Nelson, Newcastle University, UK.
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Figure 7.3: JNK inhibition promotes cytoplasmic FoxO3a migration and Mfn2. (A) In silico
time-courses for nuclear unphosphorylated FoxO3a and JNK-phosphorylated FoxO3a showing
a shift towards active FoxO3a being predominantly phosphorylated by JNK over time after
stress induced premature senescence. (B) At 10 days post irradiation, the model quantitatively
predicted a decrease in total phosphorylated JNK and an increase in cytosolic fraction of FoxO3a
upon JNK inhibition (black and blue histograms). These predictions were confirmed in vitro.
MRC5 cells were irradiated to cause stress-induced senescence then incubated with a JNK
inhibitor (1µM SP600125). 10 days post irradiation, cells were stained for phosphorylated JNK
(T183/Y185) and total FoxO3a. Quantification of fluorescence intensities indicated a significant
decrease in total phosphorylated JNK (Mann-Whitney test, * P = 0.014) and a significant
increase in cytosolic fraction of FoxO3a (t-test, ** P = 0.010) (white and grey histograms). (C)
Example fluorescence images for the previous quantification. (D) Downstream of FoxO3a, the
model predicted increases in mTORC1-pS2448 phosphorylation and mitofusin2 upregulation
in a JNK-dependent manner. (E) Western blotting data confirmed the changes in mTORC1-
pS2448 and mitofusin2 levels following MRC5 cells up to 21 days post irradiation in the presence
of JNK inhibitor. See Figure 7.4 for other readouts upon in silico JNK perturbation. In vitro
experiments (Panels B:Observed, C and E) were performed by Dr Glyn Nelson, Newcastle
University, UK.
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Figure 7.4: Other simulated readouts for JNK single perturbation. After 6-9 days post irradi-
ation, the levels of AMPK dramatically decreased in a JNK inhibition treatment. Conversely,
the mitochondrial membrane potential increased although its level did not recover to levels
achieved before day 3.
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Figure 7.5: ROS inhibition improves mitochondrial membrane potential. (A) At 15 days post
irradiation, the model quantitatively predicted an increase in mitochondrial (mt) membrane
potential upon ROS inhibition (black and blue histograms). (B) Example images of control cells
(upper panel) and cells treated with SOD and catalase (100U each) in the medium (lower panel)
for 15 days post IR are shown. (C) The model prediction was confirmed by quantification of
the fluorescence intensities. Exogenous addition of SOD and catalase significantly increased the
average membrane potential (Mann-Whitney test, *** P < 0.001) in vitro. In silico inhibition
of ROS levels also partially reactivated mt membrane potential in a dose dependent manner,
with between 75 and 50% levels giving equivalent restoration of membrane potential to the in
vitro data. In vitro mt membrane potential was determined in MRC5 cells 15 days post IR using
live cell imaging of cells loaded with the mt membrane potential dependent dye TMRM, non-
potential dependent mitotracker green and nuclear counterstain Hoechst 33342. Scale bar is 10
µm. See Figure 7.6 for other readouts upon in silico ROS perturbation. In vitro experiments
(Panels B, C:Observed) were performed by Dr Glyn Nelson, Newcastle University, UK.
144
7. A dynamical mTOR-ROS model for irradiation-induced cellular
senescence
Figure 7.6: Other simulated readouts for ROS single perturbation. Upon ROS perturbation, the
insulin/TOR pathway was severely affected. In details, mTOR-pS2448 levels were increased,
whereas AMPK-pT172 were decreased. The reduction in mTOR-pS2448 led to an intensified
mTORC1-p70-S6K-dependent negative feedback loop, reducing Akt-pS473 levels. Contrary to
mTOR and AMPK dynamics, the levels of Mfn2 decreased. In addition, the system strongly
lost sensitivity after day 9-11 post irradiation. This prediction meant that a ROS inhibition
treatment alone is not expected to reverse senescence, especially after 9-11 days post irradiation.
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Figure 7.7: Predicted outcomes for double perturbations of JNK-Akt and Mfn2-ROS. (A)
Schematic model illustrating the application of a combined JNK-Akt perturbation. (B) Simu-
lation of combined JNK-Akt perturbation applied at day 0. To limit cytoplasmic FoxO3a-pS253
and to maintain JNK inhibition positive effects, intervention on cytoplasmic FoxO3a-pS253 was
applied only on the inhibition region (white square, *). Accordingly with this, Mfn2 levels and
mitochondrial (mt) membrane potential increased at day 10 post irradiation. (C) Schematic
model illustrating the application of a combined Mfn2-ROS perturbation. (D) Simulation of
combined Mfn2-ROS perturbation applied at day 0. Using the prediction obtained in B, the
double perturbation region could be largely limited to the area in the bottom (white square,
**), characterised by high Mfn2 and low ROS levels. Consistently, in this area the mt mem-
brane potential was maximised at day 10 post irradiation. From a mathematical point of view,
a double perturbation represents a function in two variables and in this case the generated
surface is seen from the top.
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Figure 7.8: Exploration of Mfn2 simulated single perturbation. Upon a gradual inhibition of
Mfn2 (blue lines), the model predicted a decrease in mitochondrial membrane potential and
ROS levels. Black line indicates no perturbation of Mfn2, blue lines indicate inhibition, magenta
lines indicate over-expression.
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Figure 7.9: Time course analysis of combined TOR-ROS perturbation. (A) In silico Mfn2
and mitochondrial (mt) membrane potential time course responses upon combined TOR-ROS
perturbation (0-300% TOR or ROS level). At days 15-21, TOR and ROS perturbation split the
Mfn2 response into two activation states (see S1, S2 divided by black line). Later, S1 almost
disappeared. (B) In silico Mfn2 response upon combined TOR-ROS inhibition (0-100% TOR
or ROS level) at days 15 or 21. The black point (100% TOR, 100% ROS) is the control, light
grey line is TOR inhibition, and dark grey circle is combined TOR-ROS inhibition. (C) In vitro
Mfn2 response upon inhibition of TOR or combined TOR-ROS at days 0, 15 or 21. Cells were
treated with 20 nM Torin1 (TOR inhibitor), or Torin1 with SOD and catalase (100U each)
(ANOVA with Tukey’s post-hoc test, * P = 0.04, ** = 0.002, n.s. = non significant). (D) In
silico mt membrane potential response upon combined TOR-ROS inhibition (from 0 to 100%
TOR or ROS level) at day 12. The white line is ROS inhibition. (E) In vitro mt membrane
potential response upon inhibition of TOR, ROS or combined TOR-ROS at day 12 (ANOVA
with Tukey’s post-hoc test, * P = 0.028, *** P < 0.001). In vitro experiments (Panels C, E)
were performed by Dr Glyn Nelson, Newcastle University, UK.
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Figure 7.10: Sequence fits selection for parameter estimation round. For each calibration round,
a sequence of 1000 fits was computed (see Table 7.1). The best 350 fits of the sequence were
selected and statistics regarding their p-values and normalised χ2 distribution were reported.
Despite the high noise applied to the initial value of the parameters before estimation, the
selected best fits clustered in each round in terms ofχ2, particularly after Round 0. This
suggested that the reported final χ2 of the model (see Table 7.3) represented a point of conver-
gence for many solutions. N=number of experimentally measured data point, #par=number
of estimated parameters, p() = p-value function.
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Figure 7.11: MOTA non-identifiability analysis for Round 0 of parameter estimation. MOTA
non-identifiability analysis reported multiple tuples of statistically significant parameter corre-
lations. However, the parameters k32, k33, k34 governing the DNA-damage module could be
fixed since no statistically significant correlation was found and their confidence intervals could
be measured. The analysis was performed on the best 35% fits of the calibration sequence
without excluding any outlier. r2=correlation, CV=coefficient of variance, #=number of times
this correlation was found. (*) r2 > 0.8 & CV > 0.1 (**) r2 > 0.8 & CV > 0.1 & #> 1.
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Figure 7.12: Plots of tuples of related parameters for Round 0. Doublets (A), triplets (B),
quadruplets (C) and quintuplets (D) of related parameters as computed by MOTA non-
identifiability analysis (see Figure 7.11) are shown. The analysis was performed over the best
35% of the fit sequence.
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Figure 7.13: MOTA non-identifiability analysis for Round 1,2 and 3 of parameter estimation.
(A) In Round 1, most of the parameters did not show statistically significant correlations and
could therefore be fixed. (B) Round 2 only reported 3 parameters as non-identifiable which were
finally determined in Round 3 (C). For each round, the analysis was performed on the best 35%
fits of the calibration sequence without excluding any outlier. r2=correlation, CV=coefficient
of variance, #=number of times this correlation was found. (*) r2 > 0.8 & CV > 0.1 (**)
r2 > 0.8 & CV > 0.1 & #> 1.
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Figure 7.14: Plots of tuples of related parameters for Round 1. Doublets (A), triplets (B) and
quadruplets (C) of related parameters as computed by MOTA non-identifiability analysis (see
Figure 7.13) are shown. The analysis was performed over the best 35% of the fit sequence.
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Figure 7.15: Plots of tuples of related parameters for Round 2. Doublets (A), triplets (B) and
quadruplets (C) of related parameters as computed by MOTA non-identifiability analysis (see
Figure 7.13) are shown. The analysis was performed over the best 35% of the fit sequence.
154
7. A dynamical mTOR-ROS model for irradiation-induced cellular
senescence
Figure 7.16: Stochastic simulation of the model. Model stochastic simulations up to 50 days
graphically showed steady-state already after 20 days for all the species. Due to high ROS
levels, the oxidative stress response forces almost all nuclear FoxO3a to be phosphorylated by
JNK. For a formal analysis indicating that the system is asymptotically Lyapunov stable see
Table 7.5. Number of stochastic runs: 500; black line indicates the means, dark grey area
indicates 95% confidence interval of the mean and grey area indicates a standard deviation.
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Figure 7.17: Model sensitivity analysis. Sensitivity analysis was calculated in order to measure
the contribution of the kinetic rate constant parameters over the model observable variables.
The analysis was performed at day 1 (representing normal cells population, panel A), day
10 (mixed cells population, panel B) and day 20 (senescent cells population, panel C) post
irradiation. From day 1 to day 20, Mfn2 showed a decrease in sensitivity by AMPK (k3) and
by nuclear FoxO3a when unphosphorylated by JNK (k9). Interestingly, the system presented
an increase in the sensitivity of the parameters controlling DNA damage: DNA repair (k33)
and DNA damage generated by ROS (k34).
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Table 7.1: Table of the kinetic rate constants. Kinetic rate constants values and confidence
intervals were estimated in 4 calibration rounds. For each round a sequence of 1000 fits was
generated by perturbing the parameters initial values with noise of 10d∗eps, where d = 1 and
eps randomly chosen from a normal distribution N(0, 1). The best 350 fits of the sequence were
selected and MOTA non-identifiability analysis was employed for determining tuples of related
parameters requiring further calibration. At each round, the identified parameters were fixed
and their mean, standard deviation and confidence interval were reported.
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Table 7.2: Table of the initial concentrations and auxiliary parameters. Protein initial concen-
trations were directly determined from experimental time course data. Initial concentrations
of protein inactive states were calculated as the maximum peak of the relative activation level
in the time course plus two times the standard deviation at that time point. Since at time t=0
cells were treated with X-rays irradiation, the initial concentrations of active states for proteins
in the oxidative stress signalling were fixed to 0. The remaining initial concentrations were fixed
to 1 in accordance with the normalised experimental basal level, since cells were not starved of
amino acids and insulin. In Figure 7.1, the three states of mitochondrial membrane potential
(high, low, null) are here mapped with the species identifiers x22, x23 and x24, respectively.
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Table 7.3: Model fit details for each calibration round. For each calibration round, the measures
of χ2, Akaike information criterion (AIC, AIC corrected) and Bayesian information criterion
(BIC) are indicated. Since Round 0, the model was not statistically rejected (P-value(N-p) >
0.05) and showed an accurate fitting with the data. Despite being required for parameter identi-
fication, the calibration rounds did not introduce significant improvements in the overall model
fitting (see χ2, P-value(N) between Round 0 and Final Model). Between rounds the measures
P-value(N-p), AIC, AICc and BIC showed improvements due to the decrease in parameters
number p. P-value(N), p-value(N-p): χ2 tests with N or N − p degrees of freedom, where N is
the number of fitted data points and p corresponds to the number of fitted parameters.
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Table 7.4: Ordinary differential equations of the model. List of the ordinary differential equa-
tions (ODEs) for the model. Kinetic rate constants were abbreviated using the notation shown
in Table 7.1. Protein activation states (species) are reported from Table 7.2.
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Table 7.5: Lyapunov exponents of the model. The modelled system of first approximation is
regular since all the coefficients are constant. The Lyapunov exponents computed for this model
are all negative, indicating that the model is asymptotically Lyapunov stable and therefore the
trajectories eventually converge to an equilibrium. The maximum Lyapunov exponent (λ20) is
significantly high because the value for the variable Functional Mitochondria (x22) dramatically
dropped due to the initial irradiation and did not restore due to the high levels of ROS and DNA
damage. The 20 Lyapunov exponents were computed for the reduced system (20 independent
variables) using Copasi [Hoops et al., 2006] and the inner Wolf method [Wolf et al., 1985]
was configured with parameters: orthonormalisation interval: 0.0001, overall time: 50, relative
tolerance: 1e-06, absolute tolerance: 1e-10, maximum internal steps: 10000. The divergence
computed using finite divergences (algorithm defined in [Hindmarsh, 1983] and implemented
in Copasi) coincides with the sum of Lypunov exponents indicating high confidence in the
computation of the exponents.
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Chapter 8
Conclusions and outlook
This doctorate thesis presents the dynamical modelling study that I fulfilled for
three systems biology-based projects. These works led to the following results:
1. mTORC2 can be activated by a PI3K isoform which is sensitive to Wort-
mannin and independent of p70-S6K-dependent negative feedback loop (NFL);
2. AMPK can be activated by insulin through insulin receptor substrate (IRS)
and dependency on the NFL; and
3. formal mechanism underlying the initiation and consolidation of irradiation-
induced senescence state with emphasis on the role of the forkhead box
family subclass O (FoxO3).
Projects 1 and 2 focused on the mammalian target of Rapamycin (mTOR) net-
work (using HeLa and C2C12 cells). Project 3 provided a comprehensive model
of cellular ageing by integrating the mTOR pathway with the DNA-damage and
oxidative-stress response, FoxO, and mitochondrial function (using human diploid
fibroblast MRC5 cells).
Project 1 advanced our knowledge on the upstream activation of mTORC2 which
is of particular importance because: (a) mTORC2 regulates numerous ageing- and
cancer-related downstream targets, such as Akt, FoxO, SGK and PKC; (b) a link
between mTORC2 and PI3K opens interesting directions on how to pharmaco-
logically reduce PI3K and mTOR complexes activity in a combinatorial manner
without unbalancing their downstream signalling function; and (c) the discovery
of specific PI3K isoforms responsible for mTORC2 activation, all of which can
result in a new major link between mTORC2 and other cellular functions.
Project 2 aimed to extend the previous model with an AMPK module, since
mTOR is also regulated by energy, aside from growth factors and nutrients. The
162
8. Conclusions and outlook
finding that AMPK can be regulated by insulin through IRS and that this induc-
tion is reduced by the NFL highlights the following main aspects: (a) more study
is required in order to understand the significance of AMPK regulation by insulin;
(b) new drug interventions may take advantage of this interplay between AMPK
and mTORC1, by improving their function and limiting undesired consequences;
and (c) important regulatory feedback loops may still be missing and these will
notably increase the complexity of the TOR network.
Finally, Project 3 theoretically formalised the mechanism by which normal cells
become and stabilise as senescent cells upon irradiation. Importantly, this project
shows that: (a) nuclear FoxO plays different roles depending on mode of activa-
tion and the characterisation of these must be carefully investigated in order to
properly benefit from FoxO activity; (b) combinatorial intervention is necessary
to avoid undesired effects in the network; (c) reactive oxygen species (ROS) are
an important initiator and contributor for driving ageing, although other compo-
nents, such as TOR and inflammatory system, also contribute; (d) long term time
courses should also be considered for studying the progressive and irreversible
state transition during senescence; (e) irradiation-induced senescent state con-
solidation may be the result of limiting cell damage accumulation in conditions
of insufficient energy; (f) the senescent phenotype may be still reversed at later
time points if mitochondrial function is restored (mitochondria re-modelling) and
combinatorial intervention to limit internal and external cellular damage accu-
mulation is applied; and (g) since ageing is a state transition, dynamical systems
theory should be considered and applied for formalising dynamical models in age-
ing.
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C O M P U T A T I O N A L B I O L O G Y
A Dynamic Network Model of mTOR Signaling
Reveals TSC-Independent mTORC2 Regulation
Piero Dalle Pezze,1,2* Annika G. Sonntag,3* Antje Thien,4 Mirja T. Prentzell,3 Markus Gödel,4
Sven Fischer,3 Elke Neumann-Haefelin,4 Tobias B. Huber,4,5 Ralf Baumeister,3,5,6,7
Daryl P. Shanley,1,2† Kathrin Thedieck3,5,6†
The kinase mammalian target of rapamycin (mTOR) exists in two multiprotein complexes (mTORC1 and
mTORC2) and is a central regulator of growth and metabolism. Insulin activation of mTORC1, mediated by
phosphoinositide 3-kinase (PI3K), Akt, and the inhibitory tuberous sclerosis complex 1/2 (TSC1-TSC2),
initiates a negative feedback loop that ultimately inhibits PI3K. We present a data-driven dynamic insulin-
mTOR network model that integrates the entire core network and used this model to investigate the less
well understood mechanisms by which insulin regulates mTORC2. By analyzing the effects of perturba-
tions targeting several levels within the network in silico and experimentally, we found that, in contrast to
current hypotheses, the TSC1-TSC2 complex was not a direct or indirect (acting through the negative
feedback loop) regulator of mTORC2. Although mTORC2 activation required active PI3K, this was not
affected by the negative feedback loop. Therefore, we propose an mTORC2 activation pathway through a
PI3K variant that is insensitive to the negative feedback loop that regulates mTORC1. This putative pathway
predicts that mTORC2 would be refractory to Akt, which inhibits TSC1-TSC2, and, indeed, we found that
mTORC2 was insensitive to constitutive Akt activation in several cell types. Our results suggest that a pre-
viously unknown network structure connects mTORC2 to its upstream cues and clarifies which molecular
connectors contribute to mTORC2 activation.
INTRODUCTION
The kinase target of rapamycin (TOR) is conserved in all eukaryotes from
yeast to humans and is a central regulator of cellular growth, aging, and
metabolism (1, 2). As a central metabolic regulator, TOR is involved in a
multitude of human diseases, including metabolic syndromes, cancer, and
neurodegenerative diseases (1). Rapamycin is a well-known immuno-
suppressant, and rapalogs and other TOR inhibitors are applied in cancer
therapy (3). Because of its clinical importance, it is important to under-
stand the exact dynamics and interconnections within the TOR network.
TOR occurs in two functionally and structurally distinct multiprotein
complexes termed TOR complex 1 (TORC1) and TORC2. The mamma-
lian TORC1 (mTORC1) contains the specific scaffold protein Raptor and
the inhibitory binding partner PRAS40, whereas mTORC2 contains the
proteins Rictor, mSin1, PRR5, and PRR5L (1). mTORC1 controls cellular
growth, translation, transcription, and autophagy (4); mTORC2 controls
spatial growth by regulating the actin cytoskeleton (5). mTORC1 is spe-
cifically inhibited by the small macrolide rapamycin, whereas mTORC2 is
rapamycin-insensitive. Adenosine triphosphate (ATP) analog TOR kinase
inhibitors (TORKinibs) that target both mTOR complexes have also been
described (6). Although the upstream and downstream regulatory mecha-
nisms controlling mTORC1 arewell characterized, those regulating mTORC2
are less well understood.
mTORC1 is regulated by nutrients (amino acids), growth factors (in-
sulin), and energy (7). Amino acids activate the Ragulator-Rag complex to
translocate mTORC1 to lysosomes, where mTORC1 can be activated by the
small guanosine triphosphatase (GTPase) Rheb (8–10). Insulin signaling in-
duces a kinase cascade through the insulin receptor (IR), IR substrate (IRS),
class I phosphoinositide 3-kinases (PI3Ks), phosphoinositide-dependent
protein kinase 1 (PDK1), and the AGC kinase Akt (also known as PKB).
Akt inhibits the tuberous sclerosis complex 1/2 (TSC1-TSC2) dimer, which
is the inhibitory GTPase-activating protein (GAP) for Rheb (4). Through
this cascade, Akt stimulates mTORC1 activity. The best-characterized
mTORC1 substrates are the AGC kinase p70 ribosomal protein S6 kinase
(p70S6K), the translation initiation regulator 4E binding protein (4E-BP),
and the proline-rich Akt substrate PRAS40, which is an inhibitor of mTORC1
(11). By binding mTORC1, PRAS40 contributes to the inhibition of mTORC1
activity (12–16). In response to insulin, Ser183 of PRAS40 is phosphorylated
by mTORC1 (17), which releases PRAS40 from the complex and relieves
its inhibitory effect on mTORC1 (18), allowing mTORC1 to phosphoryl-
ate its downstream substrates p70S6K and 4E-BP and promote cellular
growth. Furthermore, there is a negative feedback loop (NFL) that inhibits
upstream insulin signaling upon mTORC1 activation: Active p70S6K
phosphorylates and inhibits IRS, which prevents activation of PI3K in re-
sponse to insulin (4).
mTORC2 is mainly regulated by growth factors (1), although in-
duction by nutrients has also been described (19, 20). Little is known
about the molecular mechanism by which insulin induces mTORC2. The
known substrates of mTORC2 are the AGC kinases Akt (21–24), serum-
and glucocorticoid-induced protein kinase SGK (25), and protein kinase
C a (PKCa) (26). AGC kinases must be phosphorylated twice to be fully
active (27–29): They are phosphorylated by PDK1 in the T loop and in
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the hydrophobic motif by a PDK2. Only one PDK1 exists for all AGC
kinases, but the identity of PDK2 differs among the AGC kinases.
mTORC2 is a PDK2 for Akt, SGK, and PKCa (27–29), and phos-
phorylation of Ser473 of Akt is a commonly used readout for mTORC2
activity.
Using mTORC2 substrate AGC kinases as indicators of mTORC2 ac-
tivity, the TSC1-TSC2 complex has been implicated in mTORC2 activa-
tion by insulin: TSC1-TSC2 inhibition reduces phosphorylation of the
mTORC2 substrate Akt at Ser473 (30–33). This result was surprising be-
cause TSC1-TSC2 inhibits mTORC1 (34). Two models have been pro-
posed to explain mTORC2 regulation by TSC1-TSC2, involving either
direct mTORC2 activation by TSC1-TSC2 (31, 33) or an indirect mech-
anism through an active NFL that inhibits PI3K when mTORC1 was
hyperactive in response to TSC1-TSC2 ablation (35). However, data
showing that mTORC2 contributes to proliferation in TSC2-null cells sug-
gest that mTORC2 can be active in the absence of TSC1-TSC2 (36). A
third hypothesis for mTORC2 activation is through a PI3K-independent
mechanism, which has been identified in Dictyostelium (37–40). In mam-
mals, several cellular processes that are regulated by mTORC2 have been
described as PI3K-independent (19, 26, 41–43), making the hypothesis of
PI3K-independent activation of mTORC2 conceivable.
To distinguish among the possible mTORC2 activation mechanisms
and to determine whether they acted independently or in combination,
we developed a mathematical dynamic network model. We hypothe-
sized that different modes of mTORC2 regulation would result in dis-
tinguishable, dynamic network responses. With the mathematical model,
we performed specific predictive dynamic simulations for alternative
mechanisms of mTORC2 regulation, and then these were experimentally
validated.
There are several computational studies related to mTOR signaling.
These include static network models of known molecular interactions,
for example, the map for the insulin-mTOR network (44). Dynamic
models also exist. These require information about the molecular inter-
actions and also detailed quantitative experimental time course data,
which can be generated specifically for the model (45–53) or can use data
from previous studies (45, 54–57). Much of the currently available dy-
namic models focus on the upstream insulin signaling events, such as
the binding of insulin to its receptor (50), and receptor autophosphor-
ylation and receptor-mediated substrate phosphorylation, together with
receptor cycling and endocytosis (46, 49). More extensive models in-
cluding activation of IRS, PI3K, Akt, and the NFL have been developed
with specific functional emphasis on cycling of the glucose transporter
GLUT4 (54), dendritic protein synthesis (45), or breast cancer therapy
(51). Other models address complex issues, such as joint regulation of
the NFL by insulin and amino acids (56), crosstalk with epidermal growth
factor (EGF) signaling and the mitogen-activated protein kinase (MAPK)
pathway (48), and TORC1 regulation by phosphatases in yeast (52).
Because the combined experimental-computational approaches typical-
ly address specific questions, the generated data sets are often limited,
representing one (47) or two time points (53), or representing limited parts
of the network, such as binding of insulin and insulin-like growth factor
(IGF) to their receptors (50). None of the existing models integrates
mTORC2 regulation.
Here, we report an insulin-mTOR network model integrating both
mTORC1 and mTORC2. The model was parameterized with dynamic
quantitative time course data and experimentally validated. Subsequently,
we introduced in silico and experimental network perturbations to simulate
and experimentally test alternative network structures connecting mTORC2
to upstream insulin signaling. This approach provides the benefit of
both a structural and a dynamic network analysis (58).
Our model and experimental testing indicated that in contrast to pre-
vious hypotheses, the TSC1-TSC2 complex was not a direct activator
of mTORC2 and that mTORC2 activity was insensitive to the mTORC1-
induced NFL. Furthermore, although PI3K is inhibited by the NFL, acti-
vation of the NFL-insensitive mTORC2 also required active PI3K. Hence,
all three literature-based hypotheses were excluded by our combined
simulation and experimental data. Instead, we postulate that insulin sig-
naling activates mTORC2 through a PI3K that is insensitive to the NFL;
thus, insulin triggers signaling networks that diverge upstream of Akt.
We created a network structure that fits the available experimental data
and provided experimental evidence supporting the network.
RESULTS
A dynamic insulin-regulated TOR network model
Initially, we established a static network model in SBGN (Systems
Biology Graphical Notation) format (59) of insulin-mTOR signaling
as a means to integrate current knowledge and as a platform to guide
our decision on appropriate targets for measurement (fig. S1). The choice
of boundaries for such a network and the level of molecular detail to in-
clude are subjective decisions. There is considerable existing knowledge
concerning insulin signaling and the regulation of TOR (1, 7). Although
we used this information, we needed to minimize the amount of detail
because precise dynamics for the extended graphical model could not
be defined due to the high number of parameters and the difficulty in ob-
taining sufficient experimental data. Therefore, we abstracted the extended
model on the basis of two main considerations. First, we selected regula-
tion mechanisms with an important role in dynamic behavior, such as the
activation of mTOR complexes by the presence of both amino acids and
insulin, the pathways connecting these stimuli to the mTOR complexes,
and the NFL from p70S6K to IRS. Second, we selected molecules and
interactions that we could reliably measure. To capture the network dy-
namics upon starvation and in response to amino acids plus insulin
(aa/insulin), we distributed our measurements widely across the network.
We monitored the abundance of Tyr1146-phosphorylated IR, Ser636-
phosphorylated IRS1, Ser473- and Thr308-phosphorylated Akt, Ser2448-
and Ser2481-phosphorylated mTOR, Thr246- and Ser183-phosphorylated
PRAS40, and Thr389-phosphorylated p70S6K (see the selected targets
marked with an asterisk in fig. S1).
On the basis of the molecules we could measure, we condensed our
network structure to minimize poorly defined intermediate steps between
obtainable data (Fig. 1A). The condensed network depicts insulin sig-
naling propagating from the IR through the TSC1-TSC2 complex to the
mTORC1 complex and includes p70S6K, PRAS40, and Akt. In addition,
mTORC1 induction by amino acids was included. At this point, no up-
stream pathway regulating mTORC2 was assumed. This model formed
the starting point for our dynamic study.
Readout selection for mTORC2 activity: Akt-pS473
and mTOR-pS2481
Studies suggesting that TSC1-TSC2 regulates mTORC2 commonly used
Akt phosphorylated at Ser473 (Akt-pS473) as the mTORC2 readout. However,
the phosphorylation of Akt depends on PI3K and the phosphatidylinositol
3,4,5-trisphosphate [PtdIns(3,4,5)P3] generated by PI3K, which binds to
Akt and triggers its relocalization to the plasma membrane, where Thr308
is phosphorylated by PDK1 and Ser473 is phosphorylated by mTORC2
(27). Thus, phosphorylation of Akt at either Thr308 or Ser473 depends
on PI3K activity. PI3K and Akt are inhibited in the absence of the in-
hibitory TSC1-TSC2 complex because of hyperactivation of mTORC1
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and the NFL. Consequently, under conditions of TSC1-TSC2 deficiency
and NFL activation, monitoring Akt-pS473 does not differentiate between
PI3K, PDK1, and mTORC2 activity and therefore may not be a suitable
readout to investigate the mode of mTORC2 regulation by TSC1-TSC2
(32). Other AGC kinases that are targeted by mTORC2 (SGK and PKCa)
are not ideal because they have similar issues (28, 60). The rapamycin-
insensitive autophosphorylation of Ser2481 (mTOR-pS2481) (61, 62) has
been described as mTORC2-specific (63) and as occuring in both the
mTOR complexes (64). To determine whether mTOR-pS2481 is a better
readout for mTORC2 activity than is the phosphorylation of AGC kinases
and whether monitoring mTOR-pS2481 will distinguish between PI3K and
mTORC2 activity, we determined that mTOR-pS2481 was a specific
readout for mTORC2 activity in HeLa cells. We performed complex-
specific immunoprecipitations with antibodies against Sin1 (for mTORC2) or
Raptor (for mTORC1) and assessed the amount of mTOR-pS2481 that co-
immunoprecipitated (Fig. 1B). In HeLa cells, mTOR-pS2481 was predomi-
nantly associated with mTORC2 and only weakly associated with mTORC1,
suggesting that mTOR-pS2481 is a suitable readout of mTORC2 activity.
Furthermore, whereas the mTORC1-specific readout p70S6K1-pT389 was
reduced by the mTORC1-specific inhibitor rapamycin (Fig. 1, C and D),
in agreement with Copp et al. (63), mTOR-pS2481 was not significantly
affected by short-term treatment with the rapamycin (Fig. 1, C and E). In
contrast, the TORKinib PP242 (65), which inhibits both mTOR com-
plexes, reduced the abundance of mTOR-pS2481 in a dose-dependent man-
ner (Fig. 1, C and E), which is consistent with results obtained with Torin1,
another TORKinib (64, 66). Therefore, our results suggest that mTOR-
pS2481 is reduced by mTORC2, but not by mTORC1 inactivation.
Because there are rapamycin-insensitive mTORC1 functions (67), we
also knocked down specific mTORC1 and mTORC2 components to
assess the dependence of mTOR-pS2481 on the activity of the two com-
plexes. When the mTORC1-specific component Raptor was knocked down,
mTOR-pS2481 was unchanged (Fig. 1F), whereas there was a significant
reduction in mTOR-pS2481 by 67% (three independent experiments, SEM
8%) when the mTORC2-specific component Rictor was knocked down
(representative experiment shown in Fig. 1G). Thus, both knockdown
and pharmacological experiments indicated that mTOR-pS2481 serves
as an mTORC2-specific readout in our system.
Parameterization of the network model
To parameterize the static network model, we generated semiquantitative
dynamic phosphorylation immunoblot data for network components
along the signaling cascade (Fig. 1A). We analyzed HeLa cells under
starvation conditions, meaning that they were deprived of amino acids
and growth factors for 16 hours to fully inhibit mTOR network activity,
and also cells that had been starved and then stimulated with aa/insulin
to assure full induction of both mTOR complexes. Dynamics of the
mTOR network were monitored from 1 min up to 2 hours after induction
with aa/insulin (Fig. 2A). Signals were quantitatively analyzed (see Materials
Fig. 1. Setup of a dynamic insulin-stimulated mTOR network model and confirmation of mTOR-pS2481 as
a specific mTORC2 readout. (A) Reduced graphical model of the mTOR network activated by aa/insulin
(see fig. S1 for the extended graphical model). (B) Coimmunoprecipitation (IP) of mTOR-pS2481 with Sin1 (a component of mTORC2) or Raptor
(a component of mTORC1); Mock IP, control IP with a nonspecific antibody. Data are representative of three experiments. (C) Effect of PP242 or
rapamycin on the indicated phosphorylated proteins. Data are representative of three experiments. (D and E) Quantitation of three experiments
similar to the one shown in (C) for mTORC1 readout p70-S6K-pT389 (D) and mTORC2 readout mTOR-pS2481 (E). R, rapamycin. *P < 0.05; n.s., not
significant. In (D), PP242 [200 nM, an mTOR-specific standard concentration (6)]–treated compared to dimethyl sulfoxide (DMSO)–treated control
and rapamycin-treated samples compared to DMSO control were significant. In (E), PP242 (200 nM)–treated compared to DMSO-treated control
was significant. Rapamycin (100 nM) compared to DMSO control was not significant. (F) Effect of Raptor knockdown on mTOR-pS2481. Data are
representative of three experiments. (G) Effect of Rictor knockdown on mTOR-pS2481. Data are representative of three experiments.
R E S E A R C H A R T I C L E
www.SCIENCESIGNALING.org 27 March 2012 Vol 5 Issue 217 ra25 3
 o
n
 M
a
rc
h
 2
8
, 2
0
1
2
 
s
tk
e
.s
c
ie
n
c
e
m
a
g
.o
rg
D
o
w
n
lo
a
d
e
d
 fro
m
 
167
and Methods). Because signal linearities are critical for quantitative data
generation (68), we confirmed the linear signal–to–protein amount rela-
tionships by detection of serial dilutions of whole-cell lysates (fig. S2).
We calibrated the model parameters by means of the experimental mean
time courses (Fig. 2B).
The initial concentrations of the species in their nonphosphorylated
state were determined directly from our semiquantitative data (see Mate-
rials and Methods). For all other species, the initial concentrations were set
to 0. Because it is difficult to fit large numbers of parameters to data to
estimate kinetic rate constants (69–71), which are necessary to calibrate
the model, we divided the data fitting into calibration phases and resolved
each phase with an iterative procedure (figs. S3 and S4). This procedure is
summarized by the following steps: (i) The initial values of the parameters
that needed optimization were assigned by random generation. (ii) The
calibration was repeated until a set of parameters with consistent values
was identified. (iii) This set of parameters was fixed and the remaining
free parameters were calibrated again by repeating the process. In phase
1 of the estimation of kinetic rate constants, we sought to identify isolated
modules that could be calibrated independently within the network. Be-
cause IR regulation was not affected by the rest of the network, this
module could be isolated and we could calibrate three parameters at once:
the kinetics of IR activation by insulin, dephosphorylation to a refractory
state, and transition to a receptive state. We initially generated a model that
was independent of the pathway by which mTORC2 was activated. We
temporarily modeled the regulation of the mTORC2 substrate Akt-S473
and mTORC2 component mTOR-S2481 with two autoactivation mecha-
nisms, which were then calibrated with the Akt-pS473 and mTOR-pS2481
experimental data sets. This enabled us to reproduce Akt-pS473 activation
while maintaining mTORC2 isolated from the network. During phase 2,
a total of 24 reaction rate constants were estimated with eight experimental
readouts. Finally, in phase 3, we replaced the autoactivation mechanism of
Akt-pS473 with a phosphorylation mediated by mTORC2-pS2481. Because
the initial induction of Akt-pS473 occurred before mTOR-pS2481 was in-
duced (Fig. 2, A and B), mTORC2-pS2481 alone could not reproduce the
dynamics of the experimental data for Akt-pS473. mTORC2 is not the only
PDK2 candidate that may phosphorylate Akt-S473; therefore, we introduced
an additional PDK2 species and recalibrated the phosphorylation of Akt-
S473 under the influence of the two kinases. In this phase, three kinetic rate
constants were estimated with the Akt-pS473 experimental data.
Once this process of parameterization was complete, the experimental
and simulated time courses matched well for all the analyzed mTOR
network readouts (Fig. 2B). The ordinary differential equations (ODEs)
and estimated parameters for the general model are provided in tables
S1 and S2. Identifiability analysis, which indicates whether the parameters
can be estimated with confidence from the available data, and sensitivity
analysis, which indicates how sensitive model behavior is to variation in
each parameter, for the general model are shown in figs. S5 and S6. The
identifiability analysis does not show high correlation between estimated
parameters, indicating that they can be identified.
Validation of the mTORC1 branch: Network perturbation
by gradual mTORC1 inhibition
If the parameterized model correctly represents the biological mTOR
network dynamics in response to aa/insulin, model simulations must
Fig. 2. Setup of a dynamic insulin/mTOR network model. (A) Dynamic
quantitative time course acquisition. mTOR pathway activation was
followed over time by measuring phosphorylation dynamics of central
network components. A representative experiment is shown; signal
intensities were quantified and descriptive statistics were computed
over four replicates. (B) Comparison between the simulated time
courses of the general model (solid lines) and the experimental time
courses (points, dotted error bars) within [0, 120] min. For each curve,
the c2 computed over n time points is reported as goodness-of-fit
measure.
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accurately reflect the dynamics of known network responses to a gradual
perturbation. To validate the mTORC1 branch of the model, we perturbed
the network by gradually inhibiting mTORC1 first in silico and then ex-
perimentally with an inducible Raptor knockdown (shRaptor) cell line.
The model was used to simulate the effect of gradual mTORC1 inhibition
on the activation dynamics of the direct mTORC1 substrate p70-S6K-
pT389 at several time points after induction with aa/insulin. The model
predicted a constant increase in p70-S6K-pT389 signal from 10 min
to 2 hours after induction. Furthermore, the model also predicted that
p70-S6K-pT389 would decrease starting 10 min after induction in a near-
linear manner in response to gradual Raptor (mTORC1) inhibition, where-
as there should be no detectable increase or Raptor-dependent change
in p70-S6K-pT389 below 5 min after induction (Fig. 3A). We tested the
predicted quantitative p70-S6K-pT389 response upon gradual mTORC1
inhibition (Fig. 3B) at specific time points (indicated in the simulation in
Fig. 3A by the green lines) and found that the dynamic simulations for
p70-S6K-pT389 were validated by our experimental data (Fig. 3, C and
D). Both the simulations (Fig. 3B) and the experimental results (Fig.
3D) for the change in p70-S6K-pT389 in response to gradual Raptor inhi-
bition at 20 and 45 min after induction with aa/insulin matched, showing
an overall increase in signal at 45 min after induction and no signal at
3 min after induction.
Hence, we confirmed that the model accurately simulated the dynamic
behavior of the mTORC1 substrate p70-S6K-T389 in response to aa/insulin
and to a network perturbation (Raptor inhibition). This was performed with
an experimental perturbation that was not used for parameterization.
Exploration of alternative network structures: Regulation
of mTORC2 by the TSC1-TSC2 complex
The mechanism by which TSC1-TSC2 influences mTORC2 activity is cur-
rently unclear, with both a direct activation of mTORC2 by TSC1-TSC2
and an indirect effect of the TSC1-TSC2 through mTORC1 and the NFL
suggested (31, 33, 35). The evidence for these mechanisms involves exper-
imental designs that could affect the system in a manner that could compli-
cate the interpretation, for example, overexpression of NFL-independent
PI3K versions (31) or TSC2 ablation in combination with subsequent in
vitro mTOR kinase assays (33).
To establish an approach with minimal complicating manipulations,
we applied a combined experimental-computational strategy. Because the
different suggested molecular mechanisms by which TSC1-TSC2 regulates
mTORC2 should result in mechanism-
specific changes in the dynamics of the
mTORC2 readouts, the response of the
readouts to network perturbations should
be predictable and distinguishable by our
dynamic network model. On the basis of
the existing literature, we postulated three
different hypotheses for the molecular con-
nection or lack thereof between TSC1-TSC2
and mTORC2 (Fig. 4A). (Hypothesis 1) TSC-
dependent: TSC1-TSC2 directly activates
mTORC2 in response to insulin and has op-
posite effects on mTORC1 and mTORC2.
(Hypothesis 2) NFL-dependent: mTORC2
is activated by insulin through PI3K, but in-
dependently of Akt and TSC1-TSC2; however,
mTORC2 activity can be inhibited indirect-
ly by TSC1-TSC2 ablation through NFL-
mediated inhibition of PI3K. (Hypothesis 3)
PI3K-independent: mTORC2 is activated by
insulin in a manner that is independent of
both TSC1-TSC2 and PI3K.
We translated these three alternative
modes of mTORC2 regulation into the cor-
responding network structures, reusing the
same kinetic parameters of our previous
model (Fig. 4B). To keep the hypotheses
as comparable as possible, each hypothesis
shared the network topology of the general
model but assumed a specific mTORC2 up-
stream regulator (Fig. 4B). We adopted the
following rationale: Let M be a model fit-
ting some data and S a species in M. If
a modifier (F) directly upstream of S is
selected and recalibration solely of the dy-
namics of S maintains a close fit between
the simulated time course for S and the ex-
perimental data for S, then all time course
curves downstream of S will continue to fit
their corresponding data. The model output,
Fig. 3. Validation: dynamic response of p70-S6K-pT389 to gradual Raptor inhibition. (A) Model predic-
tions for p70-S6K-pT389 dynamics in response to a perturbation of mTORC1. The curves show the
simulated response to gradual mTORC1 inhibition starting at 5 to 10 min after induction with aa/insulin.
The model was simulated with both mTORC1 overexpression and knockdown conditions. Time points
for experimental validation are indicated by green lines. (B) Simulated and quantified relative amounts
of p70-S6K-pT389 under conditions of mTORC1 reduction (0, 25, 50, 75, and 100%) at selected time
points after induction with aa/insulin. (C) Experimental validation of the effect of gradual Raptor knock-
down (shRaptor) on p70-S6K phosphorylation in starved cells induced with aa/ins for the indicated
times. Data are representative of three experiments. d, days. (D) Experimentally determined and quan-
tified p70-S6K-pT389 amounts at the indicated times after induction with aa/insulin in cells in which
Raptor was knocked down. Data are the average and SEM of three experiments. *P < 0.05; **P <
0.01; low Raptor levels compared to high Raptor levels after 20- and 45-min induction; 20- compared
to 45-min induction. Differences in p70-S6K-pT389 were significant. aa/ins, aa/insulin.
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however, after perturbation of F will not necessarily maintain a fit
with the corresponding data when the introduced upstream connec-
tion is incorrect.
We defined three new models in which the network and the parameters
of our previous model were maintained and only the mTORC2 kinetics
were reestimated according to each hypothesis (tables S1 and S3). The
Fig. 4. Three hypotheses for mTORC2 regulation by insulin. (A) Schematic
representation of the insulin-induced mTORC1-mTORC2 pathway with three
different hypotheses (1, green; 2, purple; 3, dark blue) for mTORC2 activation.
Network components that were targeted for perturbations are highlighted in
yellow. (B) Reduced graphical network model including the three hypotheses
(1, 2, and 3, indicated by the dotted lines), translated into different network
structures. (C) Comparisons of simulated time courses, calibrated for each hy-
pothesis, with experimental data. Data are for mTORC2 readouts (mTOR-
pS2481, Akt-pS473), the PI3K readout Akt-pT308, and the mTORC1 readout
p70-S6K-pT389 (see fig. S7 for curves of all other readouts).
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total goodness of fit for the general model
and each hypothesis showed that no model
could be statistically rejected (table S4).
For each hypothesis, we performed time
course simulations and experimental vali-
dation for the mTORC2 readouts mTOR-
pS2481 and Akt-pS473, the PI3K readout
Akt-pT308, and the mTORC1 substrate
p70-S6K-pT389 (Fig. 4C). The curves for
all other analyzed network components
are provided in fig. S7. The simulations
matched the experimental time courses, in-
dicating that the hypotheses were compatible
with the observed dynamics for mTORC2
activation and more generally for the mTOR
signaling network. Identifiability and sensi-
tivity analyses for the three models repre-
senting each hypothesis are shown in figs.
S8 to S13.
We next introduced gradual network
perturbations that prevented either TSC1-
TSC2 activity (TSC1-TSC2 inhibition), the
NFL (mTORC1 inhibition), or insulin acti-
vation of the mTOR complexes (PI3K inhi-
bition). For each of the three perturbations
and each of the three hypotheses, we mod-
eled the dynamic network response of the
readouts of mTORC2 activity (Fig. 5), of
mTORC1 activity (fig. S14), and of PI3K
activity (fig. S15).
Experimental testing: TSC2-
independent mTORC2 induction
From the information obtained from the al-
ternative simulations, we identified ex-
perimental setups and time points after
induction with aa/insulin for the mTORC2
readouts (mTOR-pS2481, Akt-pS473) that
would specifically distinguish among hy-
potheses 1, 2, and 3 (green lines in Fig. 5).
These predictions were then tested experi-
mentally (Figs. 6 to 8).
The models predicted that for gradual
TSC1-TSC2 inhibition, if hypothesis 1 was
correct, then the abundance of mTOR-
pS2481 would be affected by TSC1-TSC2
inhibition in a near-linear manner down to
minimum levels (Fig. 5A). In contrast, for
hypothesis 2, simulated mTOR-pS2481 dy-
namics were only slightly affected by TSC1-
TSC2 inhibition, and for hypothesis 3,
mTOR-pS2481 was not affected (Fig. 5A).
For Akt-pS473 dynamics, if hypothesis 2
or 3 is correct, then Akt-pS473 should only
be weakly affected 5 min after induction
and should exhibit a gradual decrease start-
ing 10 min after induction for the rest of
the time course (Fig. 5B). For hypothesis
1, the model predicted a stronger reduc-
tion of Akt-pS473 in response to TSC1-TSC2
Fig. 5. Simulations of network perturbations at several levels within the network and differential dy-
namic network responses for the three different hypotheses. (A) Simulated mTOR-pS2481 response
upon aa/insulin induction upon the indicated perturbations: TSC1-TSC2 (experimental equivalent:
gradual TSC2 knockdown), mTORC1 (experimental equivalent: gradual Raptor knockdown), and
PI3K (experimental equivalent: gradual PI3K inhibition with wortmannin) for hypotheses 1, 2, and 3.
The time points that were experimentally tested are indicated with green lines. (B) Simulated
Akt-pT308-pS473 response for each of the three hypotheses upon aa/insulin induction upon per-
turbations of TSC1-TSC2, mTORC1, and PI3K. The time points that were experimentally tested are
indicated with green lines.
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inhibition at all time points after induction, compared to the reduction
predicted for hypothesis 2 or 3. Thus, these simulation results indicated
that observation of mTOR-pS2481 in response to gradual TSC1-TSC2
inhibition should effectively distinguish hypothesis 1 from the other
two hypotheses.
For experimental testing, we generated an inducible short hairpin
TSC2 (shTSC2) cell line and induced TSC2 knockdown for 0, 1, 2, or
3 days, which resulted in a gradual decline in the amount of TSC2 (Fig.
6A). After starvation, cells were stimulated with aa/insulin for 5, 30,
and 60 min. Because TSC1-TSC2 is a negative regulator of mTORC1,
p70-S6K-pT389 increased as expected with gradual TSC2 inhibition (Fig.
6A). Relative quantitations for Akt-pS473 and mTOR-pS2481 at 60 min after
aa/insulin induction are shown for the simulations of the three hypothe-
ses and for the experimental data (Fig. 6B). Both the time course anal-
ysis (Fig. 6A) and the analysis of the effect of increasing knockdown of
TSC2 (Fig. 6B) on Akt-pS473 suggested that hypothesis 2 or 3 may be
correct. Hypothesis 1 of direct TSC1/2 activation of mTORC2 was clearly
excluded because mTOR-pS2481 was unaffected by TSC2 inhibition at all
time points (Fig. 6A) and at all amounts of TSC1-TSC2 inhibition (Fig.
6B). Our experimental data are in line with reported findings, indicating
that TSC1-TSC2 does affect Akt-pS473 (31, 33, 35). However, according
to our simulations, the regulation of Akt-pS473 by TSC1-TSC2 depends
on the NFL and PI3K and, thus, in the absence of TSC1-TSC2 mTORC2–
mediated phosphorylation of AktS473 is indirectly inhibited. Because the
direct mTORC2 readout mTOR-pS2481 was unchanged in the absence of
TSC1-TSC2, we can rule out TSC1-TSC2 as a direct activator of mTORC2.
We followed the same procedure that we used to identify the best ex-
perimental condition to assess whether TSC1-TSC2 indirectly controls
mTORC2 through the NFL (35) (hypothesis 2). For gradual mTORC1
inhibition and consequent NFL inhibition, all three model structures pre-
dicted an increase of Akt-pS473 with decreasing mTORC1 activity (Fig.
5B). The simulations also predicted that mTOR-pS2481would remain un-
affected in hypotheses 1 and 3 and would gradually increase in response to
mTORC1 inhibition in hypothesis 2 starting 40 min after induction with
aa/insulin. This effect should be clearly experimentally visible at 100 min
after induction with aa/insulin, and this paradigm could be used to distin-
guish hypothesis 2 from the other hypotheses.
For experimental testing, the specific mTORC1 component Raptor was
gradually inhibited by knocking down Raptor in an inducible shRaptor
cell line for 0, 1, 2, or 3 days. Cells were starved and stimulated with
aa/insulin for 45, 100, and 180 min (Fig. 7A). Verification of effective
mTORC1 inhibition in this experimental setup was performed by monitor-
ing the abundance of p70-S6K-pT389, which showed the expected reduction
in response to decreased Raptor (Fig. 3, B and D). Relative quantitations
of Akt-pS473 and mTOR-pS2481 in response to gradual Raptor inhibition
are shown for the simulations of the three hypotheses and for experimental
data at 100 min after induction with aa/insulin (Fig. 7B). As predicted for
all three hypotheses, Akt-pS473 showed a significant increase with declin-
ing Raptor levels because the NFL is inhibited (Fig. 7, A and B). The
abundance of Akt-pT308 also increased as mTORC1 was inhibited (Fig.
7A). In contrast, mTOR-pS2481 remained unaffected at all time points after
induction with aa/insulin and at all Raptor levels (Fig. 7, A and B), which
Fig. 6. mTOR-pS2481 is not directly activated by TSC1-TSC2. mTOR-pS2481
is not directly activated by TSC1-TSC2. (A) Representative immunoblot
results of the network response upon mTOR network activation in cells in
which TSC2 was knocked down for the indicated amounts of time. Data
are representative of three experiments. d, days. (B) Quantitative repre-
sentations of simulated and experimentally determined Akt-pS473 and
mTOR-pS2481 dynamics 60 min after induction with aa/ins in response
to a gradual TSC2 knockdown. (Left) Relative quantitations of the sim-
ulated Akt-pS473 and mTOR-pS2481 behavior for the three hypotheses
(Hypo 1, 2, and 3) upon gradual TSC2 knockdown. The amount of
TSC1-TSC2 is indicated as a percentage of the total in the control system
in the absence of knockdown. (Right) Quantitations of experimental re-
sults for 60 min after induction with aa/ins in cells in which TSC2 was
reduced to the indicated amounts (percent of total). Values from three
independent experiments were merged and grouped according to the
amount of TSC2. **P < 0.01; n.s., not significant; low TSC2 levels compared
to high TSC2 levels. Differences were significant for Akt-pS473 and not sig-
nificant for mTOR-pS2481.
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Fig. 7. mTOR-pS2481 is not affected by the NFL. (A) Representative immu-
noblot results of the network response upon mTOR network activation in
cells in which Raptor was knocked down for the indicated amounts of time.
Data are representative of three experiments. d, days. (B) Quantitative rep-
resentations of simulated and experimentally determined Akt-pS473 and
mTOR-pS2481 dynamics 100 min after induction with aa/ins in response
to knockdown of Raptor to the indicated amounts (percent of total in the
absence of knockdown). (Left) Relative quantitations of the simulated
Akt-pS473 and mTOR-pS2481 behavior for the three hypotheses (Hypo 1,
2, 3) upon a gradual Raptor knockdown. (Right) Quantitations of experi-
mental results 100 min after induction with aa/ins in cells in which Raptor
was knocked down to the indicated amounts (percent of total). Values from
three independent experiments were merged and grouped according to
the amount of Raptor. Data are the average and SEM. ***P < 0.001; n.s.,
not significant; low Raptor levels compared to high Raptor levels. Differ-
ences were significant for Akt-pS473 and not significant for mTOR-pS2481.
Fig. 8. mTOR-pS2481 is sensitive to the PI3K inhibitor wortmannin. (A) Repre-
sentative immunoblot results of the network response upon mTOR network
activation with aa/ins in the presence of wortmannin to inhibit PI3K. Data
are representative of three experiments. (B) Quantitative representations of
simulated and experimentally determined Akt-pS473 and mTOR-pS2481
dynamics 30 min after induction with aa/ins in cells in which PI3K activity
was inhibited to the indicated amount (percent of total activity). (Left) Rel-
ative quantitations of the simulated Akt-pS473 and mTOR-pS2481 behavior for
the three hypotheses (Hypo 1, 2, 3) in response to gradual PI3K inhibition
(percent of total activity). (Right) Quantitations of experimental results 30 min
after induction with aa/ins in cells in which PI3K was inhibited with the indi-
cated concentrations of wortmannin. Data are the average and SEM of three
experiments. *P < 0.05; ***P < 0.001; 30 nM compared to 0 nM wortmannin.
Differences were significant for both Akt-pS473 and mTOR-pS2481.
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excludes hypothesis 2. Therefore, our model and the experimental testings
allowed us to exclude the previously suggested hypothesis of an indirect
mTORC2 regulation by TSC1-TSC2 and the NFL. Hence, mTORC2 is
neither directly nor indirectly regulated by TSC1-TSC2.
Having excluded both hypotheses 1 and 2 and established that
mTORC2 induction was independent of the NFL that inhibits IRS1 and
thus PI3K activity, we directly tested whether the model and experi-
mental testing would confirm hypothesis 3, that PI3K inhibition would
not affect mTOR-pS2481 induction by aa/insulin. For gradual PI3K inhi-
bition, our simulations predicted that Akt-pS473 in all three hypotheses
would be reduced to a minimum level at all time points after induction
with aa/insulin (Fig. 5B). In contrast, the
model predicted that mTOR-pS2481 (Fig.
5A) would remain either unaffected by
PI3K inhibition (hypotheses 1 and 3) or de-
cline with decreasing PI3K starting 20 min
after induction (hypothesis 2). Because
hypotheses 1 and 2 were already excluded,
we expected PI3K inhibition to result in
the mTOR-pS2481 behavior predicted by
hypothesis 3.
To experimentally test the validity of
hypothesis 3, we starved cells, gradually
inhibited PI3K with increasing wortmannin
concentrations, and induced mTOR signal-
ing by aa/insulin for 30 and 50 min (Fig.
8A). We chose a maximal wortmannin con-
centration of 100 nM, at and below which
this inhibitor is specific for class I PI3Ks
(72). Quantification of simulated and experi-
mentally measured Akt-pS473 and mTOR-
pS2481 in response to gradual PI3K inhibition
is shown for 30 min after induction with
aa/insulin (Fig. 8B). In agreement with
our model, the dynamics of Akt-pS473 close-
ly resembled the PDK1 phosphorylation
of Akt-T308, decreasing as PI3K was inhib-
ited (Fig. 8A). The mTORC1 target p70-
S6K-pT389 behaved similarly (Fig. 8A). In
line with the literature (73) and as pre-
dicted by all three hypotheses, Akt-pS473
was already inhibited at 5 nM wortmannin
and was strongly inhibited by concentra-
tions of 10 nMwortmannin or higher (Fig. 8,
A and B). Surprisingly, mTOR-pS2481 also
was inhibited by wortmannin concentra-
tions of 20 nM or higher (Fig. 8, A and
B). Thus, our model and the experimental
testing also exclude hypothesis 3 because
mTORC2 activation appears to depend on
PI3K activity.
A novel network structure
integrating PI3K-dependent
and NFL-independent activation
of mTORC2
Our combined experimental-computational
approach showed that insulin regulates
mTORC2 through a wortmannin-sensitive
enzyme (likely PI3K), and that mTORC2 is
affected neither by the NFL nor by TSC1-TSC2. We, therefore, had to postu-
late a hypothesis 4: There is another kinase, in particular a wortmannin-
sensitive but IRS1-independent PI3K species, that is activated by the IR
and stimulates mTORC2 in response to insulin (Fig. 9, A and B). The
model did not require recalibration because the new branch for mTORC2
activation by insulin was similar to the PI3K-independent hypothesis 3 but
contained the new proposed PI3K, which is sensitive to wortmannin and
refractory to the NFL.
We experimentally verified that this hypothesis 4 model fitted the data
by showing that the simulated time courses matched the experimental
readout dynamics [Fig. 9C (mTOR-pS2481 and Akt-pS473) and fig. S16A
Fig. 9. A new hypothesis and network structure
for mTORC2 regulation by insulin. (A) Schematic
representation of the pathway for hypothesis 4:
insulin induction of mTORC2 by a PI3K (red) that
is insensitive to TSC1-TSC2 and to the S6K to
IRS-mediated NFL. (B) A computational model
corresponding to hypothesis 4. This hypothesis
was equivalent to hypothesis 3 (PI3K and TSC1-TSC2–independent activation), assuming that the
mTORC2 activator was sensitive to wortmannin. (C) The model simulation data for hypothesis 4 match
the experimental dynamic phosphorylation data. The simulated and experimentally measured dynamics
are shown for the mTORC2 readouts mTOR-pS2481 and Akt-pS473 (see fig. S16 for all other readouts). (D)
Predictions for mTOR-pS2481 and Akt-pS473 upon gradual TSC1-TSC2 knockdown match the experimen-
tal data, which are presented in Fig. 6, A and B (right side). Whereas at 60 min after induction Akt-pS473
is gradually reduced by TSC2 inhibition, mTOR-pS2481 is TSC2-insensitive. See fig. S16 for Akt-pT308 and
p70-S6K-pT389. (E) Predictions for mTOR-pS2481 and Akt-pS473 readouts upon gradual Raptor knock-
down match the experimental data, which are presented in Fig. 7, A and B (right side). Whereas at
100 min after induction Akt-pS473 is gradually induced by Raptor inhibition, mTOR‑pS2481 is Raptor-
insensitive. See fig. S16 for Akt-pT308 and p70-S6K-pT389. (F) Predictions for mTOR-pS2481 and Akt-pS473
readouts upon gradual PI3K inhibition match the experimental data, which are presented in Fig. 8, A and B
(right side). Both Akt-pS473 and mTOR-pS2481 are gradually reduced by wortmannin at 30 min after induc-
tion. See fig. S16 for Akt-pT308 and p70-S6K-pT389.
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(curves for all other readouts)]. Next, we modeled the dynamic network
response under all previously tested network perturbations (gradual TSC1-
TSC2, mTORC1, or PI3K inhibition) and compared the simulations to
our experimental data (simulation in Fig. 9, D to F, and fig. S16B; data
in Figs. 6 to 8). For each of the three network perturbations, the pre-
dictions for all readout dynamics (Fig. 9, D to F) matched the experi-
mental data (Figs. 6 to 8). Identifiability and sensitivity analyses for
hypothesis 4 are shown in figs. S17 and S18. The identifiability anal-
ysis reports low correlation between the estimated parameters, indicat-
ing that the parameters can be identified. Thus, the new network model
of a PI3K-species–dependent and NFL-independent mTORC2 induc-
tion accurately predicted the responsive-
ness of mTORC2 to PI3K inhibition, and
mTORC2 insensitivity to gradual TSC1-
TSC2 or mTORC1 inhibition.
Because a model for mTORC2 activa-
tion through an NFL-insensitive PI3K was
unexpected, we performed additional ex-
perimental testing. To confirm that the re-
duction of mTOR-pS2481 in response to
wortmannin was associated with mTORC2,
we treated cells with PP242 or wortmannin,
or knocked down Raptor and then immu-
noprecipitated mTORC2 with an antibody
recognizing Sin1 (Fig. 10A). We found that
both PP242 and wortmannin significantly
reduced mTOR-pS2481 associated with the
immunoprecipitated mTORC2 (Fig. 10B),
but that mTORC1 inhibition by shRaptor
did not affect mTOR-pS2481 associated with
the immunoprecipitated mTORC2 (Fig. 10,
A and B). These results are consistent with
the whole-cell lysate experiments (Figs.
1, E and F, and 8B) and support our pre-
vious conclusion that wortmannin inhib-
its mTORC2.
To verify the PI3K specificity of the
wortmannin effect on mTORC2, we in-
hibited PI3K by two alternative means—
with another PI3K inhibitor LY294002 or
by overexpression of the PI3K antagonist
PTEN (phosphatase and tensin homolog
deleted from chromosome 10). We found
that mTOR-pS2481 was reduced in cells ex-
posed to LY294002 at concentrations as
low as 1 mM (Fig. 10C) and in cells over-
expressing PTEN (Fig. 10D). Thus, three
separate experimental approaches indi-
cated that mTORC2 activation depends
on PI3K.
Mechanistic exploration in
several cell types: mTORC2
activation independent of Akt
The hypothesis 4 model predicted that the
PI3K-dependent, NFL-insensitive activa-
tion of mTORC2 should be insensitive
to Akt. We overexpressed myristoylated
Akt (myr-Akt), which is constitutively re-
cruited to the membrane and constitu-
tively active even without insulin (74), or a kinase-dead myr-Akt
variant (myr-Akt K179M) in HeLa and C2C12 cells and monitored
the activity of mTORC1 and mTORC2 (Fig. 10, E and F). For cells
expressing the constitutively active Akt, phosphorylation of the mTORC1
substrate p70-S6K-T389 was increased by myr-Akt, whereas it was
decreased in the cells expressing the myr-Akt K179M. In contrast,
the mTORC2 readout mTOR-pS2481 was unchanged in the presence
of either of the two myr-Akt constructs. We confirmed that mTOR-
pS2481 specifically reflected mTORC2 activity in C2C12 cells because
the amount of mTOR-pS2481 was decreased in response to the mTOR
kinase inhibitor PP242, but was unaffected by the mTORC1-specific
Fig. 10. mTORC2 activation is dependent on PI3K but
is independent of Akt. (A) Coimmunoprecipitation of
mTOR-pS2481 in HeLa cells in the presence or absence
of wortmannin, PP242, or Raptor knockdown. Mock IP,
control IP with a nonspecific antibody. Data are repre-
sentative of three experiments. (B) Quantitation of data
from three experiments similar to that shown in (A) for mTOR-pS2481 relative to total amount of immu-
noprecipitated mTOR. *P < 0.05; n.s., not significant. For PP242 and wortmannin treatments compared to
control, there were significant differences in mTOR-S2481 association with Sin1. For the Raptor
knockdown compared to control, the differences in mTOR-pS2481 association were not significant. (C)
Effect of the PI3K inhibitor LY294002 on mTOR-pS2481 and other components of the mTOR network in
HeLa cells. Data are representative of three experiments. (D) Effect of HA-tagged PTEN overexpression
on mTOR-pS2481. Data are representative of three experiments. HA, HeLa cells transfected with empty
vector control. (E) Effect of constitutively active (HA–myr-Akt) or kinase-dead (HA–myr-Akt K179M) Akt
on mTOR-pS2481 and other components of the mTOR network in HeLa cells. Data are representative of
three experiments. (F) The effect of constitutively active (HA–myr-Akt) or kinase-dead (HA–myr-Akt
K179M) Akt on mTOR-pS2481 and other components of the mTOR network in C2C12 myoblasts. The
specific Akt signal is indicated by an arrow. Data are representative of three experiments. (G) Confirma-
tion that mTOR-pS2481 is a specific mTORC2 readout in C2C12 myoblasts. The indicated proteins were
detected in cells in the presence or absence of the indicated concentrations of PP242 or rapamycin in
the continuous presence of aa/insulin. Data are representative of three experiments.
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drug rapamycin (Fig. 10G). Thus, mTORC2 activity was not induced
by Akt.
DISCUSSION
We present a dynamic mTOR network model, which is based on an in-
tegrated experimental-computational approach. We initially postulated
three different network structures for mTORC2 induction by insulin,
which guided experiments to test the hypotheses. The results of the sim-
ulations and experimental data indicated that none of the previously sug-
gested mechanisms of mTORC2 activation were accurate: TSC1-TSC2
is not a direct activator of mTORC2; TSC1-TSC2 does also not indirectly
control mTORC2 through inhibition of PI3K by the NFL; and mTORC2
activation depends on PI3K. However, the PI3K-dependent mTORC2
activation is insensitive to the NFL. We, therefore, postulated an activation
pathway involving a PI3K variant that is independent of the NFL and we
tested this hypothesis by developing a network structure that matched
the observed mTOR pathway dynamics, performing simulations, and then
experimentally verifying the predictions. Consistent with this model, ex-
perimental testing showed that mTORC2 activity was sensitive to different
modes of PI3K inhibition but was insensitive to constitutive activation of
Akt in several cell types.
Dynamic modeling has been used extensively in the study of cell sig-
naling networks, yielding many important insights related to cellular
behavior (75). Here, we use dynamic modeling to discriminate among
alternative network structures, in particular alternative modes of mTORC2
regulation. Others have used similar approaches to study the possible
network structures for the segment polarity gene network (76) and the ex-
tracellular signal–regulated kinase pathway (77). Although network testing
can be performed with a Bayesian statistical approach (77), we chose to
perform experimental testing to distinguish among the proposed net-
work topologies because our simulated conditions and outputs were ex-
perimentally tractable.
Because our approach relied on the simulation and experimental test-
ing of differential network dynamics under the assumption of alternative
network structures, this may have enabled us to identify a network struc-
ture for insulin-regulated mTORC2 activation that is different from any
other regulatory mechanism proposed thus far. Our approach enabled ex-
ploration of the network dynamics of endogenous proteins, whereas other
purely experimental studies have relied on approaches that interfere with
the dynamics under investigation, for example, overexpression of muta-
genized network components that uncouple upstream cues from feedback
inhibition (31, 33). We also confirmed mTOR-pS2481 as a specific and
direct readout for mTORC2 activity, which unlike other mTORC2 read-
outs does not require activation by the NFL-dependent PI3K. Because we
used changes in network dynamics as a means of testing alternative net-
work structures and we used the phosphorylation status of mTOR Ser2481
as the readout of mTORC2 activity, this work is distinguishable from earlier
studies (31, 33, 35), and these differences in the approach may account for
the conclusion that mTORC2’s induction is independent of TSC1-TSC2
and the NFL.
In addition to revealing a new mechanism of regulation of mTORC2
in response to insulin, our analyses revealed additional complexity in the
regulation of Akt. Model parameterization revealed more complex dy-
namics for mTORC2s target site Ser473 in the AGC kinase Akt than
for Ser2481 in mTOR, and this could not be explained exclusively by
mTORC2 activation. To integrate Akt-pS473 dynamics into the dynamic
network model, we had to estimate a second PDK2 that accounted for
the early peak of Akt-pS473 at 3 min after induction with aa/insulin (Fig.
2A). In addition to mTORC2, various other PDK2 candidates for Akt
have been reported, including DNA-PK (78, 79), ILK (80), ATM (81),
MAPKAPK-2 (82), PKC (83, 84), Pak1 (85), and even Akt autophos-
phorylation (86), any of which may contribute to Akt-pS473 dynamics
under different metabolic conditions. Furthermore, we observed that upon
network perturbations involving the NFL, the dynamics of mTOR-pS2481
were different from those of Akt-pS473, with only the latter resembling
the PDK1 phosphorylation on Thr308 of Akt (Figs. 6A and 7A). Thus,
the AGC kinase targets of mTORC2 were not suitable readouts of
mTORC2 activity and could not be used in our system to analyze the
dependence of mTORC2 activity on TSC1-TSC2 because TSC1-TSC2
inhibition induces NFL that inhibits PI3K, which in turn can affect AGC
kinase phosphorylation by their PDK2s, independently of the actual
PDK2 activity. Because of this complexity in Akt phosphorylation dynam-
ics, we chose mTOR-pS2481 as the readout of mTORC2 activity. Although
mTOR-pS2481 has been identified on Raptor-associated mTOR (mTORC1)
and is rapamycin-sensitive in 3T3-L1 adipocytes (62, 64), rapamycin did
not affect mTOR-pS2481 in whole-cell lysates of human embryonic kid-
ney (HEK) 293 cells (64) or Tag Jurkat cells (61). Soliman et al. (64)
concluded that the rapamycin-insensitive, mTORC2-associated mTOR-pS2481
signal predominated over the rapamycin-sensitive, mTORC1-associated
mTOR-pS2481 signal in HEK293 cells, possibly due to a relatively low abun-
dance of mTORC1 compared to mTORC2. We also found that mTOR-
pS2481 was predominantly associated with mTORC2 in HeLa cells, which
we used for our experimental testing.
Our model assumes that the NFL is exclusively executed by p70-S6K,
phosphorylating and thereby inhibiting IRS. GRB10-dependent IR inhibi-
tion in response to activated mTORC1 may also contribute to the NFL
(87, 88), thus adding more complexity to the NFL mechanism. Although
the identification of GRB10 as a contributor to the NFL is mechanistically
relevant, the effect is the same, namely, the inhibition of IRS in response to
mTORC1 activity, and is readily detected by the reduction of Akt-pT308
upon high mTORC1 activity. Given the need to reduce the complexity of
our model to enable parameterization, we did not introduce these mecha-
nisms separately into our model, but combined them into one step.
Our data suggested that mTORC2 activity is independent of the NFL,
which is consistent with previous studies (31, 33). To ensure that we
achieved full activation of both mTOR complexes and thus activation
of the NFL, we stimulated the cells with both amino acids and insulin
induction. We experimentally observed the activation of the NFL starting
45 min after induction, as measured by IRS1-pS636 (Fig. 2, A and B).
Thus, under conditions in which the NFL was active, network perturba-
tions inducing or inactivating the NFL did not affect mTORC2 activity as
measured by mTOR-pS2481.
Although mTORC2 activity was independent of the NFL, it was de-
pendent on PI3K activity (Fig. 8, A and B). The dynamics of mTOR-
pS2481 were not affected by inhibition of the TSC1-TSC2 complex or
mTORC1, but were inhibited by pharmacological inhibition of PI3K or
reduction in its downstream signaling by overexpression of PTEN. Be-
cause pharmacological inhibitors can have off-target effects, we used
a maximum wortmannin concentration of 100 nM, which has been re-
ported to specifically inhibit only class I PI3Ks (72). Although we found
that mTOR-pS2481 dynamics were less sensitive to wortmannin than were
the dynamics of the PDK1-targeted Akt-pT308, mTOR-pS2481 inhibition
occurred with wortmannin concentrations as low as 20 nM, indicating that
mTORC2 inhibition was dependent on class I PI3K activity, which is
consistent with previous studies (61, 64). PDK1-deficient cells exhibited
a wortmannin-sensitive phosphorylation on Ser473 of Akt (89), which, al-
though not previously linked to mTORC2 activity, supports our hypothesis
of a PI3K-dependent but Akt-independent (and therefore NFL- and TSC1-
TSC2–independent) mTORC2 induction. This proposed PI3K regulatory
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mechanism was surprising because PI3K induction by insulin is gen-
erally thought to be IRS-dependent (1), and IRS is inhibited by active
p70-S6K and thereby mediates the NFL. Consequently, we propose
that mTORC2 is induced by a PI3K species that is different from the
PI3K that induces mTORC1, because mTORC1 activity strictly de-
pends on TSC1-TSC2 and the NFL (1, 7).
In our new proposed model for mTOR activation by insulin and amino
acids, Akt should activate mTORC1 through the canonical insulin–IRS–
PI3K–Akt–TSC1-TSC2 pathway, but should not participate in mTORC2
activation, which is induced by a different PI3K. Indeed, we showed in
several cell lines that constitutively active Akt did not induce mTORC2
activity (mTOR-pS2481), although it did activate mTORC1. Two studies
have reported mTORC2 regulation downstream of PI3K that differs from
the canonical Akt–TSC1-TSC2 signaling axis. Direct PI3K-dependent in-
duction of mTORC2 by PtdIns(3,4,5)P3 binding (90) has been observed,
and ribosomal proteins have been described to bind and activate mTORC2
in a PI3K-dependent manner (91). Clearly, these mechanisms require fur-
ther study, which will likely reveal further molecular connectors of PI3K
and mTORC2.
What kind of mechanism could account for the observed NFL insen-
sitivity of PI3K for mTORC2 induction? The NFL is mediated by IRS,
which activates PI3K downstream of insulin and the IR (1). However, PI3K
activity has also been observed in cells devoid of IRS protein (92, 93), and
the IR may activate PI3K in part by direct binding (94). Such IRS-
independent PI3K activity might mediate NFL-independent stimulation
of mTORC2 activity. For class I PI3Ks, there are at least seven alternative
regulatory subunits and four alternative catalytic subunits, and specific
combinations of these subunits might mediate different physiologic out-
puts. Receptor binding and abundance of the isoforms are differentially
regulated by metabolic inputs, such as growth factors or amino acids (95).
We may have detected this apparently IRS-independent PI3K activation be-
cause we used simultaneous stimulation with both insulin and amino acids to
assure full induction of both mTOR complexes. In contrast, previous studies
have mainly tested the effect of a single stimulus on class I PI3K activation.
In a physiological environment, cells are confronted with multiple simulta-
neous inputs, and full activation of some PI3K isoforms can require multiple
upstream inputs (95). Hence, the existence of an NFL-independent class I
PI3K is conceivable and requires further investigation.
In conclusion, the suggested novel network structure, connecting mTORC2
to its upstream inputs, is supported by the existing literature and reveals a
need to reevaluate the mTORC2 regulatory mechanisms. The complexity of
differential mTORC1 and mTORC2 regulation that we propose highlights
the need to apply integrated computational-experimental approaches to un-
derstand complex signaling and regulatory networks. Because our dynamic
model of mTORC1 and mTORC2 signaling is a mathematical representa-
tion of the differential signal transduction toward mTORC1 and mTORC2,
it enables simulation of the signaling dynamics that are transmitted through
the network under different metabolic conditions. Moreover, despite being a
simplification, our model simulations mathematically showed that the sim-
plified system was sufficient to explain the experimental observations. The
fully parameterized model provides a resource for future work and other
modeling efforts can extend and build upon it, as well as provide a frame-
work on which pharmacological interventions can be tested.
MATERIALS AND METHODS
Lentiviral knockdown cell lines
Experiments were performed in HeLa a Kyoto cells and C2C12 myo-
blasts. For inducible knockdown of Raptor or TSC2, cells were transduced
with lentivirus encoding the tetracycline-sensitive tTR-KRAB repressor
and a DsRed reporter (96). Cells were subsequently transfected with len-
tivirus encoding the specific short hairpin RNA (target sequence Raptor:
5′-GGCTAGTCTGTTTCGAAATTT-3′, TSC2: 5′-CGACGAGTCAAA-
CAAGCCAAT-3′), and a green fluorescent protein (GFP) reporter (pLVTH
vector), both under the control of tTR-KRAB. For lentivirus-mediated
knockdown of Rictor, a pLKO.1-based short hairpin construct specific
for Rictor (Addgene plasmid 1853) and a scrambled control sequence
(Addgene plasmid 1864) were obtained from Addgene (21). HeLa cells
were transfected with viral supernatant twice as described previously (63)
and harvested 60 hours after transfection.
Overexpression of PTEN and myr-Akt variants
Plasmids were ordered from Addgene: N-terminally hemagglutinin (HA)–
tagged pSG5L HA PTEN wild type, N-terminally myristoylated and
HA-tagged pLNCX.myr.HA.Akt1, and N-terminally myristoylated and
HA-tagged, kinase-dead pLNCX.myr.HA.Akt1 K179M. Transfection
was performed with 6 mg per 6-cm dish by the use of JetPEI reagent ac-
cording to the manufacturer’s instructions. Cells were harvested 24 hours
after transfection.
Antibodies and reagents
The antibody recognizing PRAS40 (Ser183 phosphorylated) was pur-
chased from IBL. The polyclonal antibody recognizing PRAS40 (Thr246
phosphorylated) was purchased from Biosource. The monoclonal anti-
body recognizing glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was purchased from Abcam. The antibody recognizing Rictor was pur-
chased from Bethyl. Horseradish peroxidase (HRP)–conjugated goat
anti-mouse and goat anti-rabbit immunoglobulin G (IgG) were purchased
from Pierce Biotechnology (Thermo Scientific). Antibodies recognizing
Akt, phospho-Akt (Thr308), phospho-Akt (Ser473), phospho–IGF-I recep-
tor b (Tyr1131)/IRb (Tyr1146), IRS-1, phospho–IRS-1 (Ser636/639), mTOR,
phospho-mTOR (Ser2448), phospho-mTOR (Ser2481), PRAS40, p70S6K,
phospho-p70S6K (Thr389), and TSC2 were purchased from Cell Signaling
Technology. The antibody recognizing IRb was purchased from Santa Cruz
Biotechnology. Rapamycin and LY294002 were purchased from Calbiochem,
Merck. PP242 and wortmannin were purchased from Sigma-Aldrich.
Chemicals were supplied by Carl Roth if not indicated otherwise.
Immunoprecipitation
Immunoprecipitations were performed as described elsewhere (13, 19).
Lysis buffer was complemented with protease inhibitors (Complete;
Roche), Phosphatase Inhibitor Cocktail 2, Phosphatase Inhibitor Cocktail
3 (both Sigma-Aldrich), and PP242 to inhibit residual mTOR activity
after the time of lysis. Immunoprecipitations were performed with an-
tibody (5 mg/ml) [antibody recognizing Sin1, Raptor, or rabbit IgG (all
Bethyl)] and with magnetic Dynabeads Protein G (Invitrogen).
Analysis of whole-cell lysates
For calibration data sets, HeLa cells were starved for serum and amino
acids by exchanging standard growth medium for Hank’s buffered salt so-
lution (HBSS) (PAN Biotech GmbH) overnight to inhibit mTOR pathway
activity. After 16 hours of starvation, mTOR signaling was restimulated
with Dulbecco’s modified Eagle’s medium (DMEM) containing amino
acids and supplemented with 100 nM insulin (Sigma-Aldrich).
Gradual knockdowns of Raptor or TSC2 were established by induction
with doxycycline (5 mg/ml; Calbiochem, Merck) for 0, 1, 2, or 3 days.
Cells were starved for 16 hours in HBSS and mTOR signaling was induced
with DMEM (PAA) supplemented with 100 nM insulin. PP242 and rapa-
mycin were added 1 hour before lysis. Wortmannin or LY294002 was
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added 30 min before and during the stimulation with DMEM supplemen-
ted with 100 nM insulin. Cells were washed once with phosphate-buffered
saline (PBS) and lysed with TNE lysis buffer [50 mM tris-HCl (pH 8.0),
150 mM NaCl, 1% (v/v) Triton X-100 (Calbiochem, Merck), Complete
(Roche), Phosphatase Inhibitor Cocktail 2, and Phosphatase Inhibitor
Cocktail 3 (both Sigma-Aldrich)]. Protein concentrations were measured
(Protein Assay Dye Reagent Concentrate, Bio-Rad) according to the man-
ufacturer’s protocol. Concentrations were adjusted with lysis buffer. Lysates
were diluted in sample buffer [5×: 6 ml glycerol, 0.6 ml b-mercaptoethanol,
1.0 g SDS, 3.75 ml 1 M tris (pH 6.8), 2 mg bromophenol blue, and 2 ml
H2O]. Whole-cell lysates were analyzed with SDS–polyacrylamide gel
electrophoresis (SDS-PAGE) gels. Proteins were transferred to poly-
vinylidene difluoride (PVDF) membranes (Millipore), blocked with 5%
bovine serum albumin (BSA) in TBST [8 g NaCl, 0.2 g KCl, 8 g tris
(pH 7.4), 0.1% Tween 20] for a minimum of 30 min, and incubated with
the primary antibody in 5% BSA in TBST overnight with shaking at
4°C. Blots were washed three times with TBST, incubated with secondary
antibodies coupled to HRP, and washed three times with TBST before
detection.
Quantitation of immunoblots
HRP was detected with the ECL Western Blotting Substrate or the
SuperSignal West Femto reagent (Pierce Biotechnology, Thermo Scientific),
and the emitted light was detected and quantified with a chemilumi-
nescence imaging analyzer (LAS 4000 mini; Fujifilm). Obtained images
were analyzed with Multi-Gauge version 3.0 software (Fujifilm). Local
background was subtracted. All data were normalized against GAPDH.
Representative blots were exported as TIF files and processed with Adobe
Photoshop.
Modeling
CellDesigner 4.2 (97) was used to construct the model network topology
in SBGN (59). COPASI 4.7.34 (98) was used for all deterministic simula-
tions, parameter estimations, parameter scanning, and sensitivity analysis.
The deterministic simulation algorithm (LSODA) was configured with the
following parameters: duration, 1440; interval size, 1; intervals, 1440; in-
tegrate reduced model, 0; relative tolerance, 1 × 10−6; absolute tolerance,
1 × 10−12; maximum internal steps, 10,000. The algorithm used for
parameter estimation was simulated annealing (99, 100), configured with
the following parameters: start temperature, 1; cooling factor, 0.85; toler-
ance, 1 × 10−6; random number generator, 1; seed, 0. The parameter es-
timation weight method was mean square and the experiment type was
time course. The initial concentration of the species in nonphosphorylated
state was fixed to the maximum intensity of the third quantile time course,
computed from the four experimental data sets, of the corresponding ex-
perimental phosphorylated protein. This ensured that the modeled kinases
did not saturate their substrates and that the concentrations of the sub-
strates remained small. The initial concentration of the species in any other
state was fixed to 0. The initial concentration of PDK2 was assumed to be
equal to the concentration of the b subunit of the IR because the two spe-
cies are directly connected in the model. In the absence of experimental
data for the TSC complex, the initial concentration was assumed to be 10.
The models were formalized with only mass action reactions. For each
phase, the kinetic rate constants were estimated by running 350 indepen-
dent calibrations, each initialized with a random initial configuration of
the parameters. The parameter values were constrained within the in-
terval [1 × 10−4, 1] except for the Akt parameters, which were con-
strained within the interval [1 × 10−4, 10]. For each calibration phase
(F), the solutions of the estimations consistent with the data and achiev-
ing the lowest root mean square error (RMSE) were selected as the best
solutions set (BS). Among these, the solution closest to the centroid of
the BS cluster in the parameter space was selected with the following
formula:
arg min
S∈BSF
∑
N
i¼1
ðSð piÞ " miÞ
2
where BSF = {x|∀ y ∈ AllSolutions, RMSE (Model(x), Data) ≤ RMSE
(Model(y), Data)}, pi is the ith estimated parameter in S, mi is the ith
parameter mean computed from BSF, and N is the number of estimated
parameters.
Model identifiability based on correlation analysis of sensitivity tra-
jectories was calculated with SBToolbox2 and SBPDToolbox (101) for
MATLAB. SBMLToolbox 4.0.1 (102) was used to import our SBMLmod-
els into SBToolbox2. Identifiability analysis tables for the general mod-
el and the four hypotheses models are depicted in figs. S5, S8, S10,
S12, and S17.
All parameter values for the final models are given in tables S2 and S3.
The sensitivity analysis algorithm was configured for time series with the
following parameters: Delta factor, 0.001, and Delta minimum, 1 × 10−12
(figs. S6, S9, S11, S13, and S18). We also used COPASI and CellDesigner
to export the models as SBML (103) Level 2 Version 4 (models S1 to S5).
CellDesigner was used to generate the extended mTOR network model in
SBGN (59) graphical notation (model S6).
Statistics
The statistical and programming language R version 2.12.1 (104) was
used to calculate the statistics and generate the plots. The SEM was cho-
sen to estimate the statistical variability of the measured samples of exper-
imental time course. Model goodness of fit was defined by computing
Akaike information criterion (105) and c2 was calculated as follows:
c2 ¼∑
N
i¼1
yi " mðdiÞ
sðdiÞ
 2
where N is the number of experimental data points and yi − m(di) is the
ith residual between the simulated and the experimental mean data
point, which is normalized by the SD of the same data point. For the
general model and the four hypotheses, c2 and Akaike information cri-
terion measures are provided in table S4. Tukey’s honest significant
differences (HSD) test, in conjunction with one-way analysis of variance
(ANOVA), was used as statistical test for multiple comparisons among
groups of experimental data.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/5/217/ra25/DC1
Fig. S1. Extended graphical model of the mammalian TOR network.
Fig. S2. A linear relationship between Western blot signals and protein concentrations.
Fig. S3. Phases of the calibration process.
Fig. S4. Details of a calibration phase.
Fig. S5. Identifiability analysis for the general model.
Fig. S6. Sensitivity analysis for the general model.
Fig. S7. Comparison between the simulated and experimental time courses for hypotheses
1, 2, and 3 for readouts of the mTOR network.
Fig. S8. Identifiability analysis for hypothesis 1: TSC1-TSC2–dependent hypothesis
mTORC2 regulation.
Fig. S9. Sensitivity analysis for hypothesis 1: TSC1-TSC2–dependent hypothesis mTORC2
regulation.
Fig. S10. Identifiability analysis for hypothesis 2: NFL-mTORC2 regulation.
Fig. S11. Sensitivity analysis for hypothesis 2: NFL-mTORC2 regulation.
Fig. S12. Identifiability analysis for hypothesis 3: PI3K-independent mTORC2 regulation.
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Fig. S13. Sensitivity analysis for hypothesis 3: PI3K-independent mTORC2 regulation.
Fig. S14. The influence of perturbations of TSC1-TSC2, mTORC1, and PI3K on the phos-
phorylation of Akt-T308 for the three hypotheses.
Fig. S15. The influence of perturbations of TSC1-TSC2, mTORC1, and PI3K on the phos-
phorylation of p70-S6K-T389 for the three hypotheses.
Fig. S16. Simulation and perturbations for the new network structure based on hypothesis
4: PI3K-dependent, NFL-independent regulation of mTORC2.
Fig. S17. Identifiability analysis for hypothesis 4: PI3K-dependent, NFL-independent reg-
ulation of mTORC2.
Fig. S18. Sensitivity analysis for hypothesis 4: PI3K-dependent, NFL-independent regula-
tion of mTORC2.
Table S1. Ordinary differential equations of the general model and the models representing
hypotheses, 1, 2, and 3 for mTORC2 activation.
Table S2. Parameter values of the general model.
Table S3. Parameter values of hypotheses 1, 2, and 3.
Table S4. Summary of model goodness of fit.
Models S1 to S6.
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Mammalian target of rapamycin (mTOR) kinase responds to growth fac-
tors, nutrients and cellular energy status and is a central controller of cellu-
lar growth. mTOR exists in two multiprotein complexes that are embedded
into a complex signalling network. Adenosine monophosphate-dependent
kinase (AMPK) is activated by energy deprivation and shuts off adenosine
5¢-triphosphate (ATP)-consuming anabolic processes, in part via the inacti-
vation of mTORC1. Surprisingly, we observed that AMPK not only
responds to energy deprivation but can also be activated by insulin, and is
further induced in mTORC1-deficient cells. We have recently modelled the
mTOR network, covering both mTOR complexes and their insulin and
nutrient inputs. In the present study we extended the network by an
AMPK module to generate the to date most comprehensive data-driven
dynamic AMPK-mTOR network model. In order to define the intersection
via which AMPK is activated by the insulin network, we compared simula-
tions for six different hypothetical model structures to our observed
AMPK dynamics. Hypotheses ranking suggested that the most probable
intersection between insulin and AMPK was the insulin receptor substrate
(IRS) and that the effects of canonical IRS downstream cues on AMPK
would be mediated via an mTORC1-driven negative-feedback loop. We
tested these predictions experimentally in multiple set-ups, where we inhib-
ited or induced players along the insulin–mTORC1 signalling axis and
observed AMPK induction or inhibition. We confirmed the identified
model and therefore report a novel connection within the insulin–mTOR–
AMPK network: we conclude that AMPK is positively regulated by IRS
and can be inhibited via the negative-feedback loop.
Abbreviations
AIC, akaike information criterion; AMP, adenosine monophosphate; AMPK, adenosine monophosphate-dependent kinase; ATM, ataxia-
telangiectasia mutated; ATP, adenosine 5¢-triphosphate; BIC, Bayesian Information Criterion; CaMKK, Ca2+-sensitive calmodulin-dependent
protein kinase kinase; CV, coefficient of variance; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HA-myr-Akt, myristoylated version of
Akt; HRP, horseradish peroxidase; IR, insulin receptor; IRE1, inositol-requiring enzyme 1; IRS, insulin receptor substrate; LKB1, liver
kinase B1; MOTA, Mean Optimal Transformation Approach; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of
rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; NFL, negative-feedback loop; PDK1, phosphoinositide-
dependent protein kinase 1; p.i., postinduction; PI3K, phosphatidylinositol 3-kinase; PRAS40, proline-rich Akt substrate of 40 kDa; PTEN,
phosphatase and tensin homologue; p70-S6K, S6-kinase; shRaptor, inducible short hairpin Raptor knockdown;TAK1 ⁄ MAP3K7, transforming
growth factor-beta-activated kinase-1; TSC1–TSC2, tuberous sclerosis complex 1 ⁄ 2 dimer; 4E-BP, 4E-binding protein.
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Introduction
Mammalian target of rapamycin (mTOR) kinase is a
central controller of cellular growth and metabolism
and is conserved in all eukaryotes. mTOR controls
anabolic and catabolic processes, including translation,
ribosome biogenesis and autophagy, in response to
nutrients (amino acids), energy and growth factors
(insulin). mTOR exists in two multiprotein complexes
– mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2) – which are functionally and structurally
distinct: mTORC1 contains Raptor and proline-rich
Akt substrate of 40 kDa (PRAS40) as specific binding
partners and controls cellular growth, whereas
mTORC2 comprises mammalian stress–activated pro-
tein kinase–interacting protein 1 (mSIN1), proline rich
protein 5 (PRR5) ⁄PRR5-Like (PRR5L) and Rictor,
and controls apoptosis as well as spatial growth via
the actin cytoskeleton [1,2].
Being a central growth regulator, mTOR is tightly
embedded into a complex signalling network, transduc-
ing insulin signals via the insulin receptor (IR), the
insulin receptor substrate (IRS), class I phosphatidyl-
inositol 3-kinases (PI3Ks), phosphoinositide-dependent
protein kinase 1 (PDK1) and the protein kinase
A ⁄protein kinase G ⁄protein kinase C-family (AGC)
kinase, Akt (also known as PKB). Akt inhibits the
tuberous sclerosis complex 1 ⁄ 2 dimer (TSC1–TSC2),
which is the inhibitory GTPase-activating protein for
Rheb [1–4]. Via this cascade, Akt induces mTORC1.
mTORC1 phosphorylates S6-kinase (p70-S6K), the
translation initiation regulator 4E-binding protein (4E-
BP) and the mTORC1-inhibitor PRAS40 [5–12].
Whereas PRAS40 inhibits mTORC1 activity, p70-S6K
and 4E-BP mediate mTORC1 downstream effects.
Furthermore, active p70-S6K phosphorylates and
inhibits the IRS, which consequently cannot activate
PI3K in response to insulin. This mechanism results in
a negative-feedback loop (NFL), which inhibits
upstream insulin signalling upon mTORC1 activation
[2]. We have recently modelled this network and
shown that whereas mTORC1 is induced via the above
described signalling cascade, the induction of
mTORC2 occurs via a distinct PI3K that is insensitive
to the NFL [13].
mTOR not only responds to the insulin network but is
also connected to many other signalling cascades, includ-
ing adenosine monophosphate (AMP)-dependent kinase
(AMPK), Wnt signalling and the mitogen-activated pro-
tein kinase kinase kinase (MEK) ⁄ extracellular signal-
regulated kinase (Erk) pathway. To incorporate further
kinase inputs into our dynamic network model, we
decided to focus on the development of an AMPK mod-
ule. AMPK turns on catabolic adenosine 5¢-triphosphate
(ATP)-generating pathways and shuts off ATP-consum-
ing anabolic processes, such as ribosome biogenesis and
translation, in part via the inactivation of mTORC1 [14].
AMPK is activated by both energy deprivation and
by the liver kinase B1 (LKB1) (or STK11). Inhibition of
glycolytic flux leads to a high AMP ⁄ATP ratio, activat-
ing AMPK by direct, allosteric AMP binding. LKB1
activates AMPK by phosphorylating AMPK-T172 and
thereby negatively regulates mTORC1 [14]. Although
LKB1 seems to be the main upstream kinase of AMPK,
LKB1 also phosphorylates 12 other kinases [15], termed
AMPK-related kinases. The physiological functions
of these kinases are still poorly understood. Apart
from LKB1, several other kinases can phosphorylate
AMPK-T172 independently of the cellular energy sta-
tus, including Ca2+-sensitive calmodulin-dependent
protein kinase kinase (CaMKK) [16–19] and transfor-
ming growth factor-beta-activated kinase-1 (TAK1 ⁄
MAP3K7) [20–22]. Also, ataxia-telangiectasia mutated
(ATM) kinase-dependent [23,24] or inositol-requiring
enzyme 1 (IRE1)-dependent [25] induction of AMPK
have been reported.
To inhibit mTORC1 signalling, AMPK multiply
phosphorylates and activates TSC2 when cellular
energy is low [26]. In addition, AMPK also directly
phosphorylates the essential mTORC1 component
Raptor on two serine residues [27]. This phosphoryla-
tion induces 14-3-3 to bind to Raptor and is required
for mTORC1 inhibition by energy deprivation.
We observed, in the present work, that AMPK not
only responds to energy deprivation but is also
strongly activated by insulin and is further induced in
Raptor-deficient cells. These findings are in line with
others [23,28,29]; however, the underlying signalling
events have been only poorly investigated to date. In
order to define the intersection via which AMPK is
activated by the insulin network, we generated a data-
driven dynamic AMPK–mTOR network model and
used a combined modelling-experimental approach.
We compared simulations for different model struc-
tures with our observed AMPK dynamics. Hypotheses
ranking suggested that the most probable intersection
between insulin and AMPK was the IRS, and that the
effects of canonical IRS downstream cues on AMPK
are mediated via the NFL. We tested and confirmed
these predictions experimentally in multiple set-ups.
We report here a novel connection within the insulin–
mTOR–AMPK network: we conclude that AMPK is
positively regulated by IRS and can be inhibited via
the NFL.
A dynamic AMPK–mTOR network model A. G. Sonntag et al.
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Results
An insulin–TOR–AMPK model
We recently described the development of a dynamic
mTOR network model [13] that covered insulin and
amino-acid signalling as mTORC1 regulators. AMPK
is another important mTOR regulator that suppresses
mTORC1 activity in response to energy deprivation
[14] and we decided to add this regulation to our
model. We introduced the following novel connection
into the existing network structure [13]: AMPK phos-
phorylation at T172 allows AMPK to phosphorylate
the species TSC1_TSC2 at S1387, which leads to the
activation of TSC1–TSC2 and the subsequent inhibi-
tion of mTORC1. Conversely, the phosphorylation of
the species TSC1_TSC2 at T1462 by Akt_pT308 inhib-
its the TSC1_TSC2 complex, activating mTORC1.
Finally, the species Akt_pS473, PRAS40_pT246 and
PRAS40_pS183 were defined as supplementary
readouts for mTORC2, Akt and mTORC1, respec-
tively.
In order to calibrate the AMPK module and con-
nect it to our existing mTOR model, we acquired
AMPK time courses under the same conditions that
we had used for calibration of the dynamic mTOR
network model [13]. These were starvation of serum
and amino acids followed by network induction by
insulin and amino acids. AMPK is described to be
induced in Raptor-deficient cells [28,29]. Therefore, we
also investigated AMPK activity upon gradual knock-
down in an inducible short hairpin Raptor knockdown
(shRaptor) HeLa cell line. The knockdown was
induced by doxycycline treatment for 3, 2 or 0 days.
Cells were starved for 16 h and activated with insulin
and amino acids from 3 min up to 100 min postinduc-
tion (p.i.) (Fig. 1A). As previously described [13], the
direct mTORC1 substrate, p70-S6K-pT389, was acti-
vated from 20 min onwards and displayed reduced
phosphorylation upon induction of Raptor knock-
down. AMPK activity was monitored by detecting
phosphorylation at T172, reflecting active AMPK [14].
Although AMPK is known to be induced by energy
depletion [14], we found, to our surprise, that AMPK-
pT172 is also strongly induced by insulin and amino
acids, and induction was apparent at only 3 min p.i.
Overall, AMPK-pT172 induction decreased with time.
As expected, AMPK-pT172 was more strongly induced
upon Raptor knockdown, and this was observable
from 20 min p.i. onwards (Fig. 1A). Upon activation,
AMPK phosphorylates TSC2 at S1387, leading to
TSC2 activation and subsequent inhibition of
mTORC1 [26,30]. Therefore, we used TSC2-S1387 as a
second AMPK readout, to confirm our findings on
AMPK activation. Indeed, TSC2-pS1387 followed
AMPK-pT172 with some delay, starting 20 min p.i.
and was induced by insulin and amino acids, and in
Raptor knockdown cells. All signal intensities were
A
B
Fig. 1. Set up of an AMPK module. (A) AMPK is induced upon
insulin induction. A gradual Raptor knockdown was induced in HeLa
cells by doxycyline treatment for the indicated times. Cells were
serum ⁄ amino acid starved for 16 h and restimulated with amino
acids and 100 nM insulin for 3, 20, 45 or 100 min. (B)
Insulin–mTOR–AMPK model. This model integrates our previous
insulin–mTOR model with AMPK regulation. Six hypotheses of
AMPK activation are investigated (blue dotted lines). Except for the
insulin- and IR-beta (IR-b)-induced AMPK hypotheses, all others
implicitly assume AMPK as being dependent on the p70-S6K NFL.
aa or AA, amino acids; Ins, insulin.
A. G. Sonntag et al. A dynamic AMPK–mTOR network model
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quantified, and descriptive statistics were computed
over three replicates. The experimental mean time
courses were used to calibrate the model parameters.
Although it has been described previously that
AMPK is induced by insulin-like growth factor 1
(IGF-1) [23], this signalling connection has been only
poorly explored to date. Therefore, in the present
study we systematically investigated possible AMPK
activators along the insulin–mTORC1 axis. mTORC1
is maximally induced at 30-45 min p.i. [13]. As AMPK
induction by insulin peaked as early as 3 min p.i., and
AMPK was induced by Raptor knockdown (i.e.
mTORC1 inhibition), we selected, as candidate AMPK
activators, the species upstream of mTORC1:
1. Insulin, where insulin is considered as constant and
direct input to AMPK;
2. IR_beta_pY1146, reflecting IR activation;
3. IRS1_p, reflecting IRS1 activation by the IR;
4. mTORC2_pS2481, reflecting mTORC2 activation
by insulin and amino acids [13];
5. Akt_pT308, reflecting Akt activation downstream
of PI3K; and
6. TSC1_TSC2_pT1462, reflecting TSC1–TSC2 deac-
tivation by Akt.
A graphical representation of our insulin–mTOR–
AMPK model, depicting our six alternative hypotheses
of AMPK activation, is provided in Fig. 1B.
Parameter estimation and identifiability
A specific model was instantiated for each hypothesis
and calibrated using the same data sets and the Matlab
Toolbox PottersWheel [31]. Before calibrating the
models, structural identifiability analysis was per-
formed using the software GenSSI [32]. This software
calculated the symbolic solution of the problem, com-
puting Lie derivatives for each hypothesis and confirm-
ing structural global identifiability for all six models.
For the IRS1-induced AMPK model, structural identi-
fiability analysis is reported in Fig. 2A, showing that
all the parameters were structurally identified in the
first-order (blue circles) or second-order (magenta cir-
cles) identifiability tableau.
To calibrate the models, experimental time courses
upon insulin ⁄amino acid induction for nine
readouts (IR_beta_pY1146, IRS1_pS636, Akt_pT308,
Akt_pS473, mTORC1_pS2448, mTORC2_pS2481,
p70S6K_pT389, PRAS40_pT246 and PRAS40_pS183;
data set 1) in wild-type cells along the insulin–mTOR
signalling axis were used in combination with time
courses under gradual mTORC1 inhibition (Raptor
knockdown; data set 1) in wild-type cells, as measured
previously [13]. Furthermore, in order to calibrate the
species AMPK_pT172 and TSC1_TSC2_pS1387, the
five time points (0, 3, 20, 45 and 100 min p.i.; Fig. 1A)
without knockdown induction (i.e. corresponding to
wild type), were added as an additional data set (data
set 3).
Parameter estimation was executed for each model
independently over multiple data sets in order to
reduce the bias of the solution and therefore overfit-
ting. However, the addition of data sets used to cali-
brate a model can lead to a serious increment of
variance, particularly because of the increase in intrin-
sic noise in experimental data, which does not permit
to estimate the parameters of the model correctly. Our
second data set was characterized by three different
levels of Raptor knockdown, obtained by doxycycline
treatment for 0, 2 or 3 days, respectively (subsets 1-3).
We found a satisfactory bias–variance trade-off by
combinatorially and singularly testing these three sub-
sets and eventually selecting only the subset of Raptor
knockdown induced by doxycycline treatment for
3 days (subset 3). Subset 3 was selected as it repre-
sented the strongest signal reduction and consequently
novel information with respect to wild-type time
courses (data set 1) for calibrating the model. More-
over, the readouts in our data sets (data set 1, data set
2-subset 3, data set 3) were scaled in order to obtain
species time courses of similar intensity. This distrib-
utes the cost of the solution equally over the simulated
time courses, approximating the data and avoiding an
implicit preference ranking of calibration.
For calibrating the models, we only estimated the
kinetic rate-constant parameters, whereas the species
protein concentrations were determined from our
immunoblot time courses by selecting the correspond-
ing readout maximum intensity plus two standard
deviations measured at that time point. The addition
of two standard deviations to the maximum signal
peak guaranteed the avoidance of species protein-satu-
ration conditions. The kinetic rate constants regulating
PI3K-variant dynamics were fixed a priori assuming a
time course similar to the insulin receptor. In fact, no
experimental data are available for this PI3K insensi-
tive to the NFL and it is more likely that it follows the
IR-beta receptor than other curves. Furthermore, fix-
ing these parameters led us to a full structural identifi-
ability of the model.
A posterior identifiability analysis was performed
using the Mean Optimal Transformation Approach
(MOTA) plugin [31,33] after selecting the 50% of the
best fits (shown in Fig. 2B for the IRS1-induced
AMPK model). This analysis revealed that high
parameter correlations had a coefficient of variation
(CV) lower than 0.05 for all our models except for the
A dynamic AMPK–mTOR network model A. G. Sonntag et al.
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IR-beta-induced AMPK model (hypothesis 2; Fig. S1).
For this model, MOTA analysis highlighted high cor-
relation and a high CV for the pair of parameters reg-
ulating AMPK dynamics. Model identifiability was
obtained after fixing one of the two parameters and
recalibrating the other in a second round of calibra-
tion. In combination with the previous analysis, we
also checked parameter nonidentifiability by directly
Param.     r2       CV      #     Tuples
Parameters Legend:
p1   = IR_beta_phosphorylation_by_Insulin
p2   = IR_beta_pY1146_dephosphorylation
p3   = IR_beta_ready
p4   = IRS1_phosphorylation_by_IR_beta_pY1146
p5   = IRS1_p_phosphorylation_by_p70S6K_pT389
p6   = IRS1_pS636_dephosphorylation
p7   = AMPK_T172_phosphorylation
p8   = AMPK_pT172_dephosphorylation
p9   = Akt_pT308_dephosphorylation
p10 = Akt_pS473_dephosphorylation
p11 = Akt_S473_phosphorylation_by_mTORC2_pS2481_n_IRS1_p
p12 = Akt_T308_phosphorylation_by_IRS1_p
p13 = mTORC1_pS2448_dephosphorylation_by_TSC1_TSC2_pS1387
p14 = mTORC1_S2448_activation_by_Amino_Acids
p15 = mTORC2_pS2481_dephosphorylation
p16 = mTORC2_S2481_phosphorylation_by_PI3K_variant_p
p17 = p70S6K_pT389_dephosphorylation
p18 = p70S6K_T389_phosphorylation_by_mTORC1_pS2448
p19 = PRAS40_pS183_dephosphorylation
p20 = PRAS40_pT246_dephosphorylation
p21 = PRAS40_S183_phosphorylation_by_mTORC1_pS2448
p22 = PRAS40_T246_phosphorylation_by_Akt_pT308
p23 = TSC1_TSC2_S1387_phosphorylation_by_AMPK_pT172
p24 = TSC1_TSC2_T1462_phosphorylation_by_Akt_pT308
Reduced identifiability tableau
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B
Fig. 2. Identifiability analysis for the IRS1-
induced AMPK model (hypothesis 3). (A)
Structural identifiability analysis was per-
formed using the software GENSSI a priori.
In the reduced identifiability tableau, blue
circles indicate the parameters detected
directly as structurally globally identifiable at
the first-order tableau, whereas magenta
circles highlight the parameters detected as
structurally globally identifiable at the sec-
ond-order tableau after computing the sym-
bolic solution. (B) MOTA identifiability
analysis was executed using the 50% of the
best fits of the calibration fits sequence.
A correlation among a set of parameters is
indicated by the tuple of correlated parame-
ters, their correlation coefficient (r2), the CV
and the number of times that this correla-
tion was identified by varying the parame-
ters of the tuple (#). Even though high
correlations were found among some
parameters, the corresponding CV was
lower than 0.002, which can be explained
as a numeric approximation error in the fit
sequence calibration process. (*) r2 > 0.9
and CV > 0.1 (**) r2 > 0.9 and CV > 0.1 and
#>1. Param., parameter.
A. G. Sonntag et al. A dynamic AMPK–mTOR network model
FEBS Journal (2012) ª 2012 The Authors Journal compilation ª 2012 FEBS 5
187
analysing the estimated percentage of standard
deviations of the parameters, computed over the 50%
best fits, and considering nonidentifiable the parame-
ters with a standard deviation percentage higher than
a threshold of 5%. Table 1 presents the values for the
estimated parameters, with mean, standard deviation
and CV values for the IRS1-induced AMPK model
showing parameter identifiability. Sensitivity analysis
for the same model is provided in Fig. S2, showing a
balanced sensitivity among the parameters and that all
were required.
In summary, we independently calibrated six models
sharing the main network structure and differing in
AMPK activation. We were therefore able to investi-
gate our central question, of finding at which level in
the network AMPK is induced by insulin.
Intersection level of the signalling from insulin
to AMPK: model simulation analyses over
AMPK-pT172 and TSC2-pS1387 readouts
Once the parameter estimation was achieved, the simu-
lated time courses for the readouts AMPK_pT172 and
TSC1_TSC2_pS1387 of each model were compared with
the corresponding experimental time courses (see
Fig. 3). Surprisingly, we observed that the readouts
AMPK_pT172 and TSC1_TSC2_pS1387 for the IRS1-
induced AMPK model (hypothesis 3) fitted the data
with high accuracy, whereas the goodness-of-fit
decreased for species downstream of IRS1 (Akt and
TSC1-TSC2; hypotheses 5 and 6) and upstream of IRS1
(insulin, IR-beta; hypotheses 1 and 2), as indicated by
the measure v2. Furthermore, the two readouts showed
a poorer fit for the mTORC2-induced AMPK model
(hypothesis 4). At this point, we questioned whether
these local differences could lead to a possible ranking
of the overall models. In order to achieve this, several
additional likelihood-based statistical criteria, such as
the Akaike Information Criterion [34] [AIC, Akaike
Information Criterion corrected (AICc)] and the Bayes-
ian Information Criterion [35] (BIC), were used besides
the total v2, to estimate the goodness-of-fit calculated
over the entire models. These estimations allowed us to
establish a ranking of the hypotheses in accordance with
the goodness-of-fit (Table 2). All values obtained were
consistent between these measures and with the above
observations in selecting the IRS1-induced AMPK
model (hypothesis 3) as the most probable model. The
remaining simulated versus experimental time courses
for the IRS1-induced AMPK model are reported in
Fig. S3. A Systems Biology Markup Language (SBML)
model is provided for the IRS1-induced AMPK hypoth-
esis.
In summary, hypotheses ranking suggested that IRS
(hypothesis 3) was the most probable inducer of
AMPK in response to insulin. This, in turn, suggested
that downstream cues of IRS1 could affect AMPK via
the NFL, which would be in line with the observed
induction of AMPK in mTORC1-deficient cells
(Fig. 1A, [28,29]). We then tested this experimentally.
Experimental testing: AMPK activation is IRS
dependent and indirectly regulated via the NFL
Hypothesis 3 predicts that IRS will be required for
AMPK induction by insulin. We therefore tested first
whether IRS hyperactivation alone would result in
increased AMPK-T172 phosphorylation. To achieve
this we overexpressed wild-type IRS-1 (Myc-IRS-1
WT) or mutagenized IRS-1 variants, resembling either
IRS-1 constitutively phosphorylated by S6K (Myc-
IRS-1 S636 ⁄639 D) or constitutively unphosphorylated
on the same sites (Myc-IRS-1 S636 ⁄ 639 A) [36]. The
variants are NFL insensitive and whereas the D vari-
ant is less active, the A variant will be hyperactive.
The constructs were overexpressed in HeLa cells
(Fig. 4A). As expected, Myc-IRS-1 WT and Myc-IRS-1
S636 ⁄ 639 A strongly induced Akt-pT308 and
mTORC1 activity towards p70-S6K-T389, whereas
Myc-IRS-1 S636 ⁄ 639 D did not. Importantly, AMPK-
pT172 was induced moderately by Myc-IRS-1 WT and
strongly by Myc-IRS-1 S636 ⁄ 639 A, but was refractory
to overexpression of Myc-IRS-1 S636 ⁄ 639 D. This
finding is in line with hypothesis 3, which suggests the
requirement of active IRS for AMPK induction by
insulin. To further confirm our finding we also analy-
sed the AMPK target site, TSC2-S1387, upon overex-
pression of Myc-IRS-1 WT (Fig. 4B). TSC2-pS1387
was strongly induced, again suggesting positive regula-
tion of AMPK by IRS-1.
IRS-1 hyperactivation will strongly induce PI3K
activity [36], and we did not differentiate, in our
hypothesis 3, between IRS and PI3K activity. We
therefore next tested whether PI3K also positively
affects AMPK. We inhibited PI3K with wortmannin
before induction with insulin ⁄ amino acids (Fig. 4C): as
expected, wortmannin inhibited Akt-pT308, down-
stream of PI3K. In contrast, wortmannin induced
AMPK-T172 phosphorylation. To confirm this finding
in a complementary set-up, we overexpressed the PI3K
antagonist phosphatase and tensin homolog (PTEN):
PI3K generates phosphatidylinositol (3,4,5)-trisphos-
phate (PIP3), leading to the induction of PDK1, Akt
and their downstream targets; however, PTEN
dephosphorylates PIP3, thereby counteracting PI3K
activity. As expected, PTEN overexpression strongly
A dynamic AMPK–mTOR network model A. G. Sonntag et al.
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Table 1. Parameter table for the IRS1-induced AMPK model (hypothesis 3). The estimated kinetic rate constants, together with the species
concentrations, are provided. The mean, SD and per cent of the SD over the mean, computed over the 50% best fits, are also indicated.
These statistics shows that all 24 estimated parameters could be fixed at the first round of calibration. Scaling factor parameters and obser-
vable variables are also indicated. The SBML model given in Model S2 (Supporting information) is configured with these parameter values.
Parameter name (AMPK induced by the IRS1 model)
[kinetic rate constants (min)1)] Calibration [mean ± SD (%)] Value
p1 = IR_beta_phosphorylation_by_Insulin 0.124278 ± 1.21324e-05 (0%) 0.124273
p2 = IR_beta_pY1146_dephosphorylation 0.396251 ± 3.02338e-05 (0%) 0.396235
p3 = IR_beta_ready 0.0532808 ± 6.9999e-06 (0%) 0.053277
p4 = IRS1_phosphorylation_by_IR_beta_pY1146 0.00491628 ± 5.46924e-07 (0%) 0.00491599
p5 = IRS1_p_phosphorylation_by_p70S6K_pT389 1681.94 ± 3.80623 (0%) 1682.75
p6 = IRS1_pS636_dephosphorylation 0.0130526 ± 4.45303e-06 (0%) 0.01305
p7 = AMPK_T172_phosphorylation 9.79357 ± 0.0177607 (0%) 9.79766
p8 = AMPK_pT172_dephosphorylation 0.0107217 ± 4.13895e-07 (0%) 0.0107215
p9 = Akt_pT308_dephosphorylation 0.00335553 ± 3.70977e-07 (0%) 0.00335545
p10 = Akt_pS473_dephosphorylation 0.00640225 ± 1.80374e-07 (0%) 0.00640216
p11 = Akt_S473_phosphorylation_by_mTORC2_pS2481_n_IRS1_p 13.1374 ± 0.0302136 (0%) 13.1442
p12 = Akt_T308_phosphorylation_by_IRS1_p 6.9152 ± 0.0123683 (0%) 6.91811
p13 = mTORC1_pS2448_dephosphorylation_by_TSC1_TSC2_pS1387 0.0106657 ± 9.77042e-07 (0%) 0.0106652
p14 = mTORC1_S2448_activation_by_Amino_Acids 0.00438932 ± 3.03977e-07 (0%) 0.00438916
p15 = mTORC2_pS2481_dephosphorylation 0.0183743 ± 1.62188e-06 (0%) 0.0183735
p16 = mTORC2_S2481_phosphorylation_by_PI3K_variant_p 0.375358 ± 1.34923e-05 (0%) 0.375353
p17 = p70S6K_pT389_dephosphorylation 0.0113508 ± 6.03276e-07 (0%) 0.0113512
p18 = p70S6K_T389_phosphorylation_by_mTORC1_pS2448 0.0018404 ± 3.38908e-08 (0%) 0.00184043
p19 = PRAS40_pS183_dephosphorylation 2.33046 ± 0.00198802 (0%) 2.33014
p20 = PRAS40_pT246_dephosphorylation 1.60545 ± 0.00132301 (0%) 1.60513
p21 = PRAS40_S183_phosphorylation_by_mTORC1_pS2448 0.187646 ± 0.000157968 (0%) 0.187621
p22 = PRAS40_T246_phosphorylation_by_Akt_pT308 0.137756 ± 0.000112104 (0%) 0.137729
p23 = TSC1_TSC2_S1387_phosphorylation_by_AMPK_pT172 0.0365597 ± 4.61345e-06 (0%) 0.0365589
p24 = TSC1_TSC2_T1462_phosphorylation_by_Akt_pT308 0.0177568 ± 1.993e-06 (0%) 0.0177562
p25 = PI3K_variant_p_dephosphorylation Assumed 10
p26 = PI3K_variant_phosphorylation_by_IR_beta_pY1146 Assumed 0.01
Concentrations (AU)
u1 = Insulin (INPUT) Fixed 10
u2 = Amino_Acids (INPUT) Fixed 10
x1 = IR_beta Determined 16.56070782
x4 = IRS1 Determined 18.93446968
x7 = AMPK Determined 20.50644836
x9 = Akt_T308 Determined 21.41085271
x11 = Akt_S473 Determined 12.25170805
x13 = mTORC1 Determined 25.14
x15 = mTORC2 Determined 18.79587754
x17 = p70S6K Determined 14.30096315
x19 = PRAS40_S183 Determined 13.56128255
x21 = PRAS40_T246 Determined 17.55000883
x23 = TSC1_TSC2_pT1462 Determined 14.9175
x25 = PI3K_variant Determined 18.93446968
x2 = IR_beta_pY1146; x3 = IR_beta_refractory; x5 = IRS1_p; x6 = IRS1_pS636;
x8 = AMPK_pT172; x10 = Akt_pT308; x12 = Akt_pS473; x14 = mTORC1_pS2448;
x16 = mTORC2_pS2481; x18 = p70S6K_pT389; x20 = PRAS40_pS183; x22 = PRA
S40_pT246; x24 = TSC1_TSC2_pS1387; x26 = PI3K_variant_p
Fixed 0
Scaling factors
s1 = scale_IR_beta_pY1146_obs; s2 = scale_IRS1_pS636_obs; s3 = scale_AMPK_p-
T172_obs; s4 = scale_Akt_pT308_obs; s5 = scale_Akt_pS473_obs; s6 = sca-
le_TSC1_TSC2_pS1387_obs; s7 = scale_mTOR_pS2448_obs; s8 = scale_mTOR_pS2481
_obs; s9 = scale_p70S6K_pT389_obs; s10 = scale_PRAS40_pT246_obs; s11 = sca-
le_PRAS40_pS183_obs
Fixed 1
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inhibited mTORC1 activity towards p70-S6K-T389
(Fig. 4D). In agreement with our findings for wort-
mannin, increased PTEN levels activated AMPK, as
evidenced by AMPK-pT172 induction. We conclude
that AMPK is induced by IRS, but inhibited by PI3K.
The induction of AMPK in response to PI3K inhibi-
tion is in line with our own and previous findings on
AMPK induction in mTORC1-deficient cells and
might be mediated via the NFL. In other words, if
IRS is required for AMPK induction, inhibition of the
NFL (targeting IRS) should induce AMPK.
If this reasoning and our hypothesis 3 hold true,
activation of Akt and subsequent hyperactivation of
the NFL should inhibit AMPK. We tested this predic-
tion by overexpressing a myristoylated version of Akt
(HA-myr-Akt) [37], which is constitutively localized to
the plasma membrane and does not require IRS or
PI3K for its activation. As expected for Akt hyperacti-
vation, expression of HA-myr-Akt strongly induced
the Akt target site TSC2-pT1462 (Fig. 4E). TSC2-
T1462 phosphorylation leads to inhibition of the
TSC1-TSC2 complex and hyperactivates mTORC1.
Also, mTORC1 activity towards p70-S6K-T389 was
expectedly strongly induced by HA-myr-Akt overex-
pression, and p70-S6K activation induces the NFL. In
contrast, AMPK-pT172 was inhibited by HA-myr-Akt
and the same could be confirmed for the AMPK target
site, TSC2-S1387, which is required for TSC1-TSC2
activation. This result is in agreement with our model
3, predicting a negative effect of Akt on AMPK, via
the NFL and IRS. These data also directly exclude
hypotheses 5 and 6, which are on ranks 2 and 3 in our
hypotheses ranking (Table 2).
In summary, we chose here four independent experi-
mental set-ups to test the predictions of model 3,
which was ranked 1 in our hypothesis ranking. All
experiments provide strong evidence for model 3,
where IRS induces AMPK and exclude the other
hypotheses where other insulin downstream cues medi-
ate AMPK activation: we show that IRS-1 strongly
induces AMPK, whereas the PI3K-Akt-mTORC1 sig-
nalling axis suppresses AMPK (Fig. 5A). This is in line
with the NFL (downstream of PI3K, Akt and
mTORC1) suppressing AMPK, which is predicted by
our model 3. The network structure of our final model
is depicted in Fig. 5B.
What are the biological implications of our findings?
We and others show that in HeLa cells AMPK is
induced by insulin and amino acids (Fig. 1A, [23]).
However, HeLa cells are particular in the sense that
they do not express the AMPK upstream kinase,
LKB1 [23,24]. Therefore, it was important to address
whether the induction of AMPK by insulin and amino
acids, observed here, is a general feature of AMPK sig-
nalling, or whether it remains restricted to LKB1-defi-
cient cells. Hence, we tested the effect of insulin and
amino acid induction on AMPK activity in C2C12
myocytes, which are LKB1 positive (Fig. 4F). We
observed AMPK induction by insulin and amino acids
also in C2C12 cells, underlining the general importance
of our findings.
Discussion
In the present study we observed induction of
AMPK by insulin and amino acids. Although this
has been reported previously [23], ours is the first
study to explore systematically the underlying signal-
ling interconnections within the insulin–mTOR net-
work. To achieve this we systematically postulated
Table 1. (Continued).
Parameter name (AMPK induced by the IRS1 model)
[kinetic rate constants (min)1)] Calibration [mean ± SD (%)] Value
Observables (AU)
y1 = IR_beta_pY1146_obs Assigned s1*x2
y2 = IRS1_pS636_obs Assigned s2*x6
y3 = AMPK_pT172_obs Assigned s3*x8
y4 = Akt_pT308_obs Assigned s4*x10
y5 = Akt_pS473_obs Assigned s5*x12
y6 = TSC1_TSC2_pS1387_obs Assigned s6*x14
y7 = mTOR_pS2448_obs Assigned s7*x16
y8 = mTOR_pS2481_obs Assigned s8*x18
y9 = p70S6K_pT389_obs Assigned s9*x20
y10 = PRAS40_pT246_obs Assigned s10*x22
y11 = PRAS40_pS183_obs Assigned s11*x24
Compartments (AU)
c1 = Cell Fixed 1
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molecules along the insulin–mTORC1 signalling axis
as putative AMPK activators. Furthermore, we pre-
sumed that the putative AMPK inducer would be
upstream of mTORC1, first, because AMPK was
induced earlier (3 min p.i.) than mTORC1 and its
downstream targets and, second, because Raptor
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IR-beta
IRS1
mTORC2
Akt
TSC1-TSC2
AMPK
induced by TSC1 TSC2 pS1387 obs
Fig. 3. Prediction: intersection of insulin and
AMPK signalling at the level of IRS1. Simu-
lated time courses (red lines) versus experi-
mental data (blue points) for AMPK–pT172
and TSC1–TSC2–pS1387 (columns) for the
six hypotheses: insulin-induced AMPK,
IR-beta-induced AMPK, IRS-induced AMPK,
mTORC2-induced AMPK, Akt-induced
AMPK and TSC1–TSC2-induced AMPK
(rows). These predictions suggest that
AMPK could be regulated by kinases down-
stream of the IR. The IRS-induced AMPK
model showed the best fit to our experi-
mental data. Experimental data error bars
indicate the SEM calculated over three repe-
titions. The SBML model given in Model S2
(Supporting information) reproduces the
AMPK induction by IRS1. obs, observable.
Table 2. Statistical ranking of the models. N. Points = 130; K. Parameters = 24. The quality of fitting measures were used to determine a
ranking of the investigated models. The IRS1-induced AMPK model showed the lowest v2 value, indicating that this model was the most
probable (values in bold). AIC, AICc and BIC values are reported as additional measures.
Hypothesis no. AMPK induction by v2 P-value (N) P-value (N ) p) AIC AICc BIC Rank
1 Insulin 80.3086 0.999809 0.970256 367.233 378.66 436.053 5
2 IR-beta 78.1345 0.999908 0.980596 365.058 376.487 433.879 4
3 IRS1 68.0217 0.999999 0.998462 354.946 366.374 423.767 1
4 mTORC2 90.1238 0.99694 0.865145 377.048 388.476 445.869 6
5 Akt 75.5272 0.999964 0.988951 362.451 373.88 431.272 2
6 TSC1–TSC2 76.4666 0.99995 0.986376 363.391 374.819 432.211 3.
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inhibition induced AMPK (Fig. 1A). Applying a
hypothesis ranking approach, we successfully used a
dynamic insulin–mTOR–AMPK model for hypothesis
prioritization.
In accordance with our hypothesis that best fits
the data (hypothesis 3), we confirmed experimentally
that IRS activates AMPK. In contrast, all tested
IRS downstream cues within the PI3K–mTORC1
axis (PI3K, Akt, mTORC1) inhibited AMPK. This
is in line with our prioritized model where the NFL
– downstream of mTORC1 and S6K – inactivates
IRS for PI3K activation as well as for AMPK
induction. AMPK was induced by wild-type IRS and
a mutagenized IRS version that cannot be targeted
by the NFL, whereas AMPK was refractory to
expression of an IRS version that resembles constitu-
tively NFL-targeted IRS (Fig. 4A). Also this finding
strongly suggests that indeed the NFL might inacti-
vate IRS, not only for PI3K but also for AMPK
induction.
From a modelling point of view, a comprehensive
mTOR network has been studied statically, [38] and
parts of the mTOR network have been modelled dynam-
ically [13,39–45]. The network presented in this study is
A CB
ED F
Fig. 4. Experimental testing: IRS induces AMPK. (A) IRS overexpression induces AMPK. HeLa cells were harvested 24 h after transfection
with the indicated IRS-1 constructs. The mutagenized Myc-IRS-1 S6367 ⁄ 639 D construct mimics the constitutive phosphorylation by S6K,
whereas Myc-IRS-1 S6367 ⁄ 639 A resembles constitutively unphosphorylated IRS and cannot be inhibited by S6K and the NFL. (B) IRS over-
expression induces TSC2 phosphorylation by AMPK. HeLa cells were harvested 24 h after transfection with Myc-IRS-1 WT. (C) The PI3K
inhibitor wortmannin induces AMPK. HeLa cells were starved and treated with 100 nM wortmannin or carrier before restimulation with insu-
lin ⁄ amino acids. (D) Overexpression of the PI3K antagonist, PTEN, induces AMPK. HeLa cells were transfected 24 h before harvesting. Cells
were starved of serum ⁄ amino acids before restimulation with insulin ⁄ amino acids. (E) Constitutively active Akt inhibits AMPK. HeLa cells
were harvested 24 h after transfection with myristoylated Akt (HA-myr-Akt). (F) Insulin ⁄ amino acids induce AMPK in LKB1-positive C2C12
myocytes. aa, amino acids; WT, wild type.
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the most extensive mTOR–AMPK model of which we
are aware. Six models were defined and calibrated using
our experimental data. The models shared the main net-
work structure, but differed for the AMPK activation
mechanism. After repeating cycles of parameter calibra-
tion and identifiability for each model, likelihood-based
statistical measures were used to estimate a model rank-
ing, based on the goodness-of-fit between each model
and the experimental data.
In the present study we observed transient induction
of AMPK by insulin and identified active IRS as an
AMPK inducer. On the other hand, AMPK inhibits
IRS by phosphorylation of IRS-1-S794 [46–48]. Could
this mechanism be connected to the AMPK induction
by IRS observed here? It is conceivable that two
antagonistic mechanisms are mediated by IRS: when
IRS is active, it will activate AMPK – and at the same
time AMPK could directly, via IRS, contribute to the
inhibition of insulin signalling. This putative mecha-
nism clearly deserves further mechanistic investigation.
It is important to note that HeLa cells, which were
used in the present study, do not express LKB1. This
suggests that AMPK induction by insulin and IRS is
LKB1 independent, at least in HeLa cells. Which other
kinase could be responsible? AMPK phosphorylation
in HeLa (and other) cells is mediated by the kinase
ATM [23,24]. Interestingly, AMPK induction by ATM
occurs in a tyrosine-kinase dependent, but PI3K-inde-
pendent, manner [24]. This is consistent with our
finding that IRS, but not PI3K, induces AMPK
(Fig. 4A–D). Other possible candidates for LKB1-inde-
pendent AMPK induction are the kinases CaMKK
[16–19], TAK1 [20–22] or IRE1 [25].
What is the relevance of the mechanism reported
here in LKB1-expressing cells? First, Suzuki et al. [23]
reported the IGF-1 inducibility of AMPK, not only in
LKB1-deficient HeLa cells, but also in LKB1-express-
ing PANC1 cells. Also, our own data confirm the
inducibility of AMPK by insulin and amino acids in
LKB1-expressing C2C12 myocytes (Fig. 4F), suggest-
ing that this mechanism may be present in a larger
number of cell types. Furthermore, at least two other
studies have reported that AMPK is induced by
mTORC1 [28] or S6K [29] ablation in mice. This sug-
gests that IRS-dependent AMPK induction might
become particularly prominent under conditions when
the NFL is inhibited. Hence, IRS-dependent AMPK
induction may exert some of the beneficial effects that
A B
Fig. 5. New model structure: IRS is required for AMPK induction by insulin. (A) Schematic representation of the insulin-induced mTORC1
pathway, including IRS-dependent AMPK induction. Importantly, the NFL via IRS targets not only PI3K but also AMPK. Wmn, wortmannin.
(B) Insulin–mTOR–AMPK model describing IRS as a regulator of AMPK.
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have been observed for mTOR-inhibitor treatment of
metabolic and tumour diseases [49].
What could be the biological function of a transient
induction of AMPK by insulin? First, AMPK inhibits
mTORC1 signalling at two levels: TSC1–TSC2 and
mTORC1 itself. Therefore, this transient AMPK
induction in response to insulin might – in addition to
the NFL – serve as a second mechanism to prevent
mTORC1 hyperactivation. As an additional benefit,
AMPK activation might serve as a protective mecha-
nism to cellular stress under transiently increased met-
abolic rates in response to insulin.
In conclusion, we present here, to the best of our
knowledge, the most comprehensive data-driven
dynamic mTOR–AMPK network model. Our com-
bined modelling–experimental approach revealed IRS
as a mediator of AMPK induction in response to insu-
lin and strongly suggests an involvement of the
mTORC1-dependent NFL in AMPK regulation. The
impact of this novel signalling interconnection for
AMPK and mTOR biology deserves further explora-
tion. Our findings will be highly relevant to the bio-
medical field because they can have important
implications for administration of drugs targeting
mTOR and AMPK, which are commonly used in
tumour and metabolic disease treatments.
Materials and methods
Cell lines and lentiviral transduction
Experiments were performed in HeLa a Kyoto cells and
C2C12 myocytes. For inducible knockdown of Raptor,
HeLa cells were transduced with lentivirus encoding the tet-
racycline-sensitive tetracycline repressor (tTR)-Krueppel-
associated box (protein domain) (KRAB) repressor and a
DsRed reporter [50]. Cells were subsequently transfected
with lentivirus encoding the Raptor-specific shRNA (target
sequence: 5¢-GGCTAGTCTGTTTCGAAATTT-3¢) and a
green fluorescent protein reporter (pLVTH vector), both
under the control of tTR-KRAB.
Overexpression of IRS, PTEN and myristoylated
Akt variants
N-terminally and hemagglutinin (HA)-tagged pSG5L HA
PTEN wt (#10750), N-terminally myristoylated and HA
tagged pLNCX.myr.HA.Akt1 (#9005) and N-terminally
myristoylated and HA-tagged kinase dead pLNCX.myr.
HA.Akt1 K179M (#9006) were ordered from Addgene.
IRS1 constructs were a kind gift from A. Tzatsos [36].
Transfection was performed with 6 lg of construct
per 6-cm dish using JetPEI reagent according to the
manufacturer’s instructions. Cells were harvested 24 h
after transfection.
Antibodies and reagents
The monoclonal anti-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) IgG1 was purchased from Abcam (Cam-
bridge, UK). The anti-HA IgG 2b k (clone 12CA5) was
purchased from Roche. Horseradish peroxidase (HRP)-
conjugated goat anti-mouse and goat anti-rabbit IgGs were
purchased from Pierce Biotechnology (Thermo Scientific,
Rockford, IL USA). All other antibodies were purchased
from Cell Signalling Technology (Danvers, MA, USA).
Doxycycline for knockdown induction was purchased from
Calbiochem, Merck (Darmstadt, Germany). Wortmannin
was purchased from Sigma Aldrich (St Louis, MO, USA).
Chemicals were supplied by Carl Roth (Karlsruhe, Germany)
unless indicated otherwise.
Analysis of cell lysates
Where indicated, HeLa cells were starved for serum and
amino acids by exchanging standard growth medium for
Hank’s balanced salt solution (HBSS) overnight to inhibit
mTOR pathway activity. After 16 h of starvation, mTOR
signalling was restimulated for 30 min with DMEM con-
taining amino acids and supplemented with 100 nm insulin
(Sigma Aldrich).
Gradual knockdown of Raptor was established by induc-
tion with 5 lg mL)1 of doxycycline (Calbiochem, Merck) for
0, 2 or 3 days. Wortmannin treatment: Wortmannin was
added to HBSS 30 min before restimulation for 30 min with
Dulbecco’s modified Eagle’s medium (DMEM), which was
supplemented with 100 nm insulin and wortmannin. Cells
were washed once with NaCl ⁄Pi and lysed with TNE lysis buf-
fer [50 mm Tris ⁄HCl, pH 8.0, 150 mm NaCl, 1% (v ⁄ v) Triton
X-100 (Calbiochem, Merck), Complete (Roche, Mannheim,
Germany), Phosphatase Inhibitor Cocktail 2 and Phospha-
tase Inhibitor Cocktail 3 (both Sigma Aldrich)]. Protein con-
centrations were measured using the Protein Assay Dye
Reagent Concentrate (Bio-Rad, Hercules, CA, USA) accord-
ing to the manufacturer’s protocol. Concentrations were
adjusted with lysis buffer. Lysates were diluted in sample buf-
fer (5·: 6 mL of glycerol, 0.6 mL of beta-mercaptoethanol,
1.0 g of SDS, 3.75 mL of 1 m Tris, pH 6.8, 2 mg of Bromo-
phenol Blue and 2 mL of H2O). Whole-cell lysates were analy-
sed using SDS ⁄PAGE. Proteins were transferred to
poly(vinylidene difluoride) membranes (Millipore, Billerica,
MA, USA), blocked with 5% BSA in TBST (8 g of NaCl,
0.2 g of KCl, 8 g of Tris, pH 7.4, 0.1% Tween 20) for a mini-
mum of 30 min and incubated with the primary antibody in
5% BSA in TBST overnight with shaking at 4C. Blots were
washed 3· with TBST, incubated with secondary antibodies
coupled to HRP and washed 3·with TBST before detection.
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Modelling
The illustrated graphical model in SBGN graphical nota-
tion [51] was designed using CellDesigner 4.2 [52]. The
Matlab Toolbox PottersWheel [31] was used for designing
and calibrating the models. The parameters for each of the
models were estimated by 1000 fits with a parameter distur-
bance noise of 0.4 using the best fit as the starting value.
For each fit a maximum of 250 iterations with v2 and
parameter tolerances of 1e)07 were run using the optimiza-
tion algorithm, TrustRegion. To reduce the computation
time, cvodes integrator was selected and configured with
the following parameters: maximum number of
steps = 1500, relative tolerance = 1e)06 and absolute tol-
erance = 1e)08.
The reactions representing the dynamics of the models
were described by mass action laws. Only the kinetic rate
constants were estimated, and the interval [1e)06, 1e+04]
was selected as constraint for each parameter. The protein
initial concentrations were directly determined from our
experimental data and scaled to distribute the fitting qual-
ity over the model. Experimental error bars indicate SEM.
The dynamics for the species PI3K-variant were assumed
by reproducing the dynamics of the insulin receptor,
whereas its initial concentration was the same of the IRS1
species.
Structural identifiability was calculated a priori using
GenSSI [32]. The model in Potterswheel format was
exported in SBML and converted to Octave format using
The System Biology Format Converter (SBFC) (available
from sourseforge.net). Then, the model in Octave format
was adapted for the software GenSSI. Symbolic solutions
for each model were computed, setting 10 as the maximum
number of iterations.
After executing each sequence fits, parameters were con-
sidered as nonidentifiable when their CV, measured in the
best 50% fits of the calibration sequence, were higher than
5%. In combination with this preliminary analysis, the Pot-
tersWheel plugin MOTA was used to confirm the parame-
ter nonidentifiability and to assess the relations between the
target parameter and the others.
3D sensitivity analysis was performed using PottersWheel
and is provided in Fig. S2. We also used PottersWheel to
export the models as SBML [53] Level 2 Version 4.
Statistics
The goodness-of-fit statistical measures v2 [31], AIC, AICc
[34] and BIC [35] were used in order to rank the hypothe-
ses. All these measures were directly computed using
PottersWheel Toolbox.
The statistical and programming language r v. 2.13.1 [54]
was selected for the graphic representation of the identifi-
ability matrix computed with MOTA.
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